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Abstract 
Lentiviral Vector Mediated Haematopoietic Stem Cell Gene 
Therapy For Mucopolysaccharidosis Type IIIA  
Alexander William Walker Langford‐Smith 
The University of Manchester, Doctor of Philosophy (PhD) 2012 
Mucopolysaccharidosis  type  III  (Sanfilippo)  is  comprised  of  four  phenotypically 
similar  lysosomal  storage  disorders  (MPS  IIIA‐D)  caused  by  the  deficiency  of 
enzymes  that  catabolise  heparan  sulphate  (HS).  Progressive  accumulation  of  HS 
results  in  abnormal  behaviour,  progressive  cognitive  and motor  impairment  and 
death in mid‐teens. There are currently no treatments for MPS III.  
To  assess  the  effect  of  novel  therapeutics  in  the  mouse models  of  MPS  III  it  is 
necessary to examine the effect on primary storage of HS, secondary storage and 
behaviour. The reported behaviour of MPS  IIIA and B mice  is conflicting therefore 
we developed a one‐hour open field test, performed at the same time of day during 
a period of hyperactivity observed in a previous circadian rhythm study of MPS IIIB 
mice. At  8 months  of  age MPS  IIIB mice were  hyperactive, with  increased  rapid 
exploratory  behaviour  and  a  reduction  in  immobility  time.  The  MPS  IIIA  mice 
presented with  the  same behavioural phenotype  as  the MPS  IIIB mice  and were 
significantly  hyperactive  at  4  and  6 months  of  age  and  also  displayed  a  reduced 
sense of danger. The hyperactivity and  reduced  sense of danger observed  in  the 
mice is consistent with the patient phenotype.  
Whilst haematopoietic stem cell transplant (HSCT)  is the standard therapy used to 
treat the similar HS storage disorder MPS  I Hurler,  it  is  ineffectual  in MPS  IIIA. We 
hypothesise that HSCT failure in MPS IIIA is due to insufficient enzyme production in 
the  brain  by  donor‐derived  microglial  cells.  By  increasing  expression  of  N‐
sulphoglucosamine  sulphohydrolase  (SGSH)  we  may  be  able  to  treat  MPS  IIIA. 
Therefore we compared the effect of HSCT using normal haematopoietic stem cells 
(WT‐HSCT)  to  lentiviral  overexpression  of  SGSH  in  normal  cells  (LV‐WT‐HSCT)  or 
MPS  IIIA  cells  (LV‐IIIA‐HSCT)  in  MPS  IIIA  mice,  using  the  behavioural  tests 
developed. 
SGSH activity  in the brain of MPS  IIIA recipients was not significantly  increased by 
WT‐HSCT, but was significantly increased by LV‐IIIA‐HSCT and LV‐WT‐HSCT. HS was 
significantly  reduced  by  all  transplants  but  the  best  treatment was  LV‐WT‐HSCT. 
Neuroinflammation,  indicated  by  the  number  of  microglia  in  the  brain,  was 
significantly  reduced  by  all  treatments  but  remains  significantly  elevated.  GM2 
gangliosides were significantly reduced by WT‐HSCT and LV‐WT‐HSCT and were no 
longer significantly elevated, but LV‐IIIA‐HSCT had no significant effect. Critically LV‐
WT‐HSCT  corrected  the  behaviour  at  4  and  6  months  of  age  whilst  the  other 
treatments had no significant effect.  
LV‐WT‐HSCT  and  WT‐HSCT  reduced  GM2  gangliosides  and  neuroinflammation 
equally  but  only  LV‐WT‐HSCT  corrected  behaviour  and  primary  HS  storage, 
suggesting they are the important factors in MPS IIIA pathology. 
LV‐WT‐HSCT corrects the neurological phenotype in MPS IIIA mice and is a clinically 
viable  approach  to  treat  MPS  IIIA  and  other  neuropathic  lysosomal  storage 
disorders. 
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1.1 Mucopolysaccharide Diseases 
1.1.1 Lysosomal Storage Disorders 
Lysosomal storage disorders (LSD) are a family of over fifty genetic diseases that 
result in intra-lysosomal accumulation of undegraded macromolecules (Wraith 
2002). These multisystem progressive disorders occur at a frequency of around 1 in 
7,500 live births (Meikle et al. 1999; Poorthuis et al. 1999). The majority of LSDs are 
caused by inactivation of an enzyme involved in the degradation of substrates 
within the lysosome. For example, Mucopolysaccharidosis type I is caused by 
inactivity of the enzyme α-L-iduronidase and Mucopolysaccharidosis type IIIA by a 
lack of N-sulphoglucosamine sulphohydrolase (SGSH, sulphamidase) activity. 
However, proteins involved in lysosomal maintenance, enzyme activation, 
transporters and receptors are also causes of disease.   
Lysosomal storage disorders can be grouped by primary storage material. Some 
LSDs are primarily lipid storage disorders; gangliosides are accumulated in GM1 
gangliosidosis, Sandhoff and Tay-Sachs. Glucosylceramide and glucosylsphingosine 
are stored in Gaucher disease, sphingomyelin in the family of Niemann-Pick 
diseases and sulphatide in Metachromatic Leukodystrophy. Another group of LSDs 
accumulate glycogen, such as Pompe disease. 
 As the stored molecules differ in various LSDs the clinical symptoms vary, but they 
are characteristically progressive disorders due to gradual substrate accumulation. 
This usually results in a progressive loss of function of the affected tissue or tissues. 
The tissues affected vary with the stored substrate and the severity of disease.   
1.1.2 Mucopolysaccharide Diseases 
Mucopolysaccharide (MPS) diseases are a subset of lysosomal storage disorders 
that accumulate glycosaminoglycans (GAG). They have an incidence of 
approximately 1 in 26,000 live births in the UK (UK MPS Society). All the MPS 
diseases are caused by deficiencies in enzymes involved in GAG degradation, 
resulting in the accumulation of GAGs in the lysosome, cells and extracellular 
matrix. Different subtypes of MPS were originally classified by their clinical 
Chapter 1 – Introduction 
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phenotype but now specific enzyme deficiency and clinical severity are also 
considered (Table 1-1).  
The symptoms and the severity of the diseases differ but all present with 
developmental problems.  
MPS type I is an autosomal recessive disease caused by mutations in the IDUA gene 
coding for the enzyme α-L-iduronidase. The variation in severity within MPS I is so 
large that it is characterised as three separate diseases based on clinical 
observation; a severe form called MPS I Hurler (MPS IH), an intermediate form 
called MPS I Hurler/Scheie (MPS IH/S), and a mild form called MPS I Scheie (MPS IS). 
The latter two possess residual enzyme activity, whilst Hurler is usually the result of 
total enzyme inactivation by a stop or frameshift mutation. The life expectancy for 
MPS IH is 7.9 years, MPS IH/S patients survive until on average 21.6 years and MPS 
IS sufferers have a normal life expectancy (Moore et al. 2008). These variable 
phenotypes are due to the location and type of mutation in IDUA. Single amino acid 
changes in the catalytic domain of an enzyme can dramatically affect the activity of 
the enzyme, whereas changes in other regions of the enzyme may have little effect. 
MPS IH manifests with severe progressive neurodegeneration, organomegaly, 
dysostosis multiplex in the bones and joints and coarse facial features. 
Morquio syndrome (MPS IVA and B) presents primarily with severe skeletal 
abnormalities and organomegaly caused by keratan sulphate (KS) storage. MPS VI 
and IX present with skeletal and/or joint problems and are associated with 
dermatan sulphate (DS) and chondroitin sulphate (CS) storage. MPS I, II and VII 
store dermatan sulphate (DS) (MPS VII stores CS as well) and present with skeletal 
abnormalities, however they also store heparan sulphate which appears to be 
associated with neurodegeneration. MPS III mainly stores heparan sulphate, 
resulting in a primarily neuronal phenotype.  
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MPS Alternative name Missing Enzyme 
Major 
Phenotype 
Gene 
Stored 
GAG 
MPS IH* Hurler Syndrome 
α-L-iduronidase 
Neuronal/ 
skeletal 
Idua DS, HS MPS IH/S* Hurler-Scheie 
MPS IS* Scheie Syndrome 
MPS IIA
†
 
Hunter Syndrome iduronate 2-sulphatase 
Neuronal/ 
skeletal 
Ids DS, HS 
MPS IIB
†
 
MPS IIIA Sanfilippo Syndrome A 
N-sulphoglucosamine 
sulphohydrolase 
Neuronal Sgsh HS 
MPS IIIB Sanfilippo Syndrome B 
α-N-
acetylglucosaminidase 
Neuronal Naglu HS 
MPS IIIC Sanfilippo Syndrome C 
heparin-α-
glucosaminide N-
acetyltransferase 
Neuronal Hgsnat HS 
MPS IIID Sanfilippo Syndrome D 
N-acetylglucosamine-
6-sulphatase 
Neuronal Gns HS 
MPS IVA Morquio Syndrome A 
galactosamine (N-
acetyl)-6-sulphate 
sulphatase  
Skeletal Galns KS 
MPS IVB Morquio Syndrome B β-1-galactosidase Skeletal Glb1 KS 
MPS VI 
Maroteaux-Lamy 
Syndrome 
arylsulphatase B Skeletal Arsb CS, DS 
MPS VII Sly Syndrome β-glucuronidase 
Neuronal/ 
skeletal 
Gusb CS, DS, HS 
MPS IX 
Hyaluronidase 
Deficiency 
hyaluronoglucosamini
dase 1 
Skeletal/ joints Hyal1 CS, DS 
Table 1-1 MPS family of diseases 
* MPS IH is the severe form of MPS I, MPS IS is the mild form and MPS IH/S is an intermediate form. 
† MPS IIA is the severe form of MPS II and MPS IIB is the mild form. 
 
1.1.2.1 MPS III (Sanfilippo) 
MPS III, or Sanfilippo disease contains four subtypes; A, B C and D. MPS IIIA is the 
most common in Northern Europe and IIIB in the Mediterranean regions (Emre et 
al. 2002). In the UK from 1990-2006 there have been 126 patients identified with 
MPS III with an incidence of 1:83,000 live births. Of those, 71% (89 patients) are 
MPS IIIA giving an incidence of 1:116,000 live births (Heron et al. 2011). Types A, B, 
C and D are deficient in different enzymes; N-sulphoglucosamine sulphohydrolase 
(SGSH), α-N-acetylglucosaminidase (NAGLU), heparin-α-glucosaminide N-
acetyltransferase (HGSNAT) and N-acetylglucosamine-6-sulphatase, respectively. In 
all types of MPS III, HS is stored, and the different subtypes are clinically 
indistinguishable, although MPS IIIC usually has a slower progressive phenotype 
than MPS IIIA or B.  The first symptoms of MPS III can manifest as early as 7 months 
(± 1.2 months), though diagnosis occurs on average at 4.6 years (± 2.6 years) 
(Meyer et al. 2007). The first symptoms are delayed developmental milestones and 
behavioural changes, which include sleep disturbances, hyperactivity, a reduced 
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sense of danger and aggressive behaviour (Bax et al. 1995; Fraser et al. 2002; 
Valstar et al. 2008; Malm et al. 2010; Wegrzyn et al. 2010). The majority (86-92%) 
of MPS IIIA patients have coarse facial features (Meyer et al. 2007; Heron et al. 
2011). Other clinical symptoms include recurring diarrhoea and ear nose and throat 
infections (Sivakumur et al. 1999). As demonstrated in Table 1-2 and Table 1-3, 
development is initially relatively normal, then individuals begin to progressively 
lose their motor functions and cognitive abilities (Meyer et al. 2007; Heron et al. 
2011). The maximum developmental age achieved is on average 3-4 years (Valstar 
et al. 2011). The clinical phenotype and progression of MPS IIIA and B are 
indistinguishable (see Table 1-3) and patients die on average at 15 years of age 
(Cleary et al. 1993; Meyer et al. 2007; Heron et al. 2011). 
 
Speech Cognitive Function Motor Function 
Age ± SD /yrs Age ± SD /yrs Age ± SD /yrs 
Impairment of speech 
2.8 ± 1.9 
Deterioration of cognitive 
function 
3.0 ± 1.4 
Clumsy walking 
4.1 ± 3.6 
Speech difficult to 
understand 
5.7 ± 2.7 
Loss of interest in 
environment 
8.2 ± 3.7 
Aided walking 
9.9 ± 4.3 
Loss of speech 
8.2 ± 3.7 
Unresponsiveness 
13.1 ± 4.2 
Wheel 
chair/immobile 
12.4 ± 5.3 
Table 1-2 Clinical progression of MPS IIIA 
This table demonstrates the deterioration of speech, cognitive and motor functions in a study of 
German MPS IIIA patients adapted from Meyer et al. 2007.  
 
Measure Median/yrs ± SD MPS IIIA MPS IIIB 
Independent walking 1.3 ± 0.4 1.1 ± 0.3 
Two-word combination 3.0 ± 1.1 2.6 ± 2.6 
Onset of cognitive delay 3.0 ± 1.4 3.5 ± 1.3 
Abnormal behaviour 3.5 ± 3.3 4.0 ± 6.8 
Loss of independent walking 10.2 ± 3.8 13.3 ± 9.4 
Loss of relational interactions 10.0± 3.7 12.0± 3.5 
Table 1-3  Clinical progression of MPS IIIA and IIIB 
This table demonstrates the deterioration and similarity of French MPS IIIA and B patients, adapted 
from Heron et al. 2011. 
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1.2 Mucopolysaccharide Disease Pathology  
1.2.1 Primary Storage 
The primary storage material in all Sanfilippo diseases is heparan sulphate (HS), but 
how HS causes neurodegeneration is not known. HS has many important roles that 
may be dysregulated by changes in the sulphation pattern or amount of HS that 
may influence the disease phenotype.  
HS is the primary storage material and can be measured directly using electrospray 
ionisation tandem mass spectroscopy (Mason et al. 2006), however this is an 
expensive technique and hard to optimise. The heparin cofactor II–thrombin 
complex is a biomarker that is elevated in serum from patients with MPS I, II, III, IV 
and VI (Randall et al. 2006; Randall et al. 2008; Clarke et al. 2011; Langford-Smith et 
al. 2011c). However while it is a good biomarker for those MPS diseases that store 
DS (e.g. MPS I), HS  causes a smaller elevation in heparin cofactor II–thrombin 
complex levels so it is less effective in MPS III and is not significantly elevated in the 
MPS IIIA and B mouse models (Langford-Smith et al. 2010). 
1.2.1.1 Heparan Sulphate Structure and Function 
HS is a glycosaminoglycan (GAG) formed from repeating disaccharides, of 
glucuronic acid (GlcA) or iduronic acid (IdoA) linked to N-acetylglucosamine 
(GlcNAc) (Turnbull et al. 2010). HS comprises N-acetylated (NA) regions that have 
undergone limited modifications that consist mainly of GlcA-GlcNAc repeats. This 
basic repeat can then be modified. Highly sulphated S-domains are typically 3-8 
disaccharides long and are modified by N- and O- sulphation. Epimerization of most 
glucuronic acid (GlcA) to iduronic acid (IdoA) also occurs. There are also NA/NS 
domains where alternating N-acetylation and N-sulphation occurs and a mix of GlcA 
and IdoA is present.  
The range of modification of HS and their presence in the extracellular matrix and 
on the cell surface means that they can regulate protein-protein interactions by 
altering protein structures, increasing protein stability and limiting protein 
movement (Bishop et al. 2007; Turnbull et al. 2010). Often HS chains are linked to 
proteins to form proteoglycans, which facilitates these interactions. They have a 
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rapid turnover of 3-4 hours in cultured cells (Turnbull et al. 2010) and are 
responsive to extracellular signals from growth factors (Schmidt et al. 1995), 
therefore HS can act as a dynamic signal modification molecule (Turnbull et al. 
2001). HS has a diverse range of roles and includes but is not limited to, interactions 
with fibroblast growth factor and receptor, transforming growth factors, 
interleukins, chemokines, extracellular matrix and enzymes (Bishop et al. 2007).  
The roles of HS are well reviewed in (Bishop et al. 2007). 
GAG degradation is mediated by a series of enzyme reactions (Figure 1-1, Figure 
1-2, Figure 1-3, Figure 1-4). The different enzyme deficiencies can result in storage 
of slightly different forms of HS with different end structures depending on which 
step is blocked. For example in MPS IH the terminal iduronic acid residue makes up 
a larger proportion of HS than in MPS III (Holley et al. 2011). Additionally in MPS IH 
the storage of HS results in the upregulation of glucosaminyl N-deacetylase/N-
sulphotransferase (NDST) enzymes. These enzymes are responsible for defining the 
location of sulphated regions and upregulation of these enzymes increases the 
amount of N- and O- sulphation. Therefore the storage of HS can result in the 
accumulation of unusual HS end products and the increase in sulphation of HS, 
which could affect the function of HS and impact directly on disease pathology 
(Holley et al. 2011).  Similar findings have also been observed in MPS IIIB (McCarty 
et al. 2011). 
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Figure 1-1 The pathway of dermatan and chondroitin sulphate degradation  
This figure depicts the degradation of dermatan and chondroitin sulphate. The enzyme name and 
MPS disorder resulting from the deficiency of each enzyme are listed next to the relevant reaction. 
Adapted from Essentials of Glycobiology (Freeze 2009). 
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Figure 1-2 The pathway of keratan sulphate degradation  
This figure depicts the degradation of keratan sulphate. The enzyme name and MPS disorder 
resulting from the deficiency of each enzyme are listed next to the relevant reaction. Adapted from 
Essentials of Glycobiology (Freeze 2009). 
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Figure 1-3 The pathway of heparan sulphate degradation  
This figure depicts the degradation of heparan sulphate. The enzyme name and MPS disorder 
resulting from the deficiency of each enzyme are listed next to the relevant reaction. Adapted from 
Essentials of Glycobiology (Freeze 2009). 
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Figure 1-4 Glycominoglycan degradation 
This figure depicts the degradation of heparan sulphate, dermatan sulphate and keratan sulphate. 
The enzyme name and MPS disorder resulting from the deficiency of each enzyme are listed next to 
the relevant reaction. 
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1.2.2 Secondary Storage 
The secondary storage of GM2 and GM3 gangliosides and un-esterified cholesterol 
has been observed in MPS III neuronal tissue (McGlynn et al. 2004). This secondary 
storage could result from GAG inhibition of lysosomal enzymes, however the 
gangliosides often accumulate in different subcellular compartments to the stored 
GAG. This suggests that altered ganglioside synthesis or trafficking may have an 
important role in secondary storage (McGlynn et al. 2004) possibly caused by Golgi 
complex disorganisation (Vitry et al. 2010). In the brain GM2 and GM3 gangliosides 
were primarily stored in the piriform cortex, retrosplenial region, amygdala and 
cortex layer V (McGlynn et al. 2004). 
Both cholesterol and gangliosides are components of lipid rafts involved in 
signalling in neurons, leading to the hypothesis that GAG accumulation may affect 
lipid rafts and therefore signalling in MPS IIIA neurons, causing some of the clinical 
neurological symptoms (McGlynn et al. 2004).  GM2 and GM3 gangliosides also 
have a role in glycosynaptic microdomains that regulate signalling, adhesion, 
motility and growth which also might be affected (Regina et al. 2008). 
Recently DS secondary storage has been observed in MPS IIIA, B, C and D patient 
fibroblasts and potentially occurs in other tissues, although it may not be sufficient 
to have an effect on the clinical phenotype (Lamanna et al. 2011). 
1.2.3 Neuroinflammation 
Central nervous system (CNS) inflammation has also been linked to 
neurodegeneration in LSDs (Wada et al. 2000; Baudry et al. 2003; Jeyakumar et al. 
2003) including MPS I and IIIB mice (Ohmi et al. 2003) and is thought to be an 
initiating factor for neurodegeneration in Alzheimer’s and Parkinson’s diseases 
(Skaper 2007). In MPS IIIA and MPS IIIB mice, activated microglial cells and 
activated astrocytes have been identified (Savas et al. 2004; Malinowska et al. 
2010)  
HS oligosaccharides have been shown to activate microglial cells in MPS IIIB by the 
TLR4 and MyD88 receptors (Ausseil et al. 2008).  TLR4 and MyD88 knockout mice 
were crossed with the MPS IIIB mice; this resulted in a very low level of 
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neuroinflammation compared to normal MPS IIIB mice at 3 months of age.  Despite 
this, there was no change in progression of neurodegeneration. However 
neuroinflammation present at 8 months of age was caused by a HS oligosaccharide 
TLR independent mechanism. This indicates that in MPS IIIB mice 
neurodegeneration can occur independently of neuroinflammation, at least in the 
early stages of disease (Ausseil et al. 2008).  
A recent paper by Arfi et al. examined neuroinflammation, oxidative stress and 
apoptosis gene expression in MPS IIIA mice (Arfi et al. 2011). Aspirin treatment 
reduced the expression of neuroinflammatory genes and oxidative stress genes but 
had little or no effect on apoptosis related gene expression. This also supports the 
hypothesis that neuroinflammation may not cause apoptosis and 
neurodegeneration in MPS IIIA mice. However the pathology of the MPS IIIA mice in 
terms of primary or secondary storage or behaviour was not examined. Therefore 
further studies are necessary.  
1.2.4 Other Mechanisms 
1.2.4.1 Autophagy Defects 
Proteins can be degraded by two main pathways, the ubiquitin-proteasome system 
(UBS) and macroautophagy (autophagy) pathways. The autophagy pathway 
degrades cytosolic proteins and organelles (e.g. mitochondria) within 
autophagosomes (double membrane vesicles) which fuse with the lysosome 
(Mizushima et al. 2002). It is hypothesised that in LSDs, neurodegeneration is 
caused by defective autophagy, since autophagy is a lysosome dependent pathway 
and mouse model knockouts of autophagy genes result in neurodegeneration (Hara 
et al. 2006; Komatsu et al. 2006). Additionally, known autophagy target proteins are 
accumulated in other neurodegenerative disorders (Settembre et al. 2008). The 
autophagy pathway has been reported to be abnormal in MPS IIIA and Multiple 
Sulphatase Deficiency (MSD) mouse models as increased numbers of 
autophagosomes are observed using the LC3II marker (Kabeya et al. 2000), more 
mitochondria and more ubiquitin inclusion bodies are also present (Settembre et al. 
2008). 
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There are also parallels with other neurodegenerative diseases. For example, in 
Alzheimer’s disease, lysosomal accumulation is observed (Nixon et al. 2008) and 
autophagy is thought to be an important pathway in the disease (Boland et al. 
2008). In Huntington’s disease and Parkinson’s disease the aggregate forming 
proteins are also targets of the autophagy pathway.  
1.2.4.2 Tauopathy 
MPS IIIB is also thought to be a tauopathy like Alzheimer’s disease; 
hyperphosphorylated tau was detected in the medial entorhinal cortex and in older 
mice in the dentate gyrus, but the mechanism of storage is not clear (Ohmi et al. 
2009). It is not clear if hyperphosphorylated tau in this very limited region of the 
brain is relevant to the clinical pathology or treatment of MPS. Additionally some of 
the antibodies against hyperphosphorylated tau used in Alzheimer’s disease did not 
work in Ohmi et al. and two prior studies did not observe hyperphosphorylated tau 
in patients or animal models (Ginsberg et al. 1999; Hamano et al. 2008).  
1.2.4.3 Altered Metabolism 
Lysosomal storage has been demonstrated to change the energy usage within the 
cell and inhibit adipose tissue deposition. The lysosome recycles macromolecules, 
providing them as raw materials for synthesis; however, if this recycling does not 
occur then energy will have to be expended for de novo synthesis. Additionally, the 
increasing size and number of lysosomes means that extra energy will be necessary 
to maintain them. Eventually the increasing demand for energy by the lysosomes 
and de novo synthesis may lead to the cell being unable to carry out its required 
purpose and eventually it may die (Woloszynek et al. 2007).   
1.2.5 Behavioural Changes 
The primary and secondary storage in MPS III potentially cause neuroinflammation, 
changes in autophagy and alter metabolism. How these and potently other factors 
cause the distinct behavioural changes in the MPS III patients is currently unclear. A 
reduction in VAMP2, a component of the SNAP/SNARE complex that is involved in 
presynaptic neurotransmitter release and so neuronal signalling, has been observed 
in MPS IIIB mice (Malinowska et al. 2010), which could influence behaviour but 
many other pathways may also be affected. 
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When evaluating the behaviour of mice the genetic background can affect the 
behavioural outcomes. If the colony has a broad genetic background a greater 
range in behaviours may be seen, which makes determining a significant effect 
harder. Therefore mice are normally backcrossed on to a standard background such 
as C57BL/6 (Crawley 2007). The MPS IIIB mouse model was created by targeted 
disruption of the 6th exon with a 900bp insertion and has also been backcrossed 
onto the C57BL/6 background (Li et al. 1999). The MPS IIIA mouse model is a 
spontaneously occurring mouse model obtained on a mixed 129SvJ, C57BL/6, SJL, 
and CD1 background (Bhaumik et al. 1999; Bhattacharyya et al. 2001). 
Consequently the MPS IIIA mice should be backcrossed for at least 10 generations 
onto a pure background for reliable and consistent behavioural testing to be 
performed (Crawley 2007).  
1.2.5.1 Circadian Rhythm 
MPS III patients have sleep disturbances; they have trouble settling to sleep and 
frequently wake up, they also have lower levels of melatonin at night and higher 
levels during the day (Fraser et al. 2002; Fraser et al. 2005; Guerrero et al. 2006). In 
the MPS IIIB mice, circadian rhythm changes have also been observed (Heldermon 
et al. 2007; Canal et al. 2010). Canal et al examined the suprachiasmatic nucleus 
(SCN), the region of the brain that controls the circadian rhythm, and identified an 
increase in the size of the lysosomal compartment by LAMP2 
immunohistochemistry and an increase in the number of activated microglia and 
astrocytes. A reduction in vasoactive intestinal peptide (VIP) was observed which 
suggests that there is a decrease in the transmission of photic information to the 
SCN from the retinorecipient core. VIP has a role in the resetting of the circadian 
clock in response to light and is reviewed in Piggins et al. and Brown et al. (Piggins 
et al. 2003; Brown et al. 2007).  There were also changes in the distribution of  
VAMP2  staining from punctate to diffuse that may also  indicate a deregulation of 
signalling within the SCN. 
Analysis of the circadian rhythm in the mice is one way to monitor the effect of 
therapy on disease but it is a lengthy process if a large number of mice need to be 
examined.  
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1.2.5.2 Hyperactivity and a Reduced Sense of Danger 
Patients present with severe behavioural problems including aggression, 
hyperactivity and a decreased sense of danger (Cleary et al. 1993; Bax et al. 1995; 
Meyer et al. 2007; Valstar et al. 2008; Heron et al. 2011).  
MPS IIIB mice are hyperactive in circadian rhythm activity in the home cage in the 
light (Heldermon et al. 2007; Canal et al. 2010) or dark (Cressant et al. 2004). and in 
a 10 minute open field test the MPS IIIB mice were also hyperactive (Cressant et al. 
2004). However in an 8 minute open field test, half in light, half in dark, reductions 
in activity in both light and dark was observed (Li et al. 1999). Another study 
observed reduced rearing in the second 30 minutes of a 1 hour open field test but 
did not report overall differences (Fu et al. 2007).  
Similarly in MPS IIIA mice there are some papers that observe hyperactivity 
(Hemsley et al. 2005; Crawley et al. 2006) or hypoactivity (Hemsley et al. 2005; 
Crawley et al. 2006; Hemsley et al. 2007; Lau et al. 2008; Lau et al. 2010a; McIntyre 
et al. 2010) in a 3 minute open field test, but often no difference is observed.  
Therefore there is a discrepancy in the literature as to whether MPS IIIA and B mice 
are hyperactive, in line with the patient phenotype, or hypoactive which could 
correlate with later motor decline in patients.   
Mice are a prey species and display thigmotaxis where they avoid open spaces 
(Simon et al. 1994). A reduction in the sense of danger or anxiety can be inferred in 
mice as a reduction in thigmotaxis behaviour, this can be measured by examining 
the amount of time or entries into the centre of an open field or on the open arms 
of the elevated plus maze.  A reduced sense of danger in the elevated plus maze 
test was observed in MPS IIIB mice when performed in the dark (Cressant et al. 
2004) but not in the light (Fu et al. 2007).  Therefore it is not clear if the MPS IIIB 
mice display reduced thigmotaxis or have a reduced sense of danger. 
In MPS IIIA mice no difference in the time in centre of the open field was detected 
by Lau et al. (Lau et al. 2008), however this could be due to the small size of the 
open field used. In the elevated plus maze, MPS IIIA mice displayed reduced 
thigmotaxis or a reduced sense of danger, with a greater proportion of their path 
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length spent in the open arms at some ages, but no difference at others (Lau et al. 
2008; Lau et al. 2010a). Therefore it is also not clear if MPS IIIA mice display 
reduced thigmotaxis or have a reduced sense of danger. 
Due to the inconsistencies in the field we need to develop a reliable and consistent 
behavioural test before we can examine the effect of therapies on 
neurodegeneration in MPS IIIA mice.  
1.3 Current Therapies for Mucopolysaccharide and Related Diseases  
There are two main strategies for treating lysosomal storage disorders. To increase 
the rate of breakdown of substrates or to decrease the rate of production of 
substrate (substrate reduction therapy, SRT) sees Figure 1-5.   
The current treatments for MPS are outlined in Table 1-4; they are all treatments 
that aim to replace the deficient enzyme, either by direct delivery of the enzyme 
(ERT) or by introduction of a population of cells producing the enzyme. These 
treatments rely on the process of cross correction. 
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Figure 1-5 Strategies for treatment of lysosomal storage disorders 
WT = wild type (normal), LSD = lysosomal storage disorder, SRT = substrate reduction therapy. In 
normal individuals there is a balance between synthesis and degradation. In lysosomal storage 
disorders a reduction in the degradation of substrate results in accumulation of substrate. Adding 
the defective enzyme or factor increases the degradation of the substrate to reduce storage. 
Alternatively reducing the rate of synthesis to a level that can be degraded also reduces storage of 
the substrate. 
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Disease Alternative name Standard Treatment 
MPS IH Hurler Syndrome HSCT, ERT 
MPS IH/S Hurler-Scheie ERT, HSCT* 
MPS IS Scheie Syndrome ERT 
MPS IIA 
Hunter Syndrome ERT 
MPS IIB 
MPS IIIA Sanfilippo Syndrome A None 
MPS IIIB Sanfilippo Syndrome B None 
MPS IIIC Sanfilippo Syndrome C None 
MPS IIID Sanfilippo Syndrome D None 
MPS IVA Morquio Syndrome A ERT 
MPS IVB Morquio Syndrome B None 
MPS VI Maroteaux-Lamy Syndrome ERT, HSCT* 
MPS VII Sly Syndrome None 
MPS IX Hyaluronidase Deficiency None 
Table 1-4 Current standard treatments for MPS 
HSCT = Haematopoietic stem cell transplant, ERT = enzyme replacement therapy 
*HSCT performed if failed ERT  
Adapted from (Prasad et al. 2010) 
 
1.3.1 Cross Correction 
The mechanism of cross correction is outlined in Figure 1-6. During synthesis of 
lysosomal enzymes, mannose-6-phosphate (M-6-P) residues are added to sites on 
the enzyme. The M-6-P then binds to receptors that traffic the enzyme to the 
lysosome; however, a significant amount of enzyme does not bind to the receptors 
and is secreted. M-6-P receptors are present on the surface of the cell and take up 
the enzyme and traffic it to the lysosome, this can happen on the synthesising cell 
or another cell. This is known as cross correction (Fratantoni et al. 1968).  Non-
receptor mediated internalisation may also occur, although at a much lower level 
(Sly et al. 2006).  
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Figure 1-6  Enzyme production and trafficking to the lysosome 
Enzyme is produced in the rough endoplasmic reticulum and it is trafficked to the Golgi where 
mannose-6-phosphate (M-6-P) is added onto the protein. Most of the enzyme is trafficked to the 
lysosome by M-6-P binding to M-6-P receptors, however some will be secreted. The circulating 
enzyme can bind to M-6-P receptors on cells which traffic it into the lysosome. Non-receptor 
mediated cross correction can also occur but at a much slower rate. 
 
1.3.2 Enzyme Replacement Therapy 
Enzyme replacement therapy (ERT) is relatively effective at managing non-
neuronopathic forms of LSDs e.g. MPS IS. Replacement enzyme is delivered 
intravenously and taken up by mannose-6-phosphate receptors that are found on 
the surface of most cells.  Barriers to enzyme uptake, such as the blood brain 
barrier (BBB) and relatively avascular sites, preclude effective distribution of 
enzyme to sites of clinical need in severe forms of disease, thus limiting the 
effectiveness of ERT (Figure 1-7).  The BBB is made up of endothelial cells bound to 
each other by tight junctions which actively regulate the passage of 
macromolecules. Circulating enzymes and many other components of plasma are 
therefore excluded from the brain. Other regions where cross correction can be 
problematic include the growth plates of the bone which are poorly vascularised 
(McIntyre et al. 2008). 
Non-neuronopathic Gaucher disease was the first LSD to be treated with ERT, and 
ERT is now available for Fabry and Pompe diseases and MPS types I, II and VI 
(Germain 2005; Brady 2006; Beck 2007). Systemic ERT is not currently suitable for 
severe MPS diseases with neurological complications because the administered 
enzyme cannot cross the BBB. Therefore intravenous ERT is not currently a suitable 
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treatment for MPS IIIA or any other MPS where insufficient residual enzymatic 
activity is present in the CNS. 
  
Figure 1-7 Enzyme replacement therapy and haematopoietic stem cell transplant 
In enzyme replacement therapy (ERT) recombinant enzyme is delivered intravenously, it is then 
taken up by other cells by cross correction. However it is unable to pass through the blood brain 
barrier and little gets to avascular sites like bone growth plates. In a haematopoietic stem cell 
transplant (HSCT) haematopoietic stem cells (HSC) are transplanted into a recipient that has usually 
received a conditioning regimen. The HSCs repopulate the haematopoietic system and all these cells 
produce and secrete enzyme, this can cross correct cells. Circulating enzyme is still unable to cross 
the BBB but monocytes traffic from the bone marrow to the brain where they differentiate into 
microglial cells that produce enzyme within the brain that can cross correct neuronal cells. 
 
Weekly intravenous injections of enzyme are prohibitively expensive, in the UK MPS 
I treatment costs on average £144,000 per patient per year (Wraith 2006). A 
Chapter 1 – Introduction 
[Page 41] 
humoral immune response can also occur against the administered enzyme, which 
will reduce the half-life of the enzyme (Wraith et al. 2007). Therefore greater doses 
or more frequent doses will be necessary for effective therapy. In the canine model 
of MPS I, tolerising animals to exogenous IDUA decreased the production of 
antibodies and increased efficacy (Dickson et al. 2008). 
ERT is not suitable to treat MPS IIIA because the neurological phenotype is resistant 
to ERT due to exclusion of enzyme from the brain by the BBB (Wraith 2006).  
1.3.3 Stem Cell Transplantation 
Bone marrow transplantation (BMT), also known as haematopoietic stem cell 
transplantation (HSCT), is designed to provide corrective levels of enzyme and is the 
only curative therapy available for a small subset of lysosomal storage disorders. 
A myeloablative conditioning regimen is necessary to eradicate the patient’s bone 
marrow and marrow derived cells, then bone marrow or cord blood from a suitably 
matched donor is delivered. The donor cells repopulate the haematopoietic system 
and produce the deficient enzyme which circulates in the blood and can be taken 
up by peripheral organs via the M-6-P receptor. Whilst enzyme is unable to cross 
the BBB, bone marrow derived monocytes traffic across the BBB into the 
parenchyma of the brain and differentiate into microglia cells. These cells produce 
enzyme within the brain and mediate neurological cross correction (see Figure 1-7) 
(Priller et al. 2001; Streit et al. 2005). Church et al showed that in MPS I patients 
that received HSCT, those patients that received bone marrow from an unrelated 
donor had a lower urinary DS/CS ratio, which indicates a reduced storage of DS,  
than those transplanted with heterozygous cells from a related donor (Church et al. 
2007; Wynn et al. 2009b). This suggests that there may be an enzyme dose effect in 
HSCT in MPS I. 
HSCT is currently the most effective therapy for the severe form of MPS I (Hurler 
syndrome). A recent European study reported that of 93 patients who received 
cord blood transplants between 1995 and 2007, the three year survival rate is 77%. 
Of these, 97% achieved full chimerism and of these, normal enzyme activity were 
achieved in 97% of cases (Boelens et al. 2009). A more severe conditioning regimen, 
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using the chemotherapy drug Busulfan in combination with cyclophosphamide, 
improved engraftment and survival significantly to 93% after a single transplant 
(Wynn et al. 2009b), and this reflects current clinical outcomes for this disease in 
the UK.  
Despite the similarities between MPS I and III, HSCT is only effective in treating the 
neurological manifestations of MPS I but not MPS III, where no preservation of 
cognitive function has been observed (Vellodi et al. 1992; Shapiro et al. 1995; 
Sivakumur et al. 1999). In MPS IIIA, transplantation with donor umbilical cord blood 
that is homozygous for normal SGSH (Martin et al. 2006; Prasad et al. 2008; Prasad 
et al. 2010) was found to be more effective than transplantation with donor cells 
that are heterozygous for SGSH (Shapiro et al. 1995; Sivakumur et al. 1999) but the 
neurological pathology remains untreated. 12 of 19 children survived the cord 
blood transplant and the disease was stabilised in 9 patients. The two patients that 
were transplanted before 2 years of age have exhibited modest gains in cognitive 
function and their behaviour is slightly improved (Prasad et al. 2010). Therefore, it 
appears that an increase in enzyme activity due to use of a homozygous donor 
instead of a heterozygous donor can lead to some improvement in disease 
pathology, but it is probably still insufficient to correct the neurological symptoms. 
This suggests that there may be an enzyme dose response in MPS IIIA.  
In the mouse models of MPS IIIA (Lau et al. 2010a) and MPS IIIB (Heldermon et al. 
2010), bone marrow transplant was unable to correct the abnormal behaviour of 
the mice. In the MPS IIIB mice only 25% blood donor chimerism was achieved and 
1% of normal NAGLU activity in the brain (Heldermon et al. 2010). In MPS IIIA mice 
90% blood chimerism was achieved. There are several possible reasons for this; 
donor-derived cells may be unable to home to the brain and secrete enzyme, SGSH 
and NAGLU may not be secreted or taken up as well as IDUA in MPS I, or the 
enzyme requirement for a clinically significant response may be significantly higher 
in MPS IIIA than in MPS I. 
1.3.4 Substrate Reduction Therapy 
Substrate reduction therapy (SRT) aims to decrease the amount of substrate 
produced rather than increasing the rate of breakdown of the stored molecule 
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(Figure 1-5). This could be achieved using small molecule inhibitors that block 
enzymes involved in the production of GAGs. These inhibitors may be able to cross 
the BBB and penetrate tissue that does not respond to ERT or BMT. SRT is not 
currently routinely used in MPS diseases but it is in other lysosomal storage 
disorders. 
The proof of principle for the LSD field is N-butyldeoxynojirimycin (NB-DNJ) (Platt et 
al. 1994), which is an is an inhibitor of glycolipid synthesis, which has been used to 
successfully reduce storage of GM2 gangliosides in the Tay-Sachs mouse model 
(Platt et al. 1997) and to reduce GM2 ganglioside storage, delay the onset of 
disease and improve survival of Sandhoff mice (Jeyakumar et al. 1999). NB-DNJ 
(Miglustat) has been approved for mild to moderate non-neuropathic (type I) 
Gaucher’s disease (Cox et al. 2000) and more recently Niemann-Pick type C, and 
while it is less effective than ERT, it is a less invasive and cheaper alternative 
(Moyses 2003; Zimran et al. 2003).  It has been tested in a double blind clinical trial 
(ORPHA87555) in MPS III but was stopped due to a lack of improvement or 
stabilisation in behavioural and cognitive tests (Vineland adaptive behaviour scale, 
sleep disturbance questionnaire, hyperactivity measured by Conners scale and the 
development age determined by the Borel Maisonny Petit test) and despite 
Miglustat being detected in the brain, no difference was observed in cerebrospinal 
fluid ganglioside levels (Guffon et al. 2011). 
Rhodamine B inhibits chain elongation in GAG synthesis by inhibiting sugar 
precursor formation and/or glycosyl transferase (Kaji et al. 1991). This was the first 
SRT therapy for MPS tested in vivo in MPS IIIA mice (Roberts et al. 2006). This 
inhibitor was shown to decrease GAGs in urine, liver and brain, but no reduction in 
spleen size was observed. However in humans, Rhodamine B has caused mucous 
membrane and skin irritation and at effective doses it is quite toxic (Dire et al. 
1987), thus less toxic Rhodamine derivatives will need to be developed and 
evaluated.  
Genistein is an isoflavone that acts as a non-specific protein tyrosine kinase 
inhibitor. This has been shown to reduce GAG synthesis in MPS I, II, IIIA and IIIB 
patient fibroblasts by blocking epidermal growth factor receptor (Piotrowska et al. 
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2006). An open-label, pilot clinical study with children suffering from MPS IIIA and B 
was performed with oral genistein for 12 months. This study revealed no side 
effects, a significant decrease in urinary GAGs, a change in hair morphology, an 
improvement in cognitive functions in 80% of patients and stabilisation in 20% of 
patients. However, there was no placebo control in this study and behavioural 
measures were based on parents’ observations (Jakobkiewicz-Banecka et al. 2007). 
A recent study in our laboratory has demonstrated that in the mouse model of MPS 
IIIB, long term genistein treatment reduced lysosomal size, heparan sulphate and 
neuroinflammation in the cerebral cortex and hippocampus and corrected the 
aberrant behaviour of the MPS IIIB mice (Malinowska et al. 2010). A clinical trial is 
now being planned in Manchester. 
Reduced production of heparan sulphate may be an effective therapy for MPS IIIA. 
However, there is a risk that decreased production of HS will result in production of 
under-glycosylated proteins, which may cause deficient protein function. 
Additionally SRT therapy may work best as a supplement to other therapies that 
increase the degradation of substrate.  
1.3.4.1 Substrate Optimisation Therapy 
An alternative to substrate reduction is substrate optimisation; in MPS IIIA a 
disproportionately high proportion of 2-sulphated heparan sulphate is stored. 
Zacharon Pharmaceuticals have developed a 2-O sulphation inhibitor called ZP2345. 
This inhibitor led to a 30% reduction in HS storage in MPS IIIA mice over a 6 week 
period. Their hypothesis is that the 2-O sulphated heparan sulphate is the hardest 
form to degrade and by reducing this they have increased the rate of HS 
degradation (Brown et al. 2010).  
Therefore substrate optimisation therapy is another small molecule approach that 
should be able to penetrate the brain and may be beneficial to MPS IIIA patients; 
however it may work best when combined with a therapy to also increase enzyme 
activity.  
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1.4 Therapies in Development  
There is currently extensive research investigating different approaches to treat 
MPS diseases as outlined in Table 1-5, Gene therapy approaches will be discussed in 
section 1.6 after an introduction to gene therapy. 
Therapy Disease Pre Clinical Clinical Trial 
Modified ERT 
– insulin 
receptor 
antibody 
MPS I Rhesus monkeys (Boado et al. 
2008) 
 
Modified ERT 
– transferrin 
MPS I Mice (Osborn et al. 2008)  
Modified ERT 
– IGF-II 
MPS VII Mice (LeBowitz et al. 2004)  
Modified ERT 
– amino acid 
MPS VII Mice (Montano et al. 2008)  
Intrathecal 
ERT 
MPS I Rat (Belichenko et al. 2005) 
Dog (Kakkis et al. 2004) 
NCT00215527, 
NCT00786968, 
NCT00852358 
MPS II  NCT00920647 
MPS IIIA Mouse (Hemsley et al. 2008b) 
Dog (Hemsley et al. 2009b) 
NCT01299727, 
NCT01155778 
Convection 
enhanced ERT 
Type 2 Gaucher Rat (Lonser et al. 2005) NCT00244582 (Lonser et 
al. 2007).   
Niemann–Pick 
A 
Mice (Dodge et al. 2009)  
Neural Stem 
Cells 
Sandhoff Mice (Lee et al. 2007; 
Jeyakumar et al. 2009) 
 
Chaperone Type 1 Gaucher Fibroblasts (Chang et al. 2006) AT2101 NCT00446550, 
NCT00813865 
Tay-Sachs and 
Sandhoff  
Fibroblasts (Maegawa et al. 
2007) 
Pyrimethamine, 
NCT01102686 
Fabry Mice (Fan et al. 2007) Migalastat NCT00925301 
Nonsense 
mutation  read 
through 
Muscular 
dystrophy 
Muscle cells(Welch et al. 2007) NCT00847379 
MPS I Cells (Hein et al. 2004)  
SRT - 
Genistein 
MPS III Mice (Malinowska et al. 2010) Low dose  
(Piotrowska et al. 2008) 
High dose Genistein trial 
starting 2012 in 
Manchester 
SRT - 
Rhodamine B 
MPS IIIA Mice (Roberts et al. 2007)  
Substrate 
Optimisation 
therapy 
MPS IIIA Mice (Brown et al. 2010)  
Anti-
inflammatory 
Sandhoff and 
Niemann–Pick 
type C 
Mice (Jeyakumar et al. 2004; 
Smith et al. 2009). 
 
MPS IIIA Aspirin, Mice (Arfi et al. 2011)  
Table 1-5 Therapeutic strategies in development for MPS 
Examples of current therapies in development for neuropathic MPS and relevant disease where the 
approach has not been tested in MPS. Partly adapted from (Anson et al. 2011)  
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1.4.1 Receptor Modified Enzyme Replacement Therapy 
Enzymes involved in GAG catabolism are unable to cross the BBB due to their large 
size and non-lipid nature. Various protein fragments that can bind to receptors and 
enable transfer across the BBB have been coupled to lysosomal enzymes to 
facilitate their transfer across the BBB.  For example, IDUA has been coupled to an 
anti-insulin receptor antibody that enables active transport across the BBB and into 
the brain of Rhesus monkeys (Boado et al. 2008).  Also, transferrin has been 
coupled to IDUA which facilitated the uptake of IDUA into the brain and, in the 
short term, reduced stored GAGs in the cerebellum of MPS I mice (Osborn et al. 
2008). 
A fragment of the insulin-like growth factor II (IGF-II) has been fused to β-
glucuronidases (GUSB), the deficient enzyme in MPS VII, which allowed enhanced 
uptake via binding to the bifunctional IGF-II cation-independent M-6-P receptor 
(LeBowitz et al. 2004). Acidic amino acid tags have also been added to GUSB, which 
enhanced trafficking to bone and brain and increased persistence of the enzyme 
(Montano et al. 2008). 
Fc tagged GUSB has been constructed for in utero therapy. IgG antibodies are 
recognised by the Fc receptor, which mediates transcytosis across the syncytial 
trophoblast layer of the placenta into the foetus. The Fc tagged GUSB was able to 
pass into the foetus 100 times more than normal GUSB (Grubb et al. 2008). 
 None of these approaches have been attempted for MPS III. However in ongoing 
work in our laboratory we have observed that 9 out of 10 patients with MPS IH 
developed high titre antibodies against the enzyme following ERT (Saif, 
Unpublished data).  
1.4.2 Central Nervous System Enzyme Replacement Therapy 
ERT delivered directly into the brain via the intrathecal space or cerebrospinal fluid 
is in development (Savas et al. 2004; Hemsley et al. 2007; Hemsley et al. 2008b; 
Hemsley et al. 2009b). This may be an effective, though invasive therapy for MPS 
IIIA that targets the CNS. A murine in vivo study, funded by Shire Human Genetic 
Therapies Ltd., demonstrated reduction in storage of GAGs and the number of 
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ubiquitin-positive lesions. However in the cuneate nucleus region, the number of 
lesions did not decrease. This may indicate the irreversibility of some changes that 
occur in MPS IIIA brains (Hemsley et al. 2007). The majority of the mice that 
received the enzyme produced an antibody response against SGSH; this was not 
associated with adverse effects, although there was some mortality associated with 
the surgical procedure. A subsequent study used a higher dose of enzyme and 
demonstrated improved penetration of enzyme into the brain and a decrease in HS 
storage, the number of lysosomes and activated microglia (Hemsley et al. 2008b). 
CNS ERT has also been evaluated in a pilot study in the MPS IIIA Huntaway dog 
model. An increase in SGSH and a decrease in HS was observed in many brain 
regions however antibodies against recombinant human SGSH were present and 
moderately severe meningitis occurred (Hemsley et al. 2009b). The best results 
were in one dog that recieved the highest dose (Crawley et al. 2011), however this 
dose was approximately 5 times the dose that will be administered in the high dose 
of the ongoing clinical trial and approximately 45 times the low dose. Intrathecal 
ERT has also been evaluated in MPS VI cats with a tolerisation regimen that reduced 
the production of antibodies against the recombinant enzyme (Auclair et al. 2010).    
A clinical trial for intrathecal ERT in MPS IIIA has recently started in Manchester, 
funded by Shire Human Genetic Therapies Ltd (NCT01299727, NCT01155778).  
Recombinant human SGSH is being administered using an intrathecal drug delivery 
port either monthly or fortnightly. However the hyperactive behaviour of the MPS 
IIIA patients is making delivery into the spinal ports difficult. It has also been 
reported that drug delivery ports can become infected (Boviatsis et al. 2004).  
1.4.3 Convection Enhanced Central Nervous System Enzyme Replacement 
Therapy 
One of the biggest challenges in CNS ERT is the distribution of enzyme throughout 
the brain. Convection enhanced delivery is a system to deliver macromolecules in 
the brain through positive pressure over a longer period of time than a standard 
injection (Bobo et al. 1994). This approach has been evaluated in the Niemann–Pick 
A mouse model, a decrease in storage of sphingomyelin and a partial improvement 
in motor function was observed (Dodge et al. 2009), and in normal rats and 
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primates convection enhanced delivery has been used with glucocerebrosidase (the 
deficient enzyme in Gaucher’s disease) where enzyme was widely distributed in the 
brain (Lonser et al. 2005).  One neuropathic Gaucher disease patient was treated in 
a clinical trial of convection enhanced delivery of glucocerebrosidase 
(NCT00244582), in a 9 month follow up period the patient’s neurologic baseline had 
stabilised and there were no signs of toxicity (Lonser et al. 2007).  CNS ERT and 
convection enhanced delivery is reviewed in (Macauley et al. 2009). 
1.4.4 Neural Stem Cells 
In newborn Sandhoff mice, murine and human neuronal stem cells were 
transplanted. This resulted in an increase in enzyme activity to 4.5% of normal, a 
decrease in storage and improved survival. These neural stem cells are thought to 
replace lost neurons and provide a corrective source of enzyme within the brain 
(Lee et al. 2007).  In symptomatic Sandhoff mice neural stem cells increased 
enzymatic activity and improved behaviour, storage of glycosphingolipids and 
survival (Jeyakumar et al. 2009).  
None of these approaches have been tested in MPS IIIA, but it is a promising 
approach; however this approach might work best with autologous neural stem 
cells that have been transduced by a gene therapy vector to increase expression of 
the deficient enzyme (see section 1.6.3). 
1.4.5 Chaperone 
Missense mutations in lysosomal enzymes can result in them being degraded in the 
endoplasmic reticulum. However chaperones that bind to the enzyme can rescue 
the enzyme from degradation and facilitate correct folding of the enzyme. 
Chaperones are typically small molecules so they should be able to cross the BBB 
and increase enzyme activity within the brain. Chaperones are also typically 
inhibitors of the enzymes at high concentrations so low concentrations must be 
used. 
The first example of this type of therapy in lysosomal disease is in Fabry disease. 1-
Deoxy-galactonojirimycin (DGJ), an active site inhibitor, was administered to Fabry 
fibroblasts in low concentrations (Fan et al. 1999) and to mice expressing human α-
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galactosidase containing the R301Q missense mutation, this resulted in an increase 
in α-galactosidase (Fan et al. 2007). DGJ, also known as Migalastat hydrochloride or 
AT1001, is currently in phase III clinical trial (NCT00925301) (Fan et al. 2010). There 
is also a clinical trial in Type 1 Gaucher using AT2101 (Isofagomine tartrate, 
NCT00446550, NCT00813865) and in Tay-Sachs and Sandhoff Disease using 
Pyrimethamine (NCT01102686). 
Chaperones could be used to treat those MPS IIIA patients that have missense 
mutations that benefit from chaperone therapy. 2-acetamido-1,2-
dideoxynojirimycin (2AcDNJ) and 6-acetamido-6-deoxycastanospermine (6AcCAS) 
have been identified as potential chaperones for MPS IIIB (Ficko-Blean et al. 2008) 
and glucosamine is a potential chaperone in MPS IIIC (Feldhammer et al. 2009). 
1.4.6 Nonsense Mutation Read Through 
Nonsense mutations give rise to UAA, UAG or UGA codons in the mRNA, this results 
in translational termination and mRNA decay (Mendell et al. 2001). Initially 
Gentamycin was used as the pharmacological agent, and results in stop codon read 
through, however toxic side effects limit the effectiveness of the compound. 
Gentamycin has been used in MPS I fibroblasts containing Q70X and W402X 
mutations and successfully increased enzymatic activity (Hein et al. 2004).  
PTC124 (Ataluren) is a newer compound that induces read through of nonsense 
mutations and has been evaluated in human muscle cells from muscular dystrophy 
patients and in mdx mice where it successfully increased dystrophin production 
(Welch et al. 2007). This led to a clinical trial, however the phase IIb study was 
terminated in 2010 because the primary endpoint of improved walk distance in 6 
minutes was not met (NCT00847379). The use of nonsense mutation read through 
therapy is reviewed in more detail in (Beck 2010; Smid et al. 2010). 
In summary this approach may be applicable to those patients with suitable 
mutations but so far it has not been evaluated successfully. However being a small 
molecule based treatment it is likely to be able to penetrate and treat the brain.  
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1.4.7 Anti-inflammatory 
Neuroinflammation is present in many LSDs including MPS IIIA. In Sandhoff and 
Niemann-Pick disease type C1 mice, non-steroidal anti-inflammatory (NSAID) 
treatment delayed the onset of disease and improved the survival (Jeyakumar et al. 
2004; Smith et al. 2009).  
In MPS VI rats the anti-TNF-α drug Remicade had a beneficial effect  in reducing 
joint inflammation and pathology (Simonaro et al. 2010) and has a greater effect 
using the rat-specific anti-TNF-alpha drug, CNTO1081, and in combination with ERT 
(Eliyahu et al. 2011). In MPS IIIA mice, 6 months of aspirin treatment reduced the 
expression of neuroinflammatory genes and oxidative stress genes but had little or 
no effect on apoptosis related gene expression (Arfi et al. 2011). Unfortunately, this 
study did not examine any other pathological markers of disease or behaviour. 
Therefore anti-inflammatory treatment in MPS III could be beneficial in 
combination with a treatment that would reduce the storage of GAGs.  
1.4.8 Combination Therapies 
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in conjunction with NB-
DNJ, a substrate reduction therapy designed to reduce lysosomal storage, has 
shown a synergistic effect in a mouse model of Sandhoff disease (Jeyakumar et al. 
2004). The mice lived longer, maintained their coordination and strength longer 
than untreated controls and had fewer activated astrocytes and microglia in the 
brain. Similar improvements were also observed in Niemann-Pick disease type C  
mice (Smith et al. 2009) 
In the Sandhoff mouse model a synergy was observed with substrate reduction 
therapy with NB-DNJ or NB-DGJ, and neural stem cell transplant with an 
improvement in survival (Lee et al. 2007).  Again, none of these approaches have 
been tested in MPS IIIA.  Additionally HSCT has also been combined with SRT by NB-
DNJ in Sandhoff mice and there was an improved life expectancy and motor 
function, however GM2 gangliosides were not reduced further (Jeyakumar et al. 
2001). 
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1.4.9 Gene Therapy  
Gene therapy intends to provide a permanent source of enzyme in deficient cells 
that is sufficient to overcome the enzyme deficiency and may also be able to cross 
correct other cells (Ponder et al. 2007). Gene therapy can be used to incorporate 
functional copies of the gene into the patient’s DNA, which are then transcribed 
and translated in the long term to produce active enzyme. This approach may 
provide an extremely powerful treatment for lysosomal storage disorders, and is 
the focus of this study. 
 
1.5 What Is Gene Therapy? 
The main gene therapy approaches include gene replacement, gene repair or gene 
addition. Gene replacement aims to replace the mutated gene with the correct 
version of the gene. Low levels of homologous recombination limit the efficacy of 
this approach (Shesely et al. 1991). Gene repair aims to correct the mutated portion 
of the gene; however, this technology is not currently as advanced as gene addition 
(Brenner 1999; Parekh-Olmedo et al. 2007). The first two approaches have the 
advantage that the gene is still controlled correctly by the cell.  
The third and most popular approach to gene therapy is gene addition. This 
approach seeks to add a new copy of the gene to the cell where it can be 
transcribed and translated. The gene can either integrate into the genome or be 
maintained episomally. Regardless of the approach, gene therapy must achieve 
several things: i) successful delivery of the gene to the target cells, ii) avoidance of 
an immune response, iii) localisation to the nucleus, iv) adequate and controlled 
expression of the target gene(s) and v) low toxicity. 
1.5.1 Gene Therapy Vectors 
The method of gene delivery to target tissues and cells is an area of intensive 
research. It can be broadly broken down into two categories, non-viral and viral 
vector delivery. The differences between the main vectors currently in use are 
summarised in Table 1-6. 
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 Retroviral 
Vector 
Lentiviral 
Vector 
Adenoviral 
Vector 
Adeno-
associated viral 
Vector 
Liposomes  
(non- viral) 
Genome RNA RNA Linear dsDNA ssDNA Circular DNA 
Vector Space/kb 6 to 8 6 up to 30* 4.5 20+ 
Integrates into 
genome 
Yes Yes Very rarely Very rarely No 
Titre (viruses 
only) (pfu/ml) 
1x10
10
 1x10
10
 5x10
13
 5x10
13
 n/a 
Expression 
Duration 
Long term Long term Transient Long term Transient 
Infects Non-
Dividing cells 
No Yes Yes Yes Yes 
Advantages Stably 
integrates 
into the 
genome 
Can transduce 
non-dividing 
cells, stably 
integrates 
Large capacity, 
can transduce 
non-dividing 
cells 
Can transduce 
non-dividing 
cells, less 
immunogenic 
than adenovirus 
Large capacity 
Disadvantages Can cause 
oncogenesis, 
cannot 
infect non-
dividing cells 
Smaller than 
retroviruses, 
can cause 
oncogenesis 
Transient 
expression, 
immunogenic 
Small capacity, 
variable 
expression 
Transient 
expression, does 
not integrate, 
low transduction 
efficiency 
Table 1-6 A comparison of gene therapy vectors 
* Gutless vectors 
 
1.5.2 Non-viral Vectors 
A non-viral vector needs to be able to successfully deliver the DNA to the target cell 
without being toxic to the target cell and without the DNA being degraded both 
before and after it has entered a cell. Therefore DNA is frequently modified or 
encapsulated to avoid degradation but once inside the cell, the DNA needs to be 
released to function. 
Naked DNA is rapidly degraded in vivo by nucleases and is very hydrophilic so it 
cannot naturally transfect cells. Cationic liposomes, comprised of plasmid DNA 
surrounded by amphiphilic molecules, contain a positively charged head group 
which binds to the DNA and a lipid soluble tail that forms the liposome (Felgner et 
al. 1987). They usually have a net positive charge (Behr et al. 1989), so that they can 
bind to negatively charged DNA and to the plasma membrane for internalisation by 
receptor mediated endocytosis (Escriou et al. 1998). Another advantage of the 
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liposome is that they are resistant to nuclease digestion (Wheeler et al. 1999). 
However, they are not usually targeted to the nucleus, meaning that they must wait 
for the nuclear envelope to break down on replication before they can be 
expressed; hence they can only transfect dividing cells. They are not maintained 
episomally upon cell replication thus genes from these vectors are only expressed 
transiently.  
An alternative to cationic liposomes is polyethylenimine (PEI) which binds to the 
phosphate of DNA through amino groups. It has a considerable advantage over 
most liposomal formulations in that it is much more stable in serum as the strong 
positive charge attracts negatively charged serum proteins. PEI DNA complexes are 
taken up by receptor mediated endocytosis and PEI pH buffering allows lysosomal 
escape so that DNA can be transcribed (Boussif et al. 1995; Godbey et al. 1999). 
However nuclear targeting is still a problem.  
Nuclear targeting has been improved by using DNA with steroid derivatives bound 
to it. This was then delivered by an adenoviral vector and the steroid derivatives 
bound to and activated glucocorticoid receptors which then traffic to the nucleus, 
this is called steroid-mediated gene delivery (SMGD) (Rebuffat et al. 2001). This 
approach has also been used with PEI and the glucocorticoid steroid 
dexamethasone (Mi Bae et al. 2007).  The transfection efficacy and nuclear import 
have been further improved in vitro and in vivo using triamcinolone acetonide 
rather than dexamethasone with PEI (Ma et al. 2010). However transfection will be 
transient as the plasmid will not be replicated on cell division. 
Persistent expression of non-viral vectors is a challenge, however long term 
expression has been achieved with the use of scaffold/matrix attachment regions 
(S/MARs); these sequences are present in the eukaryotic genome and mediate the 
localisation of genes to the nuclear scaffold.  The presence of S/MARs in plasmid 
DNA has been shown to inhibit chromatin silencing and promote stability and thus 
providing long term expression (Argyros et al. 2008). Expression can also be 
enhanced by targeting the plasmid to the nucleus, which can be achieved using a 
nuclear localisation peptide attached to TetR protein that binds to the plasmid TetO 
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site (Vaysse et al. 2004). Targeting the plasmid to the nucleus also confers the 
ability to achieve expression in non-dividing cells. 
The S/MAR approach can be improved by using minicircle vectors.  The presence of 
bacterial genes in plasmids can cause immunogenicity through the presence of 
prokaryotic CpG islands and potentially silencing of gene expression (Argyros et al. 
2011). Therefore Cre recombination has been utilised to recombine plasmids into 
minicircle vectors which lack bacterial proteins, this increases transduction and thus 
expression (Bigger et al. 2001). The use of S/MAR minicircles has enhanced both the 
persistence and expression in vivo (Argyros et al. 2011).   
An alternative approach to maintain long term expression is to integrate into the 
genome.  Sleeping beauty transposons are a class of non-viral vector that integrate 
into the genome using SB transposase. These vectors integrate randomly into the 
genome, although they do favour AT rich regions, and may be able to target specific 
regions by modifying the transposase with zinc finger proteins (Yant et al. 2007). 
Zinc finger nucleases are proteins that can direct sequence specific cleavage of 
DNA. They comprise of DNA sequence specific zinc fingers that bind to the DNA and 
a cleavage domain derived from FOKI. They can be used to perform targeted 
mutagenesis of a gene by forming a double strand break, or removing a gene by 
cutting at two points. Alternatively they can be used to repair a gene by 
homologous recombination. They can also be used to perform targeted gene 
addition into a specified locus. The use of zinc finger nucleases are well reviewed by 
Carroll 2011 (Carroll 2011). They are currently in clinical trial to knock out CCR5, the 
co-receptor for HIV-1, in CD4+ T-cells to produce HIV resistance (NCT00842634 and 
NCT01044654) (Perez et al. 2008). They do however have some drawbacks, 
including off target DNA cleavage that is potentially toxic and oncogenic. They 
require the delivery of both the zinc finger nucleases and DNA to the cell, which 
could be difficult in vivo but is less of a problem for ex-vivo transduction of stem 
cells.  
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1.5.3 Viral Vectors 
As a consequence of their natural development, viruses possess many of the 
characteristics required of a gene therapy vector. They can target cells, insert their 
DNA, avoid lysosomal degradation and express their genes. Therefore, the 
modification of viruses to generate gene therapy vectors has been extensively 
studied and is reviewed in the following sections. 
1.5.3.1 Adenoviral Vectors 
Adenovirus (Ad) is a double stranded DNA virus, containing a packaging signal and 
several genes flanked by long terminal repeats. It is a common human pathogen 
that causes respiratory diseases. Adenoviral vectors only provide transient 
expression as they are maintained episomally, are not replicated during cell division 
and have high immunogenicity in humans. In first generation adenoviral vectors the 
E1 or E3 region was removed, this makes about 3kb available for a transgene. For 
production E1 must be provided in trans but E3 is not necessary. However 
expression of the remaining viral proteins elicits an immune response (Yang et al. 
1996). Therefore in the second generation vector E1 and E3 were removed and E2 
and E4 regions were inactivated. Unfortunately in vivo immunogenicity persisted 
due to residual expression of viral proteins. “Gutless” adenoviral vectors were 
created that contain no viral genes except the long term terminal repeats (LTRs) 
that allow packaging of the DNA into the virus. In order to produce “gutless” 
adenovirus, a helper virus is necessary to provide the proteins for virus production. 
The “gutless” adenovirus maintains gene expression for longer and can accept 
larger gene inserts (Schiedner et al. 1998; Morral et al. 1999).  Humans have 
immunity to most adenoviral coat proteins meaning that this response is difficult to 
avoid. Therefore polyethylene glycol (PEG) has been used to coat adenoviral 
vectors, which has increased their half life in vivo and increased their distribution 
around the body. The PEGylation decreases the clearance of the vector by 
antibodies and decreases the activation of the cellular immune response (Eto et al. 
2008). Adenoviral vector development and utility is reviewed in (Alba et al. 2005; 
Haisma et al. 2011). 
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Adenoviral vectors may be useful in treating cancers where long term expression is 
not required and first generation adenovirus is easy to grow in high titres. The 
immune response they elicit can also be harnessed in vaccination. However, they 
are not ideal for the treatment of genetic disorders such as MPS where long term 
correction is required. Adenovirus could be re-administered but continual re-
administration of the virus will trigger an even more severe immune response. 
1.5.3.2 Adeno-associated Viral Vectors (AAV) 
Adeno-associated viruses are small single-stranded DNA viruses that belong to the 
parvovirus family (reviewed in (Buning et al. 2008)). They are simple viruses 
consisting of two open reading frames of rep and cap flanked by inverted terminal 
repeats. They require the co-transfection with Ad or other viruses for replication. 
Rep encodes proteins involved in genome replication, transcriptional control, 
integration and encapsidation of the genome in capsids. Cap encodes three viral 
capsid proteins VP1, 2 and 3. Modification of these capsid proteins results in 
different cell tropisms of AAV serotypes.  Modifications of this virus to remove the 
Rep and Cap genes free up around 4kb of space for a transgene and promoter. AAV 
vector is normally produced by transient transfection of cells with a vector 
containing the transgene flanked by the ITRs, a plasmid containing rep and cap and 
an adenoviral helper plasmid. After transfection with the plasmids, the cells are left 
while vector is produced in the cell and are then lysed to harvest the vector and 
concentrated by density gradient centrifugation and/or column chromatography.  
AAV vectors can transduce non-dividing cells and do not stimulate the immune 
system to the same extent as adenoviral vectors (Xiao et al. 1997). Different 
serotypes of AAV have different capsids and can be used to transduce different cell 
types (see Table 1-7) in vivo, they are reviewed in (Vandenberghe et al. 2009) and 
(Buning et al. 2008).  
Initially a specific integration site in the genome on the short arm of chromosome 
19 was identified (19q13.3-qter) (Berns et al. 1975; Berns et al. 1995). 
Unfortunately, this specificity is present in wild type AAV but is rare in AAV vectors 
(Rutledge et al. 1997) and thus they can cause insertional mutagenesis in neonatal 
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mice (Donsante et al. 2001). However an increase in oncogenesis has not been 
observed in adult mice (Li et al. 2011). 
Capsid Target tissues 
AAV1 Muscle, Liver, Joints, Heart 
AAV2 Muscle, Liver, Joints, Lung, Eye, CNS 
AAV4 Eye, CNS 
AAV5 Liver, Lung, Eye, CNS 
AAV6 Muscle, Liver, Heart, Lung 
AAV7 Muscle, Liver 
AAV8 Muscle, Liver, Eye 
AAV9 Liver, Heart, Lung, CNS 
AAVrh.10 Lung, CNS 
Table 1-7 AAV capsid tropism 
AAV vector capsid tissue tropism adapted from (Vandenberghe et al. 2009) 
These vectors have been shown to provide long term expression of factor IX for five 
months in murine liver (Koeberl et al. 1997), expression for 4 years in the canine 
model of haemophilia by intramuscular  injection (Herzog et al. 1999) but, in phase 
II clinical trials using AAV2, a large immune response to this serotype was observed 
in haemophilia A patients with a commensurately limited correction (Kay et al. 
2000; Manno et al. 2003; Murphy et al. 2008). AAV vectors have a limited amount 
of space for the insertion of therapeutic genes and also have a small risk of 
insertional mutagenesis. Their expression can be variable and immune responses 
can occur, although this is dependent on the serotype of the virus. They are 
currently used in clinical trial in immune privileged sites such as the retina (Buch et 
al. 2008), but with immune suppression during transduction or different capsids 
they could be more widely applicable. The therapeutic use of AAV is well reviewed 
in Mingozzi et al. (Mingozzi et al. 2011).  
1.5.3.3 Retroviral Vectors 
Retroviral derived vectors are a commonly used gene therapy vector. They can 
accept an 8 kb insert, integrate randomly into the host genome and are capable of 
very long term expression. Disadvantages include variable expression, particularly 
from viral promoters, an inability to infect non-dividing cells and the risk of 
insertional mutagenesis.  
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Native retroviruses interact with receptors on the surface of cells via envelope 
proteins resulting in membrane fusion or phagocytosis. The vector core is released 
and virus RNA is converted to DNA using the reverse transcriptase enzyme, which 
the virus encodes. This pre-integration complex then gains access to the host’s 
genome during mitosis when the nuclear envelope breaks down.  
Moloney murine leukaemia virus (MoMULV) was the first viral vector that was 
developed for gene therapy (Dani 1999). The first stage of this process was to 
remove the viral genes, gag, pol and env, to make space for target gene insertion. 
The gag gene encodes matrix proteins that are necessary for viral replication, pol 
encodes reverse transcriptase, an enzyme that converts the RNA genome of the 
virus to DNA for insertion in to the host genome, and env encodes the envelope 
protein. Gag and pol are provided in trans by transient expression from ‘helper’ 
vectors, or producer cell lines. Env is usually replaced with an envelope from a 
vector that can infect cells of the same species (ecotropic) or several different 
species (amphotropic). Removing gag, pol and env genes also makes the virus 
replication incompetent as once the retrovirus has infected a cell it will be 
incapable of producing new viral particles. Sequence homology between the 
‘helper’ vectors and the target gene vector is low to minimise the risk of 
recombination and thus production of replication competent virus in the host 
(Markowitz et al. 1988b; Markowitz et al. 1988a). 
1.5.3.4 Lentiviral Vectors 
Lentiviruses, including human immunodeficiency virus (HIV), belong to the 
retrovirus family and have a similar life cycle with some more complex capabilities 
than retroviruses.  Lentiviral fusion occurs in a similar way, but lentiviral pre-
integration complexes are imported directly into the nucleus as they hijack nuclear 
import proteins (Lebeck et al. 1992). As before, DNA is integrated into the genome 
in open chromatin regions where it is transcribed and some of it is translated using 
the host’s cellular machinery to produce proteins needed for new virus formation. 
Lentiviruses are more complicated than standard retroviruses as they contain 
additional viral genes encoding regulatory elements transactivator (tat) and p19 
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(rev) and genes that enhance pathogenicity including virion infectivity factor (vif), 
viral promoter r (vpr), viral protein u (vpu) and negative replication factor (nef). 
As for retroviral vectors, lentiviral vectors have their gag and pol genes provided in 
trans. The env gene is usually replaced with an envelope from a virus that can infect 
many different species and cell types – typically the Vesicular Stomatitis Virus G 
protein (VSV-G). The virulence factors vif, vpr, vpu and nef were removed from the 
genome constructs of the first generation vectors and gag/pol/rev/tat and VSV-G 
env were provided in trans on 2 separate plasmids (Figure 1-8). To improve safety in 
second generation vectors, tat can be removed if the 5’ viral LTR is replaced with 
typically a cyclomegalovirus (CMV) promoter. Self-inactivating (SIN) vectors also 
contain a 400bp deletion in the 3' LTR, which includes the TATA box. This is 
replicated during viral reverse transcription to the 5' LTR within the transduced cell 
and results in target gene integration and two deleted LTRs. This improves safety 
because the viral promoter is disrupted, so new copies of the vector cannot be 
made. It also reduces the ability for recombination with wild-type HIV and 
decreases the chance of spontaneously generating a replication competent virus 
(Zufferey et al. 1998). 
The vector retains the LTR which contains integration signals and a packaging signal 
but, most viral genes have been removed to make them replication incompetent 
and to create space for the gene of interest and an internal promoter to drive 
expression.  
Third generation vectors usually also provide rev in trans on a separate plasmid to 
gag/pol which provides a 4 vector production system designed to further minimise 
the chance of recombination between plasmids. 
Other factors have been added to lentiviral vectors to make them more efficient. 
The woodchuck hepatitis post-transcriptional regulatory element (WPRE) and rev 
response element (RRE) enhance expression of transgenes by increasing nuclear 
export by CRM-I (Donello et al. 1998; Klein et al. 2006).  During the synthesis of the 
second DNA strand after transfection, the central poly-purine tract (cPPT) causes 
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the production of a 99 nucleotide DNA ‘flap’ which assists in the nuclear import of 
the viral genome into the host nucleus (Van Maele et al. 2003). 
Lentiviral vectors stably integrate into the host genome semi-randomly; they, like 
retroviral vectors, can cause oncogenesis by activating an oncogene or knocking out 
a tumour suppressor gene. Lentiviral vectors are less likely to cause insertional 
oncogenesis because they are more likely to integrate into a gene rather than its 
promoter region (Schroder et al. 2002; Wu et al. 2003). Thus are more likely to 
knock out one of two tumour suppressor genes by integrating into the gene than 
activating an oncogene by integrating into the promoter. 
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Figure 1-8 Production of lentiviral vector by transient transfection of 293T cells 
293T cells are transfected with plasmids, one carrying the lentiviral genome construct expressing the 
transgene driven by an internal promoter and containing modified LTRs and a packaging signal (Ψ), 
one containing gag and pol and the other env. The gag and pol genes are expressed from a plasmid 
under the RSV promoter. The env gene under a RSV promoter (usually VSV-G pseudotype) produces 
proteins that are incorporated into the plasma membrane. The Ψ signal in the viral genome enables 
the packaging of RNA into a capsid and the lentiviral vector particle buds off from the transfected 
cell into the media. The media is collected and centrifuged to concentrate the viral vector particles. 
 
1.5.4 Gene Therapy Safety 
The safety of gene therapy is a key concern. However, it is also important to 
remember the context; if a disease is untreatable, as many genetic disorders are, 
then the risks associated with the therapy become acceptable. Several possible 
risks are associated with gene therapy, some of which apply solely to the use of 
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viral vectors. There may be a large immune response to the vector, as occurred in 
an adenoviral gene therapy trial for ornithine transcarbamylase deficiency 
(Marshall 1999; Wilson 2009). The vector could be or become replication 
competent, allowing it to infect many cells in the patient with potentially toxic 
effects, although this is unlikely as all vectors are tested for the inability to replicate 
prior to testing in patients.  Integrating vectors could insert into the genome 
disrupting a tumour suppressor or promoting an oncogene and cause cancer and 
germline transduction. 
Retroviral vectors have been utilised in the current clinical successes of X-SCID (X-
linked severe combined immunodeficiency) gene therapy (Hacein-Bey-Abina et al. 
2003). X-SCID is an inherited genetic disorder caused by mutations in the cytokine 
receptor common γ chain (IL2RG) resulting in very low T-cell numbers. Patients can 
be treated with a bone marrow transplant however suitable donors do not always 
exist. There have been two X-SCID clinical trials, one based in France lead by Marina 
Cavazzana-Calvo and Alain Fischer and the other in the UK lead by Adrian Thrasher 
and Bobby Gaspar. In both cases autologous CD34+ HSCs were modified to express 
IL2RG using a retroviral vector. Nineteen out of the twenty patients across the two 
trials were treated successfully (Cavazzana-Calvo et al. 2007; Gaspar et al. 2011a). 
However, the insertion of the gene into the host genome caused activation of 
oncogenes and resulted in leukaemia in five of the patients, of which one has died 
but the other four have recovered their T-cell repertoire and are essentially leading 
normal lives (Hacein-Bey-Abina et al. 2003; Fischer et al. 2011). Bone marrow stem 
cells are mostly non-cycling (Lord et al. 1993) and are therefore more difficult to 
transduce using retroviruses (Miller et al. 1990) therefore the HSCs in this trial were 
transduced three times (Cavazzana-Calvo et al. 2000; Gaspar et al. 2004) to allow 
for sufficient transduction. This may have led to selection of the fastest growing 
cells and cells with more leukaemic potential. Additionally, the oncogenesis was 
associated with integration into LIM domain only 2 (LMO2) locus and appeared to 
be specific to X-SCID, as in ADA-SCID trials there was not the preference for LMO2 
integration and no oncogenesis has occurred (Ferrua et al. 2010; Fischer et al. 
2011).  Leukaemia has also occurred in one patient who recieved ex vivo retroviral 
gene therapy for Wiskott-Aldrich syndrome (WAS), which was also associated with 
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the LMO2 locus (Fischer et al. 2011). Therefore self inactivating (SIN) vectors have 
been designed that contain an internal promoter rather than using one in the LTR 
to drive expression of the transgene. This reduces the activation of genes 
neighbouring the integration site (Yu et al. 1986).  
Additionally it has become clear that retroviral integration is not a completely 
random process. Using the retrovirus murine leukaemia virus (MLV) and the human 
cancer HeLa cell line, it appears that retroviruses preferentially insert into 
transcriptional start regions. This can lead to activation of oncogenes and disruption 
of tumour suppressor genes (Wu et al. 2003).  A lentiviral vector was used to 
transfect the human lymphoid cell line SupT1. Insertional analysis revealed that 
lentiviruses appear to insert preferentially into active genes and local hotspots. 
Therefore, lentiviruses may have a lower risk of insertional oncogenesis than 
retroviruses, as they integrate within a gene they are less likely to activate an 
oncogene. Lentiviral integration may still disrupt tumour suppressor genes but it is 
preferential to disrupt one copy of two of a tumour suppressor gene rather than 
activating an oncogene (Schroder et al. 2002). 
A study of 3127 integration sites from HIV, MLV and avian sarcoma-leukosis virus 
(ASLV) in human cells, confirmed that lentiviruses have a preference for active 
genes, and retroviruses tend to integrate into the promoter regions of active genes 
(Mitchell et al. 2004). The MLV retrovirus favoured integrating into the CpG islands 
(regions where a cytosine nucleotide is followed by a guanine nucleotide) which are 
found in 72% of human promoters (Saxonov et al. 2006) but are sparsely located 
elsewhere in the genome. Lentiviruses appear to avoid these CpG islands (Mitchell 
et al. 2004). 
The risk of causing an immune response that causes harm to the patient or 
decreases the efficacy of the therapy is an important consideration.  To reduce this 
risk it is advisable to choose use a less immunogenic vector that reduces the 
expression of viral proteins.  
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1.6 Gene Therapy for MPS Disease 
MPS, like other lysosomal disorders, is a good target for gene therapy because tight 
regulation of the gene is not likely to be needed and cross correction occurs, 
therefore all cells do not need to be transduced for enzymatic correction to take 
place. There are several different delivery routes outlined in Figure 1-9 and Table 
1-8. 
 
Figure 1-9 Routes of gene therapy delivery 
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Therapy Disease Pre Clinical Clinical Trial 
Intravenous- non 
viral  
MPS I (Aronovich et al. 2007; Aronovich et al. 
2009; Osborn et al. 2011) 
 
MPS VII (Aronovich et al. 2007; Richard et al. 2009)  
Intravenous- viral MPS I (Hartung et al. 2004; Di Domenico et al. 
2005; Kobayashi et al. 2005; Liu et al. 
2005b) 
 
MPS IIIA (Anson et al. 2007; McIntyre et al. 2008; 
McIntyre et al. 2010) 
 
MPS VII (Daly et al. 2001; Stein et al. 2001)  
Intravenous- BBB 
Permeabilising - 
Mannitol 
MPS IIIA (Anson et al. 2007; McIntyre et al. 2008)  
MPS IIIB (McCarty et al. 2009)  
Intravenous –BBB 
Penetrating 
Vector 
MPS IIIB (Fu et al. 2011)  
Intravenous –BBB 
transduction 
MPS VII (Chen et al. 2009)  
Gene therapy –
CNS  
MPS I AAV Mice, (Desmaris et al. 2004),  
Dog (Ciron et al. 2006), 
 Primate (Ciron et al. 2009) 
 
MPS IIIA Lentivirus (McIntyre et al. 2010), 
AAV (Fraldi et al. 2007) 
AAV SAF-301 
NCT01474343 
Started 2011 
MPS IIIB AAV (Fu et al. 2002; Cressant et al. 2004; Fu 
et al. 2007; Fu et al. 2010) 
Lentivirus (Di Domenico et al. 2009) 
AAV estimated 
starting 2012 
MPS VII AAV (Frisella et al. 2001; Liu et al. 2005a; 
Cearley et al. 2007) 
Lenti (Brooks et al. 2002; Bielicki et al. 2010) 
 
Battens 
Disease 
AAV (Passini et al. 2006) NCT00151216 
(Worgall et al. 
2008), 
NCT01161576 
Gene therapy -
HSCT 
MPS I Retrovirus (Zheng et al. 2003)  
MPS I Lentivirus (Visigalli et al. 2010) In planning stage 
MPS IIIA Lentivirus – this thesis  
MPS IIIB Retrovirus (Zheng et al. 2004)  
Gene therapy - 
microglia 
MPS IIIA (Robinson et al. 2010)  
Gene therapy - 
neural stem cells 
MPS VII (Meng et al. 2003)  
Gene therapy – 
stromal cells 
MPS VII (Sakurai et al. 2004)  
Gene therapy – 
macrophages 
MPS VII (Ohashi et al. 2000)  
Table 1-8 Gene therapy strategies in development for MPS 
Examples of gene therapies in development for neuropathic MPS and relevant diseases where the 
approach has not been tested in MPS. Partly adapted from (Anson et al. 2011)  
 
 
Chapter 1 – Introduction 
[Page 66] 
1.6.1 Intravenous Gene Delivery 
The easiest route of delivery of gene therapy vector is by intravenous injection. 
1.6.1.1 Intravenous Non-viral Gene Therapy 
In non-viral gene therapy, plasmids need to be assisted in entering cells unlike viral 
vectors. One method is to deliver plasmid in a large volume very rapidly via the tail 
vein in rodents (Budker et al. 1996; Hodges et al. 2003). This method is called 
hydrodynamic delivery and results in transfection of the hepatic cells with the 
plasmid. Plasmid DNA containing the GUSB gene was delivered hydrodynamically 
via the tail vein of MPS VII mice in a volume equivalent to 10% of the mouse’s 
weight, over 5 seconds (Richard et al. 2009). 
This resulted in a high level of GUSB expression in the liver and 100-500% of normal 
activity in the serum at day 2-8, but by 60 days post injection less than 5% of 
normal activity remained. There was a significant reduction in GAG storage in the 
liver, spleen, kidney, and critically, in the brain 28 days after injection. Despite the 
significant increase in GUSB enzyme activity to 1% in the brain and the decrease in 
GAG storage by 50%, there was poor correction of cellular storage suggesting that 
the enzyme activity in the brain were insufficient. It was demonstrated that the 
GUSB activity found in the brain was not due to the presence of plasmid in the brain 
as there was no increase in GUSB mRNA levels in the brain, therefore the enzyme 
must have crossed the BBB. This uptake could have been due to the high levels of 
circulating enzyme saturating the few M-6-P receptors that are present or by a 
phagocytic process (Richard et al. 2009). 
To improve the persistence of gene expression, minicircles can be used to reduce 
gene silencing and reduce the immune response by removing pro-inflammatory 
hypo-methylated CpG motifs found in bacterial DNA. This has been evaluated in 
MPS I mice to provide long term expression (Osborn et al. 2011). The minicircle 
DNA was delivered by hydrodynamic tail vein injection and CD4 and CD8 depleting 
antibodies were used for immune suppression. The storage of GAGs in the visceral 
organs was reduced to normal levels and enzyme was expressed for 100 days with a 
10 fold drop in expression, however, further evaluation of this therapy is necessary 
to assess the therapeutic effect on the brain.  
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An alternative method to increase the duration of gene expression is to use 
sleeping beauty transposons. After hydrodynamic delivery into MPS I and VII mice 
the DNA integrated into the genome using the sleeping beauty transposon.  After 3 
months high expression (1 to 100 fold of WT levels) was observed (Aronovich et al. 
2007), however cyclophosphamide immune suppression was required. This 
approach was evaluated in NOD/SCID MPS I mice, where high expression was also 
achieved and detectable IDUA activity in the brain was associated with a reduction 
in GAG storage (Aronovich et al. 2009). It was thought that some enzyme was able 
to pass through the BBB due to the high levels of circulating enzyme.  
The hydrodynamic plasmid delivery system used to transduce the liver in mice has 
recently been shown to be applicable in transfecting skeletal muscle and the liver in 
pigs (Kamimura et al. 2009; Kamimura et al. 2010). Therefore this seems like a safe 
approach to transfect these organs and potentially other organs, however it is 
unlikely to be applicable to the brain as transfection of the liver results in a 
transient 2.5 fold increase in size that would be damaging to brain tissue.  
1.6.1.2 Intravenous Viral Vector Gene Therapy 
Intravenous gene therapy with retroviral or lentiviral vectors in adult MPS I mice 
has been unsuccessful. Unstable expression and low enzymatic activity have been 
observed (Di Domenico et al. 2005; Liu et al. 2005b). In MPS VII mice, a feline 
immunodeficiency viral vector was administered intravenously and a reduction in 
the level of GAGs was found in the liver, where most cells were transduced, but the 
overall clinical effect was limited (Stein et al. 2001). A recent MPS IIIA intravenous 
lentiviral gene therapy study has been more successful, showing 186% and 68% of 
normal SGSH activity in spleen and liver respectively. Immunohistochemistry with 
toluidine blue showed normalisation of GAGs in the liver, spleen and heart, but not 
chondrocytes. Levels of hexosamine-N-sulphate [α-1,4] hexuronic acid (HNS-UA), a 
marker of HS storage, in the brain were also decreased but no SGSH activity was 
detected there. Additionally, no behavioural observations were made, nor the 
effect on neurons recorded (Anson et al. 2007; McIntyre et al. 2008). In a further 
study by McIntyre et al, intravenous gene therapy had no effect on the storage of 
HS in the brain (McIntyre et al. 2010). 
Chapter 1 – Introduction 
[Page 68] 
The immaturity of the newborn immune system may allow stable expression of 
gene therapy vectors in mice, and neonatal mice still express M-6-P receptors on 
the BBB allowing enzyme passage into the brain (Urayama et al. 2008). Neonatal 
gene therapy by AAV, lentiviral and retroviral vectors has produced long-term 
vector expression and an improvement in disease phenotype in MPS I (Hartung et 
al. 2004; Kobayashi et al. 2005; Liu et al. 2005b) and MPS VII mice (Daly et al. 2001). 
However, neonatal gene therapy is not always an option, so alternative delivery 
methods should be considered.  
Intravenous administration of the gene vector may produce sufficient circulating 
enzyme activity to treat the peripheral tissue phenotype. Whether significant 
passage of enzyme across the BBB in MPS III can occur when there is a large excess 
of enzyme in the blood is unknown, but there is some evidence to suggest that it 
can cross the BBB in MPS I and VII mice (Urayama et al. 2004; Vogler et al. 2005; 
Urayama et al. 2008; Aronovich et al. 2009). Additionally the vector or enzyme may 
elicit an immune response that limits their expression. 
1.6.1.3 Intravenous Viral Vector Gene Therapy – Permeabilising the BBB 
To enhance enzyme expression in the brain it would be advantageous to transduce 
some of the cells within the brain to provide a source of enzyme that does not have 
to pass through the BBB. One way to do this is to use mannitol, an osmotic BBB 
disruption agent, that is used in patients and has been used to facilitate AAV uptake 
into the brain in rats (Mastakov et al. 2001). It has also been used in the MPS IIIB 
mouse model. Delivery of AAV2, 8 minutes after mannitol allowed transduction of 
cells in the brain. The timing of the dose was critical and 3,000 fewer cells were 
transduced if 20 minutes elapsed between mannitol and AAV injection. This was 
associated with a reduction in HS storage in the brain and behavioural correction 
(McCarty et al. 2009). It has also been shown to enhance transduction and 
distribution of intracranial injected AAV (Fu et al. 2007). However the use of 
mannitol with intravenous lentiviral vector has not been shown to have a clear 
benefit in MPS IIIA mice (Anson et al. 2007; McIntyre et al. 2008).  
This approach may be a minimally invasive approach to transduce some of the cells 
in the brain and correct the periphery. However an immune response may be raised 
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against the AAV capsid or the enzyme which may limit duration of expression and 
cause side effects.  
1.6.1.4 Intravenous Viral Vector Gene Therapy – Penetrating the BBB 
Another approach is to use AAV serotype 9. After intravenous delivery this AAV 
vector is able to pass through the BBB and transduce neuronal cells in neonates and 
astrocytes in adult mice (Zincarelli et al. 2008; Foust et al. 2009). This has also been 
demonstrated in cats where motor neurons were also reported to be transduced 
(Duque et al. 2009). This vector has been evaluated in the mouse model of MPS IIIB 
and also in combination with mannitol (Fu et al. 2011). In the brain, neuronal, glial 
and endothelial cells were transduced and GAG storage was reduced. This was 
associated with increased lifespan and improvements in motor behaviour. Mannitol 
pre-treatment also improved transduction in the brain.  
This promising approach has not been assessed in MPS IIIA. As with other 
intravenous approaches the disadvantage is the possibility of an immune response 
against the vector or enzyme. It will also need to be demonstrated that this vector 
will have the same tropism in patients.  
1.6.1.5 Intravenous Viral Vector Gene Therapy – Transducing the BBB 
Rather than trying to penetrate the BBB, another approach is to transduce the 
endothelial cells of the BBB (Chen et al. 2009). The brain is a highly vascularised 
organ and if you could selectively transduce the brain endothelia, these cells could 
secrete enzyme into the blood and into the brain to cross correct neuronal cells. A 
phage display library was injected intravenously into WT and MPS VII mice, the 
brain was then removed and the phage purified and re-injected five times, an 
approach known as phage panning. The DNA was sequenced from the phage and 
the common peptide sequences identified. Peptide sequences that bound to the 
MPS VII brain but not the WT brain were selected and cloned into the AAV capsid. 
This AAV was then administered to MPS VII mice with β-glucuronidase. 
Transduction of the brain endothelium was 35 fold higher than liver and better than 
unmodified AAV. This reduced the number of cells with storage vacuolation and β-
glucuronidase staining co-localised with neuronal staining suggesting that neuronal 
cells had been cross corrected.  
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This approach has not been assessed in MPS IIIA and it has not yet been 
determined if these peptide sequences will enhance brain endothelium 
transduction in patients or if specific targeting peptides will be needed for each 
disease and different ones between mouse and human. 
Intravenous delivery is the easiest route of gene therapy vector delivery, however 
this results in production of enzyme in the body not the brain and it is not clear if 
sufficient enzyme can cross the BBB even at high peripheral circulating levels. 
Therefore for some approaches, mannitol or selective transduction of the brain 
endothelium could be applicable or a viral vector with trans BBB ability could be 
used. However intravenous delivery rapidly brings the vector into direct contact 
with the immune system, which could limit transduction or cause a dangerous 
immune response. An immune response against transduced liver cells would not be 
too bad as it has a high repair capacity but this is not true of all tissue, especially 
neurons. 
1.6.2 Intracranial Gene Therapy 
In order to overcome the problem of the BBB inhibiting the passage of enzyme into 
the brain from the body, direct gene therapy into the brain has been researched. 
Adeno-associated virus has been used in the MPS IIIA mouse model to directly 
express SGSH in the CNS (Fraldi et al. 2007). Only those regions of the brain that 
were effectively transduced, including the striatum, cerebral cortex and olfactory 
bulb, showed a reduction in storage. When comparing brain slices as a whole for a 
disaccharide marker of HS storage, HNS-UA (King et al. 2006), no significant 
reduction was observed. More recently the use of a lentiviral vector expressing 
SGSH has been evaluated and a greater increase in SGSH activity and decrease in 
storage has been observed (McIntyre et al. 2010). Treating newborn MPS IIIA mice 
with a canine adenoviral vector expressing SGSH was more effective and a 
significant decrease in vacuolation and an increase in SGSH activity was observed 
but expression duration was limited (Lau et al. 2010b).  The difference in size 
between murine and human brains and the limited penetration of the virus into the 
brain may be the major limiting factors for this therapy, and could also account for 
the better response of newborn mice which have smaller brains. The serotype used 
and the location of injections is important, it has been demonstrated in MPS VII 
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mice that AAV9 was capable of transducing neuronal cells and that the vector 
spread down axonal pathways out of the region the injection. This increases the 
area of the brain that could be corrected from each injection site (Cearley et al. 
2006). 
A murine MPS IIIB study using an adeno-associated viral vector to express NAGLU 
and directly injecting into the striatum, has successfully decreased GM2 and GM3 
ganglioside storage and improved the behaviour of the mice (Cressant et al. 2004; 
Heldermon et al. 2010). This approach has also been evaluated in MPS I and VII 
mice (Frisella et al. 2001; Desmaris et al. 2004; Cearley et al. 2007).  
Intracranial gene therapy using AAV has also been evaluated in the Sandhoff 
disease mouse model. Two injections per hemisphere into the striatum and 
cerebellum at 4 weeks of age resulted in an improvement in survival from under 20 
weeks to over a year. This was associated with delayed disease onset, preservation 
of motor function and a reduction in GM2 ganglioside storage (Cachon-Gonzalez et 
al. 2006). 
There is a current clinical trial of intracranial gene therapy (NCT01474343) in MPS 
IIIA using AAV10 containing SGSH and SUMF1 and a similar trial is planned for MPS 
IIIB to start in 2012. This therapeutic approach has potential but may need to be 
combined with another gene therapy protocol, ERT or SRT, to provide enzyme for 
peripheral tissues or reduce substrate production to treat the mild somatic 
manifestations of the disease. Also, this therapy carries the risk of neurological 
damage and the effects of gene therapy in the brain are currently unknown.  
There has been a clinical trial (NCT00151216) in late infantile neuronal ceroid 
lipofuscinosis (a form of Battens disease) that used 1.8-3.2 x 1012 AAV2 vector 
particles per patient in 12 locations in the brain from 6 burr holes (3 per 
hemisphere) (Worgall et al. 2008). A low level of anti AAV2 capsid antibodies were 
detected in 4 of 10 patients. Of the 10 patients one developed status epilepticus 
and died 49 days post surgery, it could not be determined if this was related to the 
surgery, vector or the underlying disease. However there was no evidence of CNS 
inflammation.  There were 60 serious adverse events of which 34 were possibly 
Chapter 1 – Introduction 
[Page 72] 
related to the vector or surgery but it was hard to determine for certain. However 
the trial was successful in reducing the rate of decline compared to controls in the 
neurologic rating scale. A new clinical trial is now underway (NCT01161576) using 
the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector (AAVrh.10) 
rather than AAV2 as higher expression and a better distribution of AAV vector has 
been observed in rats and mice using this vector (Sondhi et al. 2007).  
Aside from the safety of this therapy, the biggest challenge is getting correction 
throughout the brain of a patient. One way, as discussed previously, is the careful 
choice of vector that can transduce CNS cells and that can spread down axons from 
the site of injection. Another important consideration is the location of the injection 
site, if you inject into an area with wide spreading projections the vector will be 
able to travel down these and transduce a larger area of the brain. This has been 
demonstrated by comparing injection into the striatum to the ventral tegmental 
area (VTA) in MPS VII mice (Cearley et al. 2007). Injections into the VTA resulted in a 
greater spread of enzyme than injection into the striatum. Another method is to 
use a convection enhanced delivery system (Bobo et al. 1994). This method delivers 
vector into the brain with positive pressure over a long period of time and is aided 
by the pulsation of the cerebral arteries (Hadaczek et al. 2006). In rhesus monkeys 
24µl was infused at 0.2µl/min for 60 minutes followed by 0.4µl/min for 30 minutes 
and resulted in widespread transduction (Kells et al. 2009). Convection enhanced 
delivery of AAV is well reviewed in Varenika et al. (Varenika et al. 2009). 
1.6.3 Ex Vivo Mediated Gene Delivery for MPS Disease 
Ex vivo gene therapy is another alternative. This involves the transduction of cells, 
typically stem cells, outside of the body before re-introduction. This approach 
commonly uses HSCs and was first demonstrated in 1984 using a murine retroviral 
vector (Williams et al. 1984). It was later demonstrated that the transduced stem 
cells were able to repopulate the haematopoietic system and that the target gene 
was expressed in vivo (Dick et al. 1985; Eglitis et al. 1985). This method of delivery 
was used in the X-SCID gene therapy trials (Hacein-Bey-Abina et al. 2003; 
Cavazzana-Calvo et al. 2007). Ex vivo gene therapy is well reviewed in (Naldini 
2011). 
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Retrovirally transduced macrophages have been used in the MPS VII mouse model. 
The intravenously administered macrophages were tolerated, persisted for 38 days 
and stored GAGs were reduced. This therapy is limited because the macrophages 
were terminally differentiated, could not migrate to the brain and have a limited 
lifespan (Ohashi et al. 2000).  Alternatively, neural stem cells that have been 
transduced to over express β-glucuronidase, could be transplanted into the brain 
which should persist as they are not terminally differentiated. This has been 
evaluated in neonatal MPS VII mice with transduced human neural stem cells. 
Lysosomal storage was reduced to nearly normal levels after 25 days, however, the 
number of transplanted cells reduced rapidly. This was thought not to be due to an 
immune response, as the same occurred in immunodeficient NOD-SCID mice, but 
was due to apoptotic cell death of the transplanted cells (Meng et al. 2003). This 
approach has also been assessed in Twitcher mice, a model of Krabbe disease 
(globoid cell leukodystrophy) (Neri et al. 2011). These mice were examined 40 days 
post neonatal transplant and 45-65% of WT enzymatic activity was achieved, which 
was associated with a reduction in storage of galactolipid in globoid cells and 
neuroinflammation. An improvement in survival was observed but this was less 
than has been previously observed with HSCT.  Interestingly doubling the injected 
cell dose had no effect on the number of cells engrafted.  
Transduction of HSCs with a lentiviral vector containing IDUA driven by an erythroid 
promoter successfully limited IDUA expression to erythrocytes in MPS I mice. There 
was an increase in the enzyme activity in the periphery, some behavioural 
improvement and in the brain, there was a decrease in vacuolation in cells lining 
microvessels. Some improvements in the brain can be caused by high circulating 
enzyme however, it was not clear what the treatment effect was in neurons within 
the parenchyma of the brain. Therefore it may be better to have enzyme producing 
cells within the brain past the BBB (Wang et al. 2009). 
Transplanted stem cells repopulate the haematopoietic system and some of their 
progeny, monocytes, migrate to the brain and become microglial cells (Priller et al. 
2001). In the rodent brains the mass of neurons is the same as the mass of non-
neuronal cells (microglia and endothelial cells) so microglial cells make up a large 
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proportion of the brain (Herculano-Houzel et al. 2006). In human brains the ratio of 
neuronal to non-neuronal cells is the same (Azevedo et al. 2009; Herculano-Houzel 
2009). Microglial cells are able to produce enzyme within the brain, thus cross 
correcting neuronal cells by providing a source of enzyme to the brain that does not 
have to pass through the BBB. The first in vivo gene therapy experiment for MPS 
was in MPS VII mice in 1993, when retroviruses were used to transduce HSC to 
express β-glucuronidase. After sub-lethal irradiation, up to 5% of HSCs were gene 
modified which was sufficient to decrease storage (Marechal et al. 1993). Mild 
conditioning regimens were also used in conjunction with retrovirus modified HSCs 
in MPS VI cats, but despite persistence of the transduced cells for 2 years, no 
clinical effect was observed (Simonaro et al. 1999). 
A decrease in neurodegeneration was observed in the brains of MPS IIIB mice that 
had received retrovirus transduced bone marrow (Zheng et al. 2004), although the 
level of gene expression was lower than might be expected using this type of 
vector. A much more impressive therapeutic effect was observed in a mouse model 
of the LSD, Metachromatic Leukodystrophy (MLD) and, like MPS IIIA, this disease 
does not normally respond to HSCT. Lentiviral transduction of HSCs ex vivo and 
transplantation into MLD mice showed a reversal in neurodegeneration (Biffi et al. 
2006). The source of ARSA, the deficient enzyme in MLD, in the brain was 
demonstrated to be from microglial cells by immunohistochemistry for HA tagged 
ARSA. Lentiviral haematopoietic stem cell gene therapy has also been evaluated 
recently in the mouse model of MPS I.  A high level of IDUA activity was achieved 
with 4.5 times normal activity in the brain, associated with behavioural correction, 
normalisation of GAGs in the brain and correction of the skeletal phenotype 
(Visigalli et al. 2010). To achieve this, on average 11 copies of the viral vector were 
integrated to each haematopoietic cell. 
Human bone marrow from MPS IH patients has been successfully transduced using 
a retroviral vector to express significant activity of IDUA that provide long term 
cross- correction in vitro. This proof of principal experiment supports the feasibility 
of the transduction of human bone marrow to express and secrete lysosomal 
enzyme (Fairbairn et al. 1996). An unsuccessful bone marrow gene therapy trial for 
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MPS I was conducted in Manchester in 1997-2000 with 3 patients, but cell 
transduction and gene expression from the retroviral vector was transient, probably 
because stem cells were not transduced to any significant extent.  An immune 
response to delivered enzyme was also noted in all 3 patients, but no serious 
adverse effects related to vector delivery were reported (Bigger, personal 
communication).  
The ex vivo haematopoietic stem cell gene therapy approach is now being applied 
in three clinical trials for lysosomal storage disorders. A clinical trial for MPS I is now 
planned by Dr Alexandra Biffi and will use a lentiviral vector rather than a retroviral 
vector to transduce the haematopoietic stem cells. This trial will transduce the 
patient’s own bone marrow cells. Additionally, Dr Mark Sands has a gene therapy 
trial pending in the USA for MPS VII. This clinical trial will attempt to transduce HSCs 
with a lentiviral vector containing the transgene, GUSB, which is deficient in MPS 
VII. They will use a non-myeloablative approach and a multiplicity of infection of 10, 
with two rounds of transduction. Dr Alexandra Biffi has started a clinical trial for 
MLD using a lentiviral vector and full myeloablative conditioning and autologous 
CD34+ cells. Three patients have already been enrolled and received transplants 
with 2 copies per cell achieved in the first patient.  
 
1.7 Lentiviral Mediated Stem Cell Gene Therapy for MPS IIIA 
MPS IIIA is currently untreatable, and patients progressively decline to a vegetative 
state followed by death in the second decade of life (Meyer et al. 2007). ERT and 
other somatic sources of enzyme are ineffective because the neurological 
phenotype is resistant, due to exclusion of enzyme from the brain by the BBB 
(Wraith 2006). Central nervous system ERT is a potential therapy that avoids the 
BBB, however, repeated intracranial injections are invasive and potentially 
dangerous (Hemsley et al. 2008b). Additionally, a humoral immune response 
against the administered enzyme may reduce its efficacy.  SRT has potential, but 
further optimisation and clinical trials are necessary (Jakobkiewicz-Banecka et al. 
2007). CNS delivery of gene therapy vector may be a viable approach to treat MPS 
IIIA if sufficient transduction of the human brain, which is 3500 time heavier than a 
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mouse brain and 17 times heavier than a macaque, (Herculano-Houzel 2009) can be 
achieved. Peripheral correction may also be required and there have only been a 
limited number of trials so far, so the risks are unknown.  
We hypothesise that following a standard HSC transplant, insufficient enzyme is 
produced to effectively treat the disease phenotype. Transducing HSC with an 
SGSH- lentiviral vector should increase the production SGSH in HSCs to achieve a 
higher level of SGSH activity than normal HSCT. The transplanted HSCs can 
repopulate the haematopoietic system and monocytes traffic across the blood 
brain barrier where they differentiate into microglia cells which will produce 
enzyme within the brain to treat the neurological phenotype. 
1.7.1 Project Aims 
1. Develop suitable behavioural measures to determine the effect of therapy on 
neurodegeneration in the MPS IIIB (Figure 1-10) and MPS IIIA (Figure 1-11) mouse 
models.  
2. Over-express SGSH in HSCs using the SFFV-SGSH lentiviral vector, followed by 
transplantation into the mouse model of MPS IIIA crossed onto the C57BL/6 
background (Figure 1-12).  
3. Perform a long-term comparison of lentiviral vectors expressing SGSH in 
transplanted MPS IIIA HSCs compared to transplants of transduced normal cells 
and normal cells alone into MPS IIIA mice, to determine the effect on enzyme 
activity, GAG and HS storage levels, HS sulphation, GM2 ganglioside secondary 
storage, neuroinflammation and behaviour. 
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Figure 1-10 Outline of MPS IIIB mouse behavioural testing (Chapter 3) 
At 8 months (32 weeks) of age, 1.5 hours into the light cycle WT and MPS IIIB mice were placed in an 
open field and their behaviour was recorded for 1 hour. Food was then placed into one corner and a 
water tower that the mice nest underneath was placed in the opposite corner. 23 hours later the 
behaviour was recorded for 24 hours. At 8 and 10 months of age the inverted screen test was 
performed 3 times for a maximum of 2 minutes each trial. At 8 and 10 months of age the bar 
crossing test was performed 3 times for a maximum of 2 minutes in a training phase and 10 minutes 
later it was performed 3 times in the testing phase. The same mice were tested at 8 and 10 months 
of age. 
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Figure 1-11 Outline of MPS IIIA mouse behavioural testing (Chapter 4) 
At 4, 6 and 8 months (16, 24 and 32 weeks) of age, 1.5 hours into the light cycle WT and MPS IIIA 
mice were placed in an open field and their behaviour was recorded for 1 hour. After a 30 minute 
break a 10 minute elevated plus maze test was performed. After a 30 minute break the 10 minute 
elevated plus maze test was repeated. After a 30 minute break the inverted screen test was 
performed 3 times for a maximum of 2 minutes per test. After a 60 minute break the bar crossing 
test was performed 3 times for up to 2 minutes in the training period. Then 10 minutes later the test 
was performed 3 times in the testing period. The same mice were tested at 4, 6 and 8 months of 
age. 
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Figure 1-12 Outline of lentiviral HSC gene therapy for MPS IIIA (Chapter 5) 
Bone marrow was removed from donor mice and lineage depleted to leave an enriched HSC stem 
cell population. HSCs were transduced or mock transduced with a lentiviral vector containing the 
human SGSH gene and transplanted into myeloablated MPS IIIA recipients. The donor HSCs 
repopulated the haematopoietic system, produced SGSH and cross-corrected affected MPS IIIA 
mouse organs. At different time points, various outcome measures were employed to determine the 
effect of the therapy. 
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2.1 Materials 
Tissue culture plasticware was sourced from Corning (Amsterdam, The 
Netherlands) unless otherwise stated. Pipette tips were from StarLab (Milton 
Keynes, UK). All chemicals were purchased from Sigma Aldrich (Dorset, UK) unless 
otherwise stated. PCR primers were synthesised by Invitrogen (Life Technologies, 
Paisley, UK) and QPCR primers and probes were synthesised by Applied Biosystems 
(Life Technologies, Paisley, UK). 
 
2.2 Maintenance of Mouse Colony 
The MPS IIIA mouse model is a spontaneously occurring mouse model caused by a 
G to A mutation at nucleotide base 91, resulting in a change from aspartic acid to 
asparagine at position 31 (Bhattacharyya et al. 2001). This results in 2-3% residual 
SGSH enzyme activity. The MPS IIIA mice were obtained on a mixed 129SvJ, 
C57BL/6, SJL, and CD1 background (Bhaumik et al. 1999; Bhattacharyya et al. 2001; 
Crawley et al. 2006). The MPS IIIB mouse model was artificially created by targeted 
disruption of the 6th exon of the NAGLU gene with a 900bp insertion (Li et al. 1999) 
and was crossed onto the C57Bl/6 background. 
The MPS IIIA and MPS IIIB mouse colonies were maintained by heterozygote x 
heterozygote breeding to produce wild type litter mates for controls. Heterozygous 
mice in the MPS IIIB colony were occasionally bred with a C57BL/6J mouse 
purchased from Harlan to maintain the background. The mice are supplied with 
standard chow and water ad libitum. All experiments were performed with local 
ethical approval and in accordance with Home Office regulation. 
2.2.1 Backcrossing MPS IIIA Mice 
The MPS IIIA mice were obtained on a mixed 129SvJ, C57BL/6, SJL, and CD1 
background, for reliable and consistent behavioural testing the mice need to be 
backcrossed on to a pure background (Crawley 2007).  Therefore heterozygous 
mice in the MPS IIIA colony were bred with a C57BL/6J mouse purchased from 
Harlan, and the heterozygous offspring was then bred with another C57BL/6J 
mouse purchased from Harlan. This was repeated for 10 generations until the MPS 
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IIIA mice can be considered to be on the C57BL/6J background (B6.Cg-Sgshmps3a/6J). 
The procedure is now occasionally repeated to maintain the background.   
An additional colony has also been set up where MPS IIIA mice (B6.Cg-Sgshmps3a/6J) 
have been crossed with the PEP3 (B6.SJL-Ptprca Pepcb/BoyJ) mouse strain to 
produce MPS IIIA mice that express the pan-leukocyte marker CD45.1 rather than 
CD45.2 (Shen et al. 1985). This allows the transplanted cells in MPS IIIA mice to be 
tracked by flow cytometry. A heterozygous mouse from the MPS IIIA colony was 
bred with a PEP3 mouse. The offspring all expressed CD45.1 and CD45.2 and were 
genotyped for heterozygous MPS IIIA status as described in 2.2.3. Heterozygous 
MPS IIIA mice expressing both CD45.1 and CD45.2 were then bred. The offspring 
from this cross then had to be genotyped for MPS IIIA status as described 2.2.3 and 
CD45.1/2 status was determined from a blood sample collected as described in 
2.16.1 and genotyped by flow cytometry as described in 2.15. A colony was then 
established from mice heterozygous for MPS IIIA status who also expressed only 
CD45.1. The background of this colony was maintained by occasionally backcrossing 
with a PEP3 mouse. 
2.2.2 Isolation of Genomic DNA 
DNA was extracted from samples using the GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma Aldrich) following the manufacturer’s instructions. Briefly; 
tissue was digested in lysis solution T (180l) with proteinase K (20l) for 4-6 hours 
at 55°C, vortexing hourly. Cells were then lysed with lysis solution C (200l). Ethanol 
(200l) was used to precipitate the DNA. The binding column was prepared by 
loading column preparation solution (500l) and centrifuging at 12,000g for 1 
minute. The DNA was then loaded onto the binding column and centrifuged at 
6,500g for 1 minute. Columns were washed twice with wash solution (500l), first 
at 6,500g, then at 12000g. The DNA was eluted in Elution Solution (10mM Tris-HCl, 
0.5mM EDTA, pH 9.0) (200l) by centrifuging at 6,500g. DNA concentration was 
determined using a Nanodrop (Thermo Scientific, Loughborough, UK), elution 
solution (1.5l) was pipetted onto the sensor to use as a blank, after reading that it 
was wiped off and 1.5µl of DNA was pipetted onto the sensor and the DNA 
concentration was determined from the absorbance by the Nanodrop software.  
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2.2.3 Genotyping MPS IIIA Mice 
The G to A mutation at the 91 position in SGSH removes a MspA1I restriction 
enzyme digestion site therefore the MPS IIIA mice can be genotyped by amplifying 
DNA by PCR and cleaving it with MspA1I.  The size of the DNA fragments can be 
used to genotype the animals. 
MPS IIIA mice were numbered by ear punching using an ear punch (Stoelting, 
Dublin, Ireland) under isoflurane anaesthesia, and the ear punches were used to 
genotype the mice. DNA was extracted from the ear punches (see section 2.2), and 
the SGSH DNA was amplified by PCR. The PCR reaction contained: 10x PCR Buffer 
(5µl, Bioline, London, UK), 0.24mM dNTPs (Invitrogen), 0.5µM forward primer (5’ 
GTGTTCCCTGCCTGCTCAC 3’ Invitrogen), 0.5µM reverse primer (5’ 
CCAGTCCCCTCATCCCACTA 3’ Invitrogen), 1M Betaine (Invitrogen), 1.5mM MgCl2 
(Bioline), 2.5 units Bioline BioPro DNA polymerase, 5µl genomic DNA and ddH2O up 
to 50µl. The thermocycling conditions were 96°C for 5 minutes followed by forty 
cycles of 96°C for 40 sec, 64°C for 40 sec and 72°C for 40 sec; and a final elongation 
phase at 72°C for 10 minutes. 
The DNA (7.8µl) was cut with MspA1I (2 units; New England Biolabs (NEB), Hitchin, 
UK), in 100µg/ml BSA and NEBuffer 4 (1µl) at 37°C for 1 hour. The DNA fragments 
were separated by gel electrophoresis (2% agarose (Sigma) in TAE buffer and 
1µg/ml EtBr). The genotype can be determined from the pattern of DNA fragments; 
wild type (WT) SGSH will be digested into 199bp, 118bp and 78bp fragments, the 
mutant (MUT) into 317bp and 78 bp and the heterozygous (HET) into 317bp, 199bp, 
118bp and 78bp. 
2.2.4 Genotyping MPS IIIB Mice 
The MPS IIIB mouse model was created by targeted disruption of the 6th exon with 
a 900bp insertion (Li et al. 1999). Therefore the size of PCR DNA fragments can be 
used to genotype the animals. 
DNA was extracted from ear punches (see section 2.2.2), and the NAGLU DNA was 
amplified by PCR. The PCR reaction contained: 10x PCR Buffer (5µl, Bioline), 
0.24mM dNTPs (Invitrogen), 0.5µM forward primer (5’ GGCAACCATGGCCTGTTTGG 
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3’ Invitrogen), 0.5µM reverse primer (5’ GGCTGACTGGGGTACCTCTTC 3’ Invitrogen), 
1M Betaine (Invitrogen), 6mM MgCl2 (Bioline), 2 units Bioline BioPro DNA 
polymerase, 3µl genomic DNA and ddH2O up to 50µl. The thermocycling conditions 
were 96°C for 3 minutes followed by 35 cycles of 96°C for 45 sec, 64°C for 45 sec 
and 72°C for 3 minutes 30 sec; and a final elongation phase at 72°C for 10 minutes. 
The DNA was separated by gel electrophoresis (1% agarose (Sigma) in TAE buffer 
and 1µg/ml EtBr). Wild type mice have a band at 900 bp, the MPS IIIB have a band 
at 1800 bp due to the presence of a 900bp insertion and the heterozygous mice 
have both bands. 
 
2.3 Behavioural Analysis 
MPS IIIB mice were analysed at 8 months (32 weeks) of age by open field, followed 
by the home cage the next day and on a different day inverted screen and 
horizontal bar crossing. The inverted screen and bar crossing test was also 
performed at 10 months of age.  
The same MPS IIIA mice and treatment groups were analysed at 4, 6 and 8 months 
(16, 24, 32 weeks) of age. The mice were first placed in the open field test, then 
after a 30 minute gap the elevated plus maze was performed. Then after a further 
30 minute rest the elevated plus maze was repeated. After another 30 minutes rest 
the inverted screen test was performed and after a 1 hour gap the horizontal bar 
crossing test was performed.  
2.3.1 Open Field 
A 1 hour open field test was performed as described previously (Malinowska et al. 
2010). For the MPS IIIB mice at 8 months of age female mice were dropped into the 
centre of an arena (260×365mm) with corn cob flooring and recorded with a digital 
camera (Sony, Tokyo, Japan) for 1 hour. For MPS IIIA a matt white acrylic arena 
(450mm wide, 450mm deep, 500mm tall) was used and the mice tested at 4, 6 and 
8 months old. The open field test was always performed 1.5 hours into the 12 hour 
light phase in the animal unit. The videos were analysed using Top Scan software 
(Clever Sys, Reston, USA) for path length, rapid exploratory behaviour, immobility 
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and frequency, path length, duration and speed in the centre of the cage. Rearing 
was manually scored by a blinded observer.  
2.3.2 Home Cage 
After the 1 hour open field test for the MPS IIIB mice, food and a water tower were 
added to the cage and the mice were allowed to acclimatise for 24 hours before the 
behaviour was recorded for 24 hours.  The behaviour was analysed using the same 
measures as the 1 hour open field. 
2.3.3 Elevated Plus Maze 
For the MPS IIIA mice 30 minutes after the open field test, the elevated plus maze 
test was performed. The mice were placed onto the end of one of the open arms of 
the elevated plus maze (two 500 mm long, 100 mm wide arms enclosed with 500 
mm high sides and two 500 mm long, 100 mm wide open arms 500mm off the 
floor, lights illuminated the open arms). The behaviour was recorded for 10 minutes 
and the arena cleaned with 70% IMS, after a 30 minute rest the test was repeated. 
The behaviour was analysed using Top Scan software to examine the time spent in 
the open arm and the number of arm entries and the path length.  
2.3.4 Inverted Screen 
For the MPS IIIA mice, 30 minutes after the elevated plus maze, the inverted screen 
test was performed (Jeyakumar et al. 1999). The mouse was placed on a 470mm 
square with a 13mm square wire mesh. The screen was rotated over 1-2 seconds 
through 180°. The rear leg moves and the duration suspended was measured for up 
to 2 minutes or until the mouse fell off. 
2.3.5 Horizontal Bar Crossing 
For the MPS IIIA mice, 60 minutes after the inverted screen test, the horizontal bar 
test was performed (Jeyakumar et al. 1999; Malinowska et al. 2010). The mouse 
was allowed to grip the centre of a metal wire 300 mm long and 2mm in diameter, 
the wire was secured between 2 posts 320mm above a padded surface. The time to 
reach the side or fall off was recorded up to two minutes. Crossing the bar in x 
seconds was scored as 240-x, staying on the bar for two minutes was scored as 120 
and falling off after y seconds was recorded as the value of y. The test was repeated 
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three times followed by a 10 minute rest before three tests from which the score 
was determined. 
 
2.4 Production of hSGSH Lentiviral Vector Transgene Plasmid 
To produce lentiviral vector a plasmid containing the transgene and other necessary 
elements outlined in Figure 2-2  are required.  A lentiviral vector backbone 
containing Att Gateway cloning sites was kindly given to us by Adrian Thrasher and 
Steven Howe (Demaison et al. 2002). Dr Fiona Wilkinson and Dr Bill Bennett 
performed Gateway cloning (Hartley et al. 2000) to insert the human SGSH 
sequence from an image clone (#5226903, Invitrogen) into the lentiviral vector 
backbone, see Figure 2-1. The resulting plasmid, pHRsin.SFFV.hSGSH.att.wpre, was 
used to produce lentiviral vector and the region of this plasmid packaged into the 
lentiviral vector is outlined in Figure 2-2.  
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Figure 2-1 Gateway cloning 
The IMAGE clone of SGSH was flanked by attB sites, the first stage was therefore to perform the BP 
reaction to cause site specific recombination of the SGSH sequence into the donor vector backbone 
and results in the SGSH gene flanked by attL sites. This entry clone can then be added to the 
destination vector (the lentiviral vector backbone created by Steven Howe) and the LR Clonase 
reaction recombines SGSH into the lentiviral vector backbone and becomes flanked by attB sites. 
The plasmid required can be selected for using the different antibiotic resistance genes in the 
plasmids and by linearising some of the plasmids. Reviewed in (Katzen 2007). 
 
Figure 2-2 Lentiviral vector  
Outline of the lentiviral vector, U3, R and U5 are parts of the LTR, Ψ is the packaging signal, RRE is 
the rev response element, cPPT is the central poly purine tract, att are Gateway clone sites, hSGSH is 
the human SGSH gene, wpre is the woodchuck hepatitis post-transcriptional regulatory element and 
SIN represents the self inactivating nature of the vector.  
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2.5 Production of Endotoxin-Free Plasmid DNA 
Chemically competent STBL4 bacterial strains (Invitrogen) were transformed with 
plasmids of interest according to manufacturer’s instructions. Colonies on Luria-
Bertani (LB) (Invitrogen) agar plates containing 100µg/ml Ampicillin were picked 
and expanded in LB/Ampicillin. Bacterial plasmid stocks were stored at -80°C in 15% 
glycerol, in LB broth containing antibiotic.  
The bacterial plasmid stock was expanded to produce plasmids for lentiviral 
production using the Endofree Megaprep kit (Qiagen, Crawley, UK) according to 
manufacturer’s instructions. In brief; bacteria were cultured overnight in 
LB/ampicillin. One 500ml culture, inoculated with 1ml saturated culture is sufficient 
for one Qiagen 2500 tip. Bacteria were lysed by alkaline lysis, the plasmid DNA was 
bound to the Qiagen anion-exchange resin at low pH and salt conditions, washed 
and eluted. The DNA was precipitated using isopropanol and washed with 70% 
ethanol. The DNA was resuspended in endotoxin-free TE (1ml; 10mM Tris, 1mM 
EDTA), filtered through a 0.1µm filter to sterilise, and the DNA concentration was 
determined using a nanodrop (Thermo Scientific).  Typically, 4mg of endotoxin free 
plasmid DNA was isolated from 1L of bacterial culture. 
 
2.6 Culturing Mammalian Cell Lines 
The HeLa cervical cancer and human embryonic kidney (HEK) 293T cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Lonza, Slough, UK), 10% 
foetal calf serum (FCS) and 2mM L-Glutamine (DMEM/10% FCS) at 37°C with 5% 
CO2. Cell lines were passaged at approximately 90% confluency. The media was 
removed and the adherent cells were washed with phosphate buffered saline (PBS). 
Trypsin (Lonza; 1ml for a 25cm2 flask, 2ml for a 75cm2 flask and 3ml for a 175cm2 
flask)  was added and incubated at room temperature (RT) for 5 minutes or until 
cells were no longer adhered to the flask. Gentle agitation assisted this process. The 
trypsin was neutralised by the addition of twice the volume of media containing 
FCS. The cells were centrifuged at 400g for 4 minutes and diluted or counted using 
a haemocytometer for replating in fresh media. The HeLa cells were typically 
passaged at 1:8 and the 293T cells at 1:10. The murine lymphoma cell line EL4 
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(ATCC Number TIB-39, Sigma) was cultured in RPMI 1640 (Lonza), 10% FCS and 
2mM L-glutamine. This suspension cell line was passaged by removing cell culture 
media (0.5 ml) and adding to fresh media (19.5 ml) in a new flask T75 flask. 
 
2.7 Production of High Titre Lentiviral Vector 
Lentiviral vector is produced in HEK293T cells by transient transfection with one 
plasmid containing the viral envelope protein, one with the gag, pol and rev genes 
and one with the transgene to be packaged as outlined in Figure 1-8. SGSH and 
enhanced green fluorescent protein (eGFP) lentiviral vectors were produced in 
batches and concentrated by centrifugation. 
On day 1, 6x106 low passage HEK 293T cells were plated per 15cm diameter dish in 
DMEM (20ml) supplemented with 10% FCS and 2mM L-glutamine. On Day 2 the 
media was replaced with DMEM/10% FCS. Plates were between 40 and 70% 
confluent. 
Plasmids were transfected using Fugene 6 (Roche, West Sussex, UK) according to 
manufacturer’s instructions. Briefly, transfection solution 1 contained 15µg DNA 
per plate of genome construct, envelope (pMD2G) and gag/pol 2nd generation 
(p∆8.91gag/pol) at a 3:1:2 ratio in H2O to a total of 18µl/plate. Transfection solution 
2 contained 44.5 µl/plate Fugene 6 (Roche) in 1437.5µl Optimem (Gibco, part of Life 
Technologies) per plate.  
Solution 2 was incubated at RT for 5 minutes and added dropwise to solution 1 
before incubation for a further 15 minutes at RT. This mixture (1.5ml) was added 
dropwise to a dish of 293T cells. After 4 hours, the media was carefully replaced 
with fresh DMEM/10% FCS. 22 or 44 dishes were produced at a time. 
The media was changed on day 3. On day 4 and 5 the media was carefully removed 
from the dishes and transferred to a 225ml graduated conical centrifuge tube (BD, 
Oxford, UK) on ice and fresh media replaced. The harvested media was centrifuged 
at 262g (1,110rpm) on a swing out rotor at 4°C for 15 minutes to remove cells and 
cellular debris. The supernatant was filtered through a 0.45µm low protein binding 
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cellulose acetate filter (capacity 1L, Nalgene). To concentrate the lentiviral vector 
the media was transferred to 50ml falcon tubes and centrifuged at 21,191g 
(13,500rpm) at 4°C for 2.5 hours. The supernatant was removed and the lentiviral 
vector pellet was resuspended in sterile PBS (50µl per 50ml tube) or formulation 
buffer (37.5mM NaCl, 19.75M Tris-HCl pH 7, 40mg/ml lactose, 1mg/ml human 
serum albumin, 5µg/ml protamine sulphate). Lentiviral vector was stored in 
aliquots of 50µl for use and 2µl for titering at -80°C.  
 
2.8 Titration of Lentiviral Vector 
The lentiviral vector from each harvest was titred using HeLa titration for GFP 
vectors and using EL4 cells and QPCR for SGSH vectors to determine the number of 
infectious lentiviral vector particles (IU/ml).  
2.8.1 HeLa Titration for Infectious Lentiviral Vector Particles 
The HeLa cervical cancer cell line (ATCC #CCL-2) was used to determine the 
infectious titre of the GFP lentiviral vector in this cell type (IU/ml). 1x105 HeLa cells 
were plated in 6 well plates in DMEM/10% FCS/2mM L-glutamine. After 4 hours at 
37°C with 5% CO2, lentiviral vector was applied to the HeLa cells in triplicate, four 
dilutions were used 1l, 0.1l, 0.05l and 0.01l. One set of three wells remained 
as controls for background auto-fluorescence and one set of three wells was 
counted to determine the number of cells present at the point of transduction. 24 
hours later the media was changed. After a further 24 hours the percentage of GFP 
expressing cells was determined by FACS analysis on a FACS Canto II Flow 
Cytometer (BD Biosciences). The cells were washed and incubated with 1ml/well 
trypsin (Lonza) for 5 minutes at RT or until the cells were detached from the plate; 
2ml of DMEM/10% FCS/2mM L-Glutamine was added to neutralise the trypsin. The 
cells were transferred to FACS tubes, spun down and washed with 2ml FACS buffer 
(PBS/2% FCS). The cells were resuspended in FACS buffer (200µl) and 100,000 
events were collected per tube on the flow cytometer. The infectious lentiviral 
vector particle (IU/ml) titre was calculated using the following equation.  
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The titre can only be accurately measured when the percentage of GFP expression 
is greater than 0.5% and less than 40% as the majority of GFP positive cells will thus 
contain only 1 copy of vector per cell.  
2.8.2 EL4 Cell Titration for Infection Lentiviral Vector Particles 
The EL4 mouse lymphoma cell line was used to determine the number of infections 
by lentiviral vectors for the GFP and SGSH vectors using QPCR to measure vector 
integrations rather than mRNA gene expression as this method does not assume 
that a cell is only transduced once.  1x105 EL4 cells in 100 µl were plated in a 96 well 
plate in RPMI/10% FCS/2mM L-Glutamine. Then lentiviral vector in five dilutions of 
1ml (1x10-3 (1l), 5x10-4, 1x10-4, 5x10-5and 1x10-5) was applied to the EL4 cells in 
duplicate. One pair of wells did not have any lentiviral vector added to act as a 
negative control in the QPCR. The cells were incubated at 37 °C with 5% CO2 for 24 
hours before the media was changed. After a further 48 hours the cells were 
transferred to 1.5ml Eppendorf tubes and cell pellets frozen. The genomic DNA was 
then isolated as described in section 2.2.2 and QPCR was performed as described in 
section 2.8.3 to determine the copy number. The infectious lentiviral vector particle 
(IU/ml) titre was calculated using the following equation. 
              
                                                 
                                             
 
2.8.3 QPCR for Lentiviral Vector Integration Copy Number  
QPCR was used to determine the number of integrations of the lentiviral vector into 
the genome. The QPCR reaction is based on a probe being cleaved in the 
polymerisation reaction. This separates a fluorophore from a quencher and the 
fluorescence emitted is detected after every cycle of the PCR reaction, this is 
plotted as a change in fluorescence against the cycle number. A standard curve is 
created using serial dilutions of a sample of known copy number, that is, a house 
keeping gene, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the 
sequence of interest. 
A fluorescence threshold is determined for each primer and probe set, this is the 
lowest delta Rn (or fluorescence) that is above background in the linear part of the 
amplification curve. The threshold cycle (Ct) is plotted in a standard curve against 
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log “genomes”. (This is a comparative measure between GAPDH endogenous 
genomes and lentiviral genomes using the probe of interest, therefore an arbitrary 
number of “genomes” can be assigned to the top value on the standard curve.) The 
GAPDH and lentiviral probe standard curves are used to determine how many 
mouse genome copies are present in the sample (GAPDH) relative to the number of 
lentiviral copies (lentiviral probe). The copy number per diploid cell is the number 
of lentiviral genomes per 2 GAPDH genomes for each sample. A standard containing 
a known number of lentiviral integrants per cell is required to generate the 
standard curve for the lentiviral and GAPDH probes using this approach. 
Primers and probe against the murine GAPDH gene (Applied Biosystems) were used 
to standardise samples as they have a known copy number of 2 per cell. The 
lentiviral vector integration sites were probed using a primer and probe set against 
the WPRE element in the lentiviral vector detailed in Table 2-1.  
Master mixes for GAPDH and WPRE were made containing 812.5µl of TaqMan 
Universal PCR Master Mix 2x (Applied Biosystems), 16.25µl of forward primer, 
16.25µl reverse primer, 16.25µl probe and 698.75µl of nuclease free water. The 
final primer and probe concentrations are outlined in Table 2-1. Each master mix 
was then divided into 24 60µl aliquots, then 2.5µl containing 1-5ng of DNA of each 
sample was added to the GAPDH and the WPRE master mix. After mixing, 25µl of 
the master mix plus sample was pipetted in duplicate into 96 well reaction plates 
(Applied Biosystems) and sealed using an optical plate seal (Applied Biosystems). 
The reaction was run in an Applied Biosystems 7500 Real Time PCR System, the 
standard thermocycling conditions were 50°C for 2 minutes, 95°C for 10 minutes 
and 40 cycles of 95°C of 15 seconds and 60°C for 60 seconds. 
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Target Primer/Probe Concentration Sequence 
GAPDH Forward primer 
Reverse primer 
Probe 
100nM 
100nM 
200nM 
5’-TGCACCACCAACTGCTTAGC-3’(by extrapolation) 
5’-AGAACATCATCCCTGCATCC-3’ (by extrapolation) 
[VIC]-Not released by Applied Biosystems 
WPRE Forward primer 
Reverse primer 
Probe 
800nM 
800nM 
200nM 
5’-CCGTTG TCAGGCAACGTG-3’ 
5’-AGCTGACAGGTGGTGGCAAT-3’ 
*FAM+5’-TGCTGACGCAACCCCCACTGGT-3’ *TAMRA+ 
Table 2-1 Primer and probe sets for QPCR 
 
2.9 Making a QPCR Standard Cell Line 
For accurate copy number determination by QPCR, a known copy number standard 
is required. The known copy number standard needs to contain the WPRE sequence 
present in the SGSH lentiviral vector, however we chose to transduce cells with the 
GFP lentiviral vector that contains the same WPRE sequence because the 
expression of GFP can be easily assessed using flow cytometry. The known copy 
number standard also needs to be a clonal cell line so that we can determine the 
number of copies of WPRE from the number and position of bands by Southern 
blotting. Therefore we decided to use the EL4 mouse lymphoma cell line (ATCC 
Number TIB-39, Sigma) as this suspension cell line expands rapidly and exists as a 
single cell suspension so that when the cells are cloned out by limiting dilution, 
clumps of cells were not present and colonies are likely to arise from a single cell. 
The EL4 cell line was transduced with the pCrimp GFP expressing lentiviral vector at 
a range of MOI (1, 2, 4, 8, 16 and 32). A sample of the EL4 cells were then analysed 
by flow cytometry for GFP expression in the FITC channel. The EL4 cells that had 
been transduced with the lowest MOI that were 95% GFP positive were selected 
and expanded. After expansion, some of the EL4 GFP positive cells were frozen and 
others checked by flow cytometry to ensure that they retained GFP expression. The 
cells were counted by haemocytometer and to confirm that they were in a single 
cell suspension, and diluted to 10 cells per 100µl. 10 cells (100µl) were pipetted into 
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the first column of 3x 96 well round bottom plates. Serial dilutions (1:2) were then 
performed across each plate using a multichannel pipette. The plates were sealed 
using breathable plate seals (Alpha Laboratories) and were cultured at 37°C, 5% 
CO2. After 3-4 weeks the cells furthest to the right of the plate were harvested. 
These colonies should have arisen from a single cell so they should have the same 
integration position in every cell.  After expanding several different colonies they 
were assessed for GFP expression by flow cytometry. One GFP positive clone was 
chosen to be cloned by limiting dilution for a second time. After the second round 
of cloning by limiting dilution the colonies were assessed again by flow cytometry 
for GFP expression. All the colonies appeared to express GFP with very similar 
profile, and mean fluorescent intensity. Therefore it appeared that the two rounds 
of cloning had succeeded in producing an EL4 GFP expressing cell line from a single 
cell.  The number of copies of WPRE, a sequence within the pCrimp vector that is 
integrated into the genome was then determined by Southern blot (see section 
2.9.1) for 5 of the cell lines to confirm that they all had the same integration pattern 
and were derived from one cell. DNA from these cells was then used as a standard 
for QPCR. 
2.9.1 Southern Blot for Assessment of Lentiviral Integration Number 
2.9.1.1 Genomic DNA Extraction 
It is important not to shear the genomic DNA during extraction for Southern 
blotting as sheared DNA would not run as discrete bands by gel electrophoresis but 
as a smear. Therefore it would not be possible to quantify the number of 
integrations of the vector into the genome. Throughout the protocol DNA is never 
vortexed but stirred with a pipette tip with a sealed end and when pipetted, the 
pipette tip ends were cut to give a larger bore (3mm). Pipetting was also performed 
very slowly. 
 5x107 EL4 cells were resuspended in 1ml TE (pH 8) and 10ml of lysis buffer was 
added (TE pH8 + 0.5% SDS + 20µg/ml RNase) for 1 hour at 37°C. Proteinase K was 
then added to a concentration of 100µg/ml and incubated at 50°C for 3 hours. After 
leaving to cool to room temperature an equal volume of phenol was added and 
gently inverted to form an emulsion. The DNA and phenol was then centrifuged at 
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5,000g for 15 minutes at 4°C. The top aqueous phase was removed and the phenol 
extraction was repeated. The DNA was precipitated by the addition of 0.2 volumes 
of 10M ammonium acetate and 2 volumes of 100% ethanol at -80°C for 30 minutes. 
The precipitated DNA was centrifuged at 5,000g for 5 minutes at RT. The DNA was 
washed twice with 70% ethanol. The DNA pellet was then air dried for 30 minutes 
and resuspended in 100µl TE (pH 8) overnight at 4°C. The DNA was quantified using 
a Nanodrop (Thermo Scientific). 
2.9.1.2 Genomic DNA Digestion 
The genomic DNA was digested. At this stage it is also important not to shear the 
DNA so when mixing, a pipette tip with a sealed end was used rather than vortexing 
or pipetting repeatedly.  Additionally all pipetting of the DNA was performed with a 
wide (3mm) bore pipette tip and very slowly. 
25µg of genomic DNA was digested with either 10U of EcoRI-HF (NEB) or 10U of 
BamHI-HF (NEB) or 5U of EcoRI and BamHI in the presence of 10x Buffer 4 and TE 
up to a total volume of 45µl. The mixture was stirred and the DNA was slowly 
pipetted into the reaction using a wide bore pipette tip. The reaction was incubated 
at 37°C for 30 minutes with half the enzyme and then the second half of the 
enzyme was added and stirred. The reaction was incubated for a further 16 hours.  
2.9.1.3 Genomic DNA Transfer 
10µg of genomic DNA per lane was then separated by gel electrophoresis (0.7% 
agarose (Sigma) in TAE buffer and 1µg/ml EtBr) for 7 hours at 40V. The gel was  
depurinated using 0.125M HCl for 10 minutes with gentle agitation. The gel was 
then transferred to denaturation buffer (1.5M NaCl, 0.5M NaOH) for 30 minutes 
with gentle agitation before a final 30 minutes in neutralisation buffer (1.5M NaCl, 
0.5M Tris Base, pH 7.5). 
The gel was then transferred onto Hybond-XL (GE, Chalfont St Giles, UK) by capillary 
transfer overnight as per manufacturer’s instructions. In brief, a platform was 
placed in a container and a wick made by placing a sheet of 3MM paper onto the 
top of the platform and into the transfer buffer (20x SSC; 3M NaCl, 0.3M sodium 
citrate pH 7). The gel was placed onto the platform, rolled with a pipette to remove 
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any air bubbles and the rest of the platform covered with plastic. Then a piece of 
Hybond-XL membrane the same size as the gel was placed on top and rolled with a 
pipette to remove any air bubbles. Then three pieces of 3MM paper cut to the size 
of the gel and soaked in transfer buffer were placed without bubbles onto the 
Hybond-XL. Then 5cm of paper towels were added with a 1kg weight on top and 
the DNA transferred to the membrane overnight. The next morning the Hybond 
membrane was placed on blotting paper and baked at 80°C for 30 minutes to fix the 
DNA before storing at 4°C wrapped in cling film. 
2.9.1.4 Producing Southern Blot Probes 
40µg of pCrimp plasmid that was used to transduce the EL4 cells was digested with 
BamHI (NEB) and XbaI (NEB) or with EcoRI (NEB) and EcoNI (NEB) with buffer 4 at 
37°C for 1 hour. The digested DNA was then mixed with 6x loading buffer (Sigma) 
and separated by gel electrophoreses on a 1% agarose gel. For the BamHI and XbaI 
digest the 751bp fragment was gel extracted from a 983bp and 7.5kb DNA 
fragment. For the EcoRI and EcoNI digest the 1kb fragment was isolated from the 
2kb and 6kb fragments.   
Gel extraction was carried out as per manufacturer’s instructions (QIAquick, 
QIAGEN). In brief 1 volume of agarose gel containing the band of interest was 
incubated with 3 volumes of buffer QG at 50°C for 10 minutes whilst shaking. After 
the gel had dissolved, 1 volume of isopropanol was added and the DNA was bound 
to the silica membrane in a column in the presence of a high salt buffer with a pH of 
less than 7.5. Impurities were washed out using 0.5ml buffer QC and 0.75ml buffer 
PE containing ethanol. The DNA were then eluted in low salt and higher pH 
conditions using 30µl of TE (pH 8.5).  
From this template DNA a radioactive probe was produced using Ready-To-Go DNA 
Labelling Beads (GE Healthcare) and radioactive P32 dCTP. The manufacturer’s 
method was followed. In brief, 25-50ng of probe DNA was denatured by heating to 
95°C for 3 minutes and then placing on ice for 2 minutes. The denatured DNA (in 
less than 45µl) was then added to 5µl of P32 dCTP (3,000 Ci/mmol) and water up to 
50µl in the ready-to-go tubes and mixed. The reaction was incubated for 5-30 
minutes at 37°C. During this time oligolabelling occurs, random 
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oligodeoxyribonucleotides present in the tube bind to the template DNA and act as 
primers for DNA synthesis by DNA polymerase with free nucleotides, including the 
radiolabeled P32 dCTP.  
After incubating at 37°C the hybridisation probe was purified from the 
unincorporated dCTP with a illustra NICK column (GE). The probe DNA was loaded 
onto a washed Sephadex G-50 column and allowed to pass though by gravity. The 
probe was then eluted by addition of buffer and gravity flow. However the 
unincorporated dCTP remains within the beads as the smallest molecules are eluted 
last as they are able to pass though the pores into the beads.  
2.9.1.5 Probe Hybridisation  
The probe was hybridised to the Hybond membrane in hybridisation tubes in a 
hybridisation oven. The Hybond-XL (GE) manufacturer’s protocol was followed. The 
membrane was pre-wet in water, the pre-warmed to 65-68°C Denhardt’s buffer (5x 
SSC (0.75M NaCl, 0.075M sodium citrate pH7), 5x Denhardt’s solution (2% BSA, 2% 
Ficoll 400, 2% Polyvinylpyrrolidone) and 0.5% SDS). The membrane was then added 
to a hybridisation tube and 30-70µl/cm2 of Denhardt’s buffer added. The probe 
produced in 2.9.1.4 was then denatured by heating to 100°C for 5 minutes before 
placing on ice for 3 minutes. 0.5-2x106 counts per ml of probe Denhardt’s buffer 
was added in prehybridisation buffer (5x SSC, 5x Denhardt’s solution, 0.5% SDS, 
40mg/L sonicated salmon sperm DNA), not directly onto the membrane. The blot 
was then hybridised overnight at 65°C. The blot was then rinsed with 2 x SSC 0.1% 
SDS, then washed twice for 5 minutes with 2x SSC/0.1% SDS, then twice for 10 
minutes with 1x SSC/0.1% SDS and finally four times for 5 minutes with 0.1x SSC/ 
0.1% SDS. The blot was then wrapped in cling film and Hyperfilm MP was exposed 
for 24 hours at -80°C (Figure 2-3).  
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Figure 2-3 Southern blot 
Five EL4 GFP clones (1-5) from the second round of cloning by limiting dilution and untransduced EL4 
cells (Control) were analysed by Southern blotting. A 1Kb ladder (Invitrogen) shows the size in Kb 
down the left hand side. (A) The genomic DNA was cut with BamHI and EcoRI and the probe was 
made using BamHI and XbaI. (B) The genomic DNA was cut with EcoRI and the  probe was made 
using EcoR1 and EcoNI. (C) The genomic DNA was cut with BamHI and the probe was made using 
BamHI and XbaI. There are consistently two bands in each of the clones (1-5) and no bands in the 
control. This indicates that two copies of the vector have integrated per cell. 
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2.10 Bone Marrow Isolation 
The donor mice were culled and sprayed with 70% ethanol to kill any bacteria, they 
were then skinned and the legs removed and placed into PBS pen/strep to kill 
bacteria. The femur, tibia, and ilium (pelvis) bones were removed from the flesh by 
scraping with a number 22 scalpel (Appleton Woods, Birmingham, UK). A 29G 
insulin syringe was used to flush bone marrow into PBS/2% FCS and cells were kept 
cold on ice throughout the procedure. Tissue debris was removed using a 70µm 
filter (Cell Trics). 5-6 volumes of ammonium chloride lysis buffer pH 7.2-7.4 (150mM 
NH4Cl, 10mM KHCO3, 0.1mM EDTA,) was applied to the bone marrow to lyse red 
blood cells. After 10 minutes incubation on ice, the lysis was stopped by the 
addition of 1 volume FCS. The cells were then washed twice with PBS 2% FCS.  
 
2.11 Haematopoietic Stem Cell Enrichment 
The haematopoietic stem cell population of murine bone marrow was enriched by 
the removal of progenitor cells using StemSep mouse progenitor enrichment kit 
(Stemcell Technologies, Grenoble, France) following the manufacturer’s instructions 
with minor modifications to conserve antibody. In brief, bone marrow cells at a 
concentration of 1x108 cells/ml in PBS/2% FCS (twice the recommended 
concentration) were incubated with normal rat serum at 4°C for 15 minutes to 
block non-specific binding of antibody. They were incubated (4°C for 15 minutes) 
with StemSep Enrichment Cocktail containing biotinylated monoclonal antibodies 
to the following cells or cell surface antigens: CD5, TER119, CD45R, Ly-6G, CD11b 
and 7-4. After washing with PBS/2% FCS, the cells were incubated at 4°C with anti-
biotin tetrameric antibody complexes for 15 minutes followed by magnetic colloid 
for 15 minutes. A 0.6” column was placed in the magnet and was primed for use by 
running room temperature PBS at 0.6 ml/min (setting 3 on a Minipuls 3 Peristaltic 
Pump, Gilson) up the column making sure there were no air bubbles and then 3 
column volumes of PBS/2% FCS down the column at 2ml/min (setting 10). The cells 
were then applied to the column and run at 2ml/min, the column was never 
allowed to run dry and extra PBS/2% FCS was added 1ml at a time for the first 5ml. 
Cells without lineage markers were able to pass through and 25ml was collected 
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and centrifuged at 300g for 10 minutes to concentrate them. Cells were 
resuspended in a suitable volume of X-VIVO-10 medium (see section 2.12). 
 
2.12 Transduction of the Enriched Haematopoietic Stem Cells 
HSCs were cultured in X-VIVO-10 medium (BioWhittaker, part of Lonza) without 
serum supplementation, containing murine SCF (Peprotech, London, UK) and mFlt3-
Ligand (R&D Technologies, Abingdon, UK), both at 50ng/ml, and mIL-6 (Peprotech) 
at 10ng/ml. The cells were cultured in 24-well plates at a concentration of 1.0 x 106 
cells per well in 1ml media. After 1 hour at 37 °C with 5% CO2, lentiviral vector was 
applied to the cells at a multiplicity of infection (MOI) of 30-60 and incubated 
overnight. 
 
2.13 Transplantation  
Recipient mice were myeloablated with 125mg/kg Busulfan (Busilvex; Pierre Fabre, 
Toulouse, France) over 5 days. Mice were manually restrained and a 25mg/kg doses 
were delivered using an insulin syringe (BD) into the peritoneal cavity every day for 
5 days in a total volume of 200µl made up with PBS. The recipients were 6-10 weeks 
old and received acidified water, irradiated food, mash and sugar free jelly during 
Busulfan treatment and for 6 weeks post BMT to prevent gastrointestinal infections 
and to encourage fluid uptake. Mice were warmed for 10 minutes in their cage on a 
hot block to dilate the blood vessels in the tail. The mouse was then placed into a 
restraining tube (Harvard Apparatus Limited, UK) and 1-2.5x105 transduced or 
untransduced lin- enriched HSCs were administered in 200µl PBS via tail vein 
injection using an insulin syringe (BD). 
 
2.14 Flow Cytometry 
Flow cytometry was carried out on a FACS Canto II Flow Cytometer (BD Biosciences) 
using FACSDiva (BD Biosciences) analysis software.  Events were separated based 
on forward and side scatter and the cell population was gated from this to exclude 
Chapter 2 – Materials and Methods 
 
[Page 101] 
cellular debris from the analysis. From this cell population the live cells were gated 
by staining with ToPro3 Iodide (Invitrogen) in the APC channel (excitation (ex) 595, 
633, 635, 647, emission (em) 660nm) and selecting the unstained cells. Cells 
without any ToPro3 Iodide staining were used to determine the position of the 
negative peak and therefore where the gate should be located. For all other 
antibody stains used in sections 2.8.1 and 2.15 an antibody isotype control for each 
fluorophore was used to determine the position of the negative peak. Automatic 
compensation was also performed to account for overlap of fluorescence between 
channels (FITC ex 488 em 519nm, PE ex 488, 532 em 578 and APC) on the flow 
cytometer. 100,000 cells were collected for each sample. 
 
2.15 Determination of Chimerism After HSC Transplantation 
Donors and recipients were distinguished by measurement of the pan-leukocyte 
markers CD45.1 and CD45.2 in the blood, bone marrow or spleen. Blood samples 
(100µl) were taken via a tail vein bleed, and sodium citrate (50µl of 4% w/v, Sigma) 
was added to prevent clotting (see 2.16.1).  After lysing the red blood cells using 
ammonium chloride lysis buffer for 10 minutes on ice twice, the cells were washed 
twice in PBS/2% FCS. The cells were incubated with PBS/2% FCS/5% mouse serum 
at 4°C for 15 minutes to inhibit non-specific binding and were stained with CD45.1 
(PE, excitation 488, 532 emission 578nm) and CD45.2 (FITC, excitation 488nm, 
emission 519) antibodies diluted 1:50 (BD Biosciences) for 30 minutes at 4°C. The 
cells were washed and resuspended in 200µl PBS/2% FCS. ToPro3 iodide was used 
to stain dead cells immediately before analysis of the cells on a BD FACS Canto II 
flow cytometer. 
 
2.16 Sample Collection From In Vivo Experiments 
2.16.1 Blood Sample Collection 
Blood was taken by tail vein bleed for detecting chimerism and to isolate plasma 
and peripheral blood mononucleocytes (PBMCs). Mice were warmed for 10 
minutes in their cage on a hot block to dilate the blood vessels in the tail. The 
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mouse was then placed into a restraining tube (Harvard Apparatus Limited, UK) and 
a small cut was made to the tail vein using a number 15 scalpel blade (Appleton 
Woods). 100µl of blood was collected with 50µl of 4% (w/v) sodium citrate to avoid 
clotting, then centrifuged at 200g for 10 minutes and the plasma supernatant 
removed and frozen in aliquots. The remaining cells were lysed twice with 
ammonium chloride lysis buffer on ice for 10 minutes as per section 2.11.  The cells 
were centrifuged at 200g for 10 minutes and the cell pellet frozen at -80°C. 
2.16.2 Perfusion  
At sacrifice, mice were perfused with Tyrode’s solution (138mM NaCl, 1.8mM CaCl2, 
0.3mM NaH2PO4, 5.6mM glucose, 12mM NaHCO3 and 2.7mM KCl) heated to 37°C 
to flush blood from the organs. This allows clearer histological analysis of the brain 
for lymphoid infiltration without masking from circulating cells and clear 
biochemical data as the brain tissue is measured not the brain and blood. Mice 
were anaesthetised with Hypnorm/Hypnovel and the heart exposed. A needle was 
inserted in the left ventricle and the Tyrode’s solution was gently injected. A cut 
was made above the right atrium. As the heart beats, Tyrode’s solution is pumped 
around the body and the blood is pumped out of the cut above the right atrium. 
The blood is displaced by the Tyrode’s solution and the organs become noticeably 
paler.  
2.16.3 Tissue Processing 
After perfusion the brain was removed and separated into two hemispheres. One 
hemisphere was fixed in 4% paraformaldehyde (PFA/PBS) and the other was snap 
frozen. The brain was fixed for 24 hours and perfused with 30% sucrose 2mM 
MgCl2/PBS for 48 hours before freezing at –80°C.  The spleen was removed and cut 
into four segments, three of which were snap frozen. The liver was also removed 
and three small pieces from the outside and the inside were snap frozen. A sample 
of spleen and liver was fixed in 4% PFA/PBS for 48 hours followed by 70% ethanol 
for 48 hours. Liver and spleen samples were progressively dehydrated, cleared in 
xylene and embedded in paraffin wax in a Microm tissue processor (Thermo Fisher). 
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2.17 Quantification of Total Protein 
The total protein concentration of tissue samples was determined using a BCA 
assay kit (Thermo Scientific) to standardise tissue samples for the SGSH and Blyscan 
assays. The assay was performed following the manufacturer’s instructions. In brief, 
a standard curve was constructed using decreasing concentrations of albumin from 
2mg/ml to 0.2mg/ml. Samples of tissue were homogenised using a pestle and 
mortar followed by sonication to lyse the cells. This was performed in 
homogenisation buffer (0.5M NaCl, 0.02M Tris pH 7-7.5) (200µl for liver and spleen, 
100µl for brain). Samples were diluted to ensure that they were within the standard 
range; plasma, monocytes, spleen and brain were diluted 1:35 and liver was diluted 
1:50. 10µl of each standard and sample was loaded in triplicate in a 96 well plate 
and BCA reagent (200µl per well) was applied. The plate was sealed and incubated 
at 37°C for 30 minutes. The absorbance at 562nm was recorded and the protein 
concentration determined using the standard curve. 
 
2.18 SGSH Enzyme Activity Assay  
SGSH sulphatase activity is determined using a two step protocol with a fluorescent 
substrate (Karpova et al. 1996). In the first reaction SGSH desulphates the substrate 
and in the second reaction α-glucosidase hydrolyses the substrate and releases a 
fluorescent product. 20mM 4-methylumbelliferyl-α-D-N-sulphoglucosaminide.Na 
(MU-αGlcNS; Moscerdam, Oegstgeest, The Netherlands) and protease inhibitor 
(1.9mM Pefabloc; Roche Diagnostics) in substrate buffer (143mM Na-barbital, 
143mM  Na-acetate buffer, 0.7% NaCl, 0.02% (w/v) Na-azide, pH 6.5) are incubated 
with 40µg of protein for monocytes, plasma, liver and spleen or 60µg of protein for 
brain in 10µl at 47°C for 17 hours. Samples were run in duplicate in a black 96 well 
plate (Nunc, Thermo Fischer). The desulphation reaction was stopped with double 
concentrated McIlvaine’s solution Pi/Ci (0.4M NaHPO4, 0.2M citric acid, 0.02% 
NaN3, pH 6.7). 10U/ml α-glucosidase (10µl/well) was added to hydrolyse and 
release the fluorescent 4-Methylumbelliferyl (4MU) in an incubation of 24 hours at 
37°C. The reaction was stopped with 0.5M NaHCO3/0.5M Na2CO3/0.025% (w/v) 
Triton X-100 pH 10.7. A standard curve was constructed from 4MU of standard 
Chapter 2 – Materials and Methods 
 
[Page 104] 
concentration (66.67µM) diluted in stop buffer and the fluorescence at excitation 
360nm and emission 460nm was measured on a Synergy HT Microplate Reader 
(BioTek, Bedfordshire, UK).  
 
2.19 Blyscan Assay for Total Glycosaminoglycans 
The total amount of sulphated glycosaminoglycans were analysed using the Blyscan 
assay kit (Biocolor, Carrickfergus, UK). Samples of tissue were homogenised using a 
pestle and mortar followed by sonication to lyse the cells. This was performed in 
homogenisation buffer (0.5M NaCl, 0.02M Tris pH7-7.5) using 200µl for liver and 
100µl for brain. Protein concentration was then determined using the BCA assay 
(Section 2.17).   To prepare samples 20µg of actinase E was added to 100µl of 
standard or tissue supernatant containing 100µg of protein. The tissue was 
incubated at 55°C for 20 hours and then the temperature was raised to 100°C for 5 
minutes. After cooling the sample was centrifuged at 3,000g for 10 minutes. The 
sample supernatant was then incubated with 1,9-dimethymethylene blue for 30 
minutes whilst shaking. The samples were centrifuged at 10,000g for 15 minutes at 
4°C. The pellet of GAGs was incubated with dye dissociation reagent for 15 minutes 
at room temperature before reading absorbance using a spectrophotometer at 
656nm. The quantity of sulphated GAGs was calculated using a standard curve of 
known concentration samples. 
 
2.20 AMAC for Heparan Sulphate 
AMAC analysis of heparan sulphate (HS) in brain tissue was performed by Dr 
Rebecca Holley as described in (Deakin et al. 2008; Holley et al. 2011). Firstly the HS 
was extracted from one tenth of a brain by homogenisation in 10ml PBS using a 
Dounce homogeniser and treated with 1mg Pronase (100µg/ml) for 4 hours at 37°C 
followed by addition of 100µl Triton X-100 (1% v/v) for 2 hours at RT and a final 
Pronase treatment with an additional 1mg of Pronase for 4 hours at 37°C. HS was 
isolated by passing the digested tissue through a pre-equilibrated 1cm DEAE-
Sephacel column and washing with 50ml of 0.25M NaCl, 30mM NaP, pH 7. The HS 
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was then eluted with 5ml of 1.5M NaCl/20mM NaH2PO4 and desalted using a pre-
packed PD10 column (GE Healthcare). 1ml aliquots of the eluted HS were loaded 
onto the PD10 column and allowed to run to waste, before washing with 2ml of 
water and running to waste. A second 2ml of water was then added, and the eluant 
was collected (HS fraction), before the column was washed with 20ml of water to 
remove the salt, ready for the next 1ml aliquot of sample to be added. The 
resultant heparan sulphate in water was then freeze dried. The HS was then 
digested with heparinase I, II and III (Seikagaku) at a concentration of 5mIU of each 
in 100µl of 0.1M NaC2H3O and 0.1M Ca(C2H3O2)2 pH7 overnight and freeze dried for 
a second time.  
The resulting HS disaccharide units were dissolved in 10µl of 0.1M 2-aminoacridone 
(AMAC) in 85% Me2SO 15% CH3COOH for 20 minutes at RT. 10µl of 1M NaBH3(CN)  
was then added and incubated for 16 hours at RT. The fluorescently AMAC-labelled 
HS disaccharides were then separated by reverse phase high performance liquid 
chromatography (RP-HPLC) on a Zorbax Eclipse XDB-C18 RP-HPLC column (3.5µm, 
2.1mm × 150mm Agilent Technologies, Edinburgh, UK) equilibrated with 0.1M 
ammonium acetate. After a 2ml gradient of 0-10% methanol the HS disaccharides 
were eluted in 50ml of a 10-30% methanol solution at 1ml/min. Disaccharides were 
detected by in-line fluorescence (excitation at 425nm and emission at 520nm).  
Disaccharides were identified by comparison with known disaccharide standards 
(Iduron, Manchester, UK), following labelling with AMAC and RP-HPLC, as described 
above. Relative quantification of the percentage contribution of each disaccharide 
species was determined following integration of fluorescent peak area and 
application of an AMAC labeling efficiency correction factor to account for the 
different amount of labeling of the different HS forms as described previously 
(Deakin et al. 2008; Holley et al. 2011). Total heparan sulphate levels were 
compared by summing the total fluorescent units.   
 
Chapter 2 – Materials and Methods 
 
[Page 106] 
2.21 Immunohistochemistry 
2.21.1 Preparation of Mouse Brains for Free Floating Immunohistochemistry 
The snap frozen hemisphere of brain processed in 2.16 was cut using a Zeiss Hyrax 
S30 microtome. The cerebellum of the brain was removed and the rest mounted in 
OCT (Raymond A Lamb, part of Thermo Fisher) on the microtome and the 30µm 
sections were collected into 3x 96 well plates containing TBSAF (15% sucrose, 30% 
ethylene glycol, 0.05% NaN3 in TBS) and stored at 4°C. 
2.21.2 GM2 Gangliosides 
Secondary storage of GM2 gangliosides was assessed using an antibody against 
GM2 gangliosides. 4 equally spaced sections of brain from 0.26 to -1.94mm relative 
to bregma were placed in a 24 well plate and the endogenous peroxidase activity 
was blocked with 600µl of PBS/1% H2O2 for 30 minutes. The sections were washed 
for 4x 5 minutes with PBS + 0.01% saponin. Non-specific background staining was 
blocked with PBS + 1% bovine serum albumin (BSA) /10% normal goat serum 
(Vector Labs) and 0.03% saponin for 1 hour. The sections were then washed for 4x 5 
minutes with PBS/0.01% saponin.  
The primary antibody (a gift from Dr Dobrenis and Prof Walkley) was diluted 1:40 in 
PBS with 1% normal goat serum, 1% BSA and 0.02% saponin overnight at 4°C. The 
sections were washed for 4x 5 minutes with PBS/0.01% saponin. The sections were 
incubated with a biotinylated goat anti mouse IgM secondary antibody (Vector 
Labs) for one hour diluted 1:200 in PBS with 1% normal goat serum, 1% BSA and 
0.02% saponin. The sections were then washed for 4x 5 minutes with PBS/0.01% 
saponin and incubated with avidin/biotin (Vector Labs) (5µl solution A + 5µl 
solution B per ml of PBS/0.01% saponin) for 60 minutes. The sections were then 
washed for 4x 5 minutes with PBS and incubated with DAB substrate containing 
nickel (Vector SK-4100) for 5 minutes. The reaction was stopped with ice cold PBS 
and washed twice with PBS before mounting onto positively charged slides (Thermo 
Scientific Superfrost Plus).  
The slides were left overnight to dry and then rehydrated in TBS for 5 minutes 
before progressively dehydrating them with increasing concentrations of ethanol 
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followed by xylene. The cover slips were mounted using DPX (Merck, Nottingham, 
UK).  
Four sections per mouse, with an n of 5 mice per group, were examined under a 
light microscope (Axiovision, Carl Zeiss, Welwyn Garden City, UK). From each of the 
4 sections the same two regions of the cortex were photographed at the same time 
and under the same setting for all mice. The images were quantified using Image J 
software to quantify the level of black GM2 ganglioside staining and the 
background staining was deducted.  
2.21.3 Isolectin B4 for Microglial Cells  
Neuroinflammation was assessed by staining with isolectin B4 for microglial cells. 4 
equally spaced sections of brain from 0.26 to -1.94mm relative to bregma were 
placed in a 24 well plate and the endogenous peroxidase activity was blocked with 
600µl of TBS 1% H2O2 for 30 minutes. The sections were then washed with TBS, 
2mM MgCl2, 1mM CaCl2 for 5 minutes 3 times. The sections were then incubated 
with isolectin B4, a lectin from Bandeiraea simplicifolia conjugated to peroxidase 
(BSI-B4; Sigma) diluted 1:200 overnight at 4°C in TBS/MgCl2/CaCl2. The sections 
were washed for 4x 5 minutes with TBS/MgCl2/CaCl2 and incubated with DAB 
substrate (Vector SK-4100) for 22 seconds. The reaction was stopped with ice cold 
TBS and washed twice with TBS before mounting onto positively charged slides 
(Thermo Scientific Superfrost Plus). 
The slides were left overnight to dry and then rehydrated in TBS for 5 minutes 
before staining with Mayer’s haematoxylin for 5 minutes. The sections were rinsed 
in PBS pH 8 until it run clear and then rinsed in water. The sections were 
progressively dehydrated with increasing concentrations of ethanol followed by 
xylene. The cover slips were added using DPX (Merck).  
The number of activated microglial cells was quantified from two fields of view of 
cortex on four sections from each mouse.  
2.21.4 LAMP2 for Lysosomal Compartment 
A section from -0.84mm relative to bregma from 2 mice per group was stained for 
LAMP2, a lysosomal membrane protein, to demonstrate the size of the lysosomal 
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compartment. Sections were placed in a blocking solution of 5% goat serum, 
1mg/ml BSA and 0.1% Triton X-100 in TBS and incubated at room temperature for 1 
hour to stop non-specific binding. The sections were then stained with LAMP2 IgG 
(2μg/ml) in blocking solution, a control section was also stained with rat IgG at the 
same concentration as the LAMP2 antibody. The sections were incubated overnight 
at 4°C and washed for 4x 5 minutes with TBS followed by staining with Alexa 488 
goat anti-rat (green) 1:1000 in blocking solution and incubated for 1 hour at room 
temperature in the dark to avoid photo bleaching. After washing once with TBS the 
sections were incubated with 300nM DAPI for 15 minutes at room temperature to 
stain all nuclei. After 4x 5 minute washes with TBS the sections were mounted on 
positively charged slides (Thermo Scientific Superfrost Plus) and after excess TBS 
was removed, ProLong Gold Anti-fade mounting medium (Invitrogen) was added, 
followed by the cover slip. The slides were then kept in the dark until examination 
by confocal microscopy. Representative regions of the cortex have been shown.  
 
2.22 Statistical Analysis 
Data were analysed by Student’s t-test, by one way ANOVA or two way ANOVA with 
Tukey post hoc test and by MANOVA using JMP version 8 (SAS Institute Inc, Cary, 
NC, USA) where applicable.  The F value is given for each comparison, together with 
degrees of freedom and the probability of error in Chapter 3. Where data failed 
normality tests it was log transformed so that it was normally distributed. 
Significance was assumed for probabilities of 0.05 or lower. Survival analysis was 
performed in SPSS version 19 (IBM, New York, US) using Kaplan-Meier analysis with 
Mantel-Cox log rank pairwise comparisons.  
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3.1 Abstract 
Mucopolysaccharidosis IIIB (MPS IIIB) is a lysosomal storage disorder characterised 
by severe behavioural disturbances and progressive loss of cognitive and motor 
function. There is no effective treatment, but behavioural testing is a valuable tool 
to assess neurodegeneration and the effect of novel therapies in mouse models of 
disease.   
Several groups have evaluated behaviour in this model, but the data are 
inconsistent, often conflicting with patient natural history. We hypothesise that this 
discrepancy could be due to differences in open field habituation and home cage 
behaviour. Eight month old wild type and MPS IIIB mice were tested in a 1 hour 
open field test, performed 1.5 hours after lights on, and a 24 hour home cage 
behaviour test performed after 24 hours of acclimatisation. In the 1 hour test, MPS 
IIIB mice were hyperactive, with increased rapid exploratory behaviour and reduced 
immobility time. No differences in anxiety were seen.  Over the course of the test, 
differences became more pronounced with maximal effects at 1 hour. The 24 hour 
home cage test was less reliable. There was evidence of increased hyperactivity in 
MPS IIIB mice, however, immobility was also increased, suggesting a level of 
inconsistency in this test. 
Performance of open field analysis within 1-2 hours after lights on is probably 
critical to achieving maximal success as MPS IIIB mice have a peak in activity around 
this time. The open field test effectively identifies hyperactive behaviour in MPS IIIB 
mice and is a significant tool for evaluating effects of therapy on 
neurodegeneration. 
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3.2 Introduction 
Mucopolysaccharidosis type IIIB (MPS IIIB, OMIM #252920), or Sanfilippo 
syndrome, is caused by a deficiency in the lysosomal enzyme, α-N-
acetylglucosaminidase as a result of mutations in the NAGLU gene (O'Brien 1972; 
Zhao et al. 1996). NAGLU deficiency impairs lysosomal degradation of heparan 
sulphate in the brain, resulting in enlarged lysosomes, secondary storage of 
gangliosides and cholesterol (Constantopoulos et al. 1978; McGlynn et al. 2004), 
severe neuroinflammation (Ohmi et al. 2003; Canal et al. 2010) and progressive 
cellular and organ dysfunction (Valstar et al. 2008). Patients present with severe 
behavioural problems including aggression, hyperactivity, a decreased sense of 
danger and sleep disturbances (Cleary et al. 1993; Fraser et al. 2005; Moog et al. 
2007) leading to progressive neurodegeneration and death in the second decade of 
life, although the phenotype varies considerably (Meyer et al. 2007; Heron et al. 
2011).   
There is currently no effective therapy for MPS IIIB, but substrate reduction therapy 
(Malinowska et al. 2009; Malinowska et al. 2010), enzyme replacement therapy (Yu 
et al. 2000), and gene therapy and stem cell therapy approaches (reviewed in 
Valstar et al., 2008) have been evaluated.  Surrogate clinical biomarkers for MPS IIIB 
have only recently been forthcoming and are still in development (Langford-Smith 
et al. 2010; Langford-Smith et al. 2011c) therefore the behavioural phenotype of 
the mouse model remains an important tool for measurement of treatment effect 
on the severe neurodegenerative phenotype seen in both mice and patients. 
The mouse model of MPS IIIB has previously been reported to demonstrate 
alterations in circadian rhythms as measured in the home cage, including increased 
activity in the light (Heldermon et al. 2007; Canal et al. 2010) or dark (Cressant et al. 
2004). Interestingly, none of these studies, including our own, demonstrated overall 
increases in activity of MPS IIIB mice. In contrast, an 8 minute open field analysis of 
the MPS IIIB mouse model, half in light, half in dark, showed reductions in activity in 
both light and dark phases (Li et al. 1999), whilst a separate study observed reduced 
rearing in the second 30 minutes of a 1 hour open field test (Fu et al. 2007).  This 
Chapter 3 – MPS IIIB Behaviour 
[Page 112] 
contrasts with observations of hyperactivity in MPS IIIB mice in a 10 minute open 
field test (Cressant et al. 2004). 
MPS IIIB mice also demonstrate a reduced sense of danger in some situations. Fear 
conditioning was normal in the contextual fear test but reduced in tone fear test (Li 
et al. 1999) which could be caused by differences in sensory function, whilst no 
changes in the acoustic startle response have been observed (Fu et al. 2007). A 
reduced sense of danger (increased entry to open arms) has been observed in the 
elevated plus maze test when performed in the dark (Cressant et al. 2004) but not 
in the light (Fu et al. 2007).  Therefore, again it is not clear if the MPS IIIB mice 
mimic the pathology seen in patients where they have a reduced sense of danger. 
These disparities may reflect different testing conditions, and require definitive 
characterisation in both the home cage and open field to determine a reliable 
phenotype.  
 
3.3 Methods 
3.3.1 Mouse Maintenance 
MPS IIIB mice (Li et al. 1999) were maintained by heterozygous breeding as 
described (Canal et al. 2010) on a C57BL/6J background with occasional 
backcrossing to the C57BL/6J line (Harlan, UK) to maintain the background. WT and 
MPS IIIB KO female littermates were used for all behavioural analysis. All 
procedures were ethically approved and in accordance with the UK Home Office 
and European Union (2010/63/EU) regulations. Mice had access ad libitum to food 
and water and were housed under a 12 hour light-dark cycle.  
3.3.2 Behavioural Testing 
The 1 hour open field test was performed as described previously (Malinowska et 
al. 2009; Malinowska et al. 2010). In brief, 8 month old female mice (n=6 WT, n=6 
MPS IIIB) were dropped into the centre of an arena (260×365mm) containing corn 
cob flooring and the behaviour was recorded with a digital camera (Sony) for 60 
minutes. The open field test was performed 1.5 hours after the lights were turned 
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on in a randomised blinded fashion. The behaviour was analysed using Top Scan 
software (Clever Sys. Inc. Reston, USA). The path length, rapid exploratory 
behaviour (speed >90mm/s), immobility (speed <0.05mm/s) and frequency, path 
length, duration and speed in the central 25% of the cage were analysed. 
Rearing was manually counted by an observer blinded to the genotype of the mice. 
The number of supported rears (using the side of the cage) and unsupported rears 
were counted for the first 10 minutes of the 1 hour open field.  
In the 24 hour home cage test a mouse (n=6 WT, n=7 MPS IIIB) was placed in a cage 
(260×365mm) with food and a plastic water tower where water is accessible and 
the mice can nest underneath (Figure 3.3A). Behaviour in this area could not be 
analysed as it is hidden from view. The mice were allowed to acclimatise for 24 
hours before 24 hours of filming.  When the lights were turned off, infra red lights 
automatically turned on to illuminate the mice for the night-vision enabled camera. 
Behaviour was analysed as for the 1 hour open field using the same measures and 
Top Scan Suite software (Cleversys Inc, Reston, VA, USA). 
The inverted screen test was performed at 8 months (n=4 WT, n=5 MPS IIIB) and 10 
months (n=3 WT, n=4 MPS IIIB) of age by placing the mouse on a 470mm square 
screen covered with a 13mm square wire mesh and rotating the screen through 
180° over 1-2 seconds. The mouse was suspended upside down above a padded 
surface and the number of rear leg moves was counted and the amount of time 
spent suspended up to a maximum of 2 minutes was recorded.  
The horizontal bar test was performed as described previously (Malinowska et al. 
2010) at 8 months (n=6 WT, n=7 MPS IIIB) and 10 months (n=3 WT, n=4 MPS IIIB) of 
age. In brief a 300mm metal wire 2mm in diameter was secured between 2 posts 
320mm above a padded surface. The mouse was allowed to grip the centre of the 
wire and the time to fall or reach the side was recorded, after two minutes the test 
was stopped. Crossing the bar in x seconds was scored as 240-x, remaining on the 
bar was scored as 120 and falling off the bar after y seconds was recorded as the 
value of y. The test was repeated three times as a practice run followed by a 10 
minute rest prior to three tests where the score was recorded.   
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3.3.3 Statistical Analysis 
Data were analysed using JMP software (SAS Institute Inc, Cary, NC, USA) and 
MANOVA repeated measure analysis and one way ANOVAs were used, where 
appropriate, to determine differences between groups (Genotype) and within 
groups (Illumination). The F value is given for each comparison, together with 
degrees of freedom and the probability of error. Significance is assumed at 
probabilities of less than 0.05. 
3.4 Results  
In order to test the hypothesis that MPS IIIB mice, like patients, are more 
hyperactive and have a reduced sense of danger, groups of 6-7, 8 month old female 
wild type (WT) and MPS IIIB mice were monitored for 1 hour for habituation 
behaviour in the open field. In order to check the reliability of the home cage test, 
following 24 hours of acclimatisation, we monitored the same mice in the home 
cage environment for a further 24 hours. We also performed tests of motor 
function at 8 months and 10 months of age to monitor motor decline. 
To compare the open field test (Figure 3-1A) to previous studies and to determine 
the minimum time required to achieve consistent significance, we have presented 
the data as per minute activity graphs and analysed the first 3 and 10 minutes of 
the test as well as the total 60 minutes for significance, using a student’s t test 
(Cressant et al. 2004; Hemsley et al. 2005). MPS IIIB mice travel more than 3 times 
as far as WT mice over the duration of the trial (Figure 3-1B) with significant 
differences observed in the first 3 (F1,10=13.63, p=0.004), 10 (F1,10=19.69, p=0.001) 
and  60 minutes (F1,10=20.70, p=0.001) of the trial.  
Rapid exploratory behaviour was monitored by the frequency (Figure 3-1C) and 
duration (Figure 3-1D) of speed over 90mm/s. Highly significant increases in both of 
these parameters were observed in MPS IIIB mice at 3, 10 and 60 minutes after 
commencement of the test (F1,10=17.98–33.11, p=0.002-p=0.0002). The 
supplementary video (supplementary video 3-1) shows the median mouse from 
each group over the median 2 minutes of the open field test (minutes 29-31), 
running at 4 times normal speed, in which many of these behaviours can be 
observed. 
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Figure 3-1 One hour open field – activity 
At 8 months of age 6 WT (white squares) and 6 MPS IIIB (black squares) mice were placed in the 
centre of a cage 260 x 365mm outlined in (A) and the behaviour was recorded for 1 hour. The results 
of the open field behaviour are presented as a 1 hour period with the average of every minute 
presented and as a bar chart of the first 3 minutes, first 10 minutes and whole hour. Error bars 
represent the standard error of the mean (SEM). p values were calculated by t-test. The mean 
average path length in meters (B), frequency of rapid exploratory behaviour (speed> 90mm/s) (C), 
duration of rapid exploratory behaviour (speed> 90mm/s) (D), frequency of immobility (E) and 
duration of immobility (F) are presented. 
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We also monitored frequency (Figure 3-1E) and duration (Figure 3-1F) of immobility 
over the period of the test.  MPS IIIB mice had a consistently reduced frequency and 
duration of immobility but this was only significant when measured at 10 and 60 
minutes (F1,10=16.67–60.24 p=0.008- p<0.0001) and was not significant at 3 minutes 
(F1,10=2.99–1.97, p=0.11–p=0.19). In these cases, the groups became more 
significantly different as the analysis period was extended. Interestingly, this 
appears to be due to an initial similarity in the behaviour of the two groups when 
the mice were first placed in the cage, that rapidly diverges over time (Figure 3-
1E,F). 
As a prey species, mice tend to display thigmotaxis (Simon et al. 1994), and thus 
show a reduced tendency to enter the central part of an open field arena.  In Figure 
3-2A the frequency of entries into the centre of the open field was recorded every 
minute for 1 hour. Figure 3-2B shows the path length in the central area and shows 
a very similar pattern. In the first minute, the WT and MPS IIIB mice are 
indistinguishable, but diverge in subsequent minutes with the MPS IIIB mice 
entering the centre more frequently and travelling further. This results in no 
significant differences between WT and MPS IIIB mice in the first 3 minutes 
(F1,10=4.63–2.33, p=0.57–0.16) but a significant increase in MPS IIIB centre entries 
and path length after 10 minutes (F1,10=8.29–9.04, p=0.02-0.01) and a greater 
significant difference after 60 minutes (F1,10=21.19–23.45, p=0.001-0.0007).  MPS 
IIIB travel at significantly higher speeds in the central area (Figure 3-2C) with 
improving significance from 3 (F1,10=13.52, p=0.0043) to 10 (F1,10=22.50, p=0.0008) 
to 60 minutes (F1,10=78.65, p=0.000005).  This parameter is consistent with the 
overall rapid exploratory behaviour and may not be related to a reduced sense of 
danger. Figure 3-2D shows that there is no clear difference in the duration spent in 
the centre of the open field, after 3 minutes there is no significant difference 
(F1,10=2.58, p=0.140), at 10 minutes the WT mice spend significantly more time in 
the centre (F1,10=10.03, p=0.010); however after 60 minutes there is no significant 
difference (F1,10=1.48, p=0.251). Both groups of mice spent significantly more time 
in the sides of the test area than in the centre (not shown) (F1,10=296.36, p=9x10
-9), 
thus they both display a tendency to thigmotaxis. Overall these data suggest that 
although MPS IIIB mice enter the central area more frequently and travel further 
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and more rapidly in this area, there is no significant reduction in the sense of 
danger in MPS IIIB mice in this test in terms of the duration spent within the central 
area. 
 
Figure 3-2 One hour open field – centre and rearing 
At 8 months of age 6 WT (white squares) and 6 MPS IIIB (black squares) mice were placed in a cage 
outlined in Figure 3-1A and the behaviour was recorded for 1 hour. The results of the open field 
behaviour are presented as a 1 hour period with the average of every minute presented and as a bar 
chart of the first 3 minutes, first 10 minutes and whole hour. Error bars represent the SEM. p values 
were calculated by t-test. The frequency of entering the centre (A), path length in the centre of the 
cage in meters (B), the speed in the centre in mm per second (C) and time spent in the centre in 
seconds (D), the frequency of rearing (E) are presented. 
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Finally, we measured rearing activity of mice over the first 10 minutes of the open 
field test (Figure 3-2E). This is not measurable using our automated system and was 
therefore scored by hand. No significant difference was identified in the number of 
unsupported rears (F1,10=1.51, p=0.247), supported rears using the side of the cage 
(F1,10=0.256, p=0.624) and total rears (F1,10=1.21, p=0.297) between MPS IIIB or WT 
mice. 
The same groups of female mice were acclimatised in the same test arena as the 
open field for 24 hours by supplying bedding, a house, food and water ad libitum 
(Figure 3-3A). Home cage behaviour was then monitored for the subsequent 24 
hours.   
Figure 3-3B shows the average path length travelled by groups of 6-7 WT or MPS 
IIIB mice in 20 minute intervals over 24 hours, split into two equal 12 hour light or 
dark periods. All mice have significantly increased path length in darkness than in 
light (Illumination; F1,11=15.46 p=0.002) and over 24 hours, MPS IIIB mice have a 
significant increase in path length over their WT counterparts, travelling on average 
656m compared to 298m for WT mice (Genotype; F1,11=5.29, p=0.03). However, 
there are no significant differences between MPS IIIB and WT when measured in 
only darkness (Genotype; F1,11=2.56, p=0.138) or light (Genotype; F1,11=3.22, 
p=0.100). This suggests that a minimum of 24 hours observation in the home cage is 
required to show significant differences in path length. 
Rapid exploratory behaviour is measured as frequency (Figure 3-3C) and duration 
(Figure 3-3D) of speed over 90mm/s as before. All mice have an increased 
frequency of speed over 90mm/s in darkness compared to light (Illumination; 
F1,11=9.23, p=0.013). MPS IIIB mice have a borderline significantly increased 
frequency of speed over 90mm/s over the entire 24 hour period (Genotype; 
F1,11=4.05, p=0.057) and an almost significant difference between genotypes when 
this is measured in light (Genotype; F1,11=4.27, p=0.063) but not in darkness 
(Genotype; F1,11=2.48, p=0.144) alone, due to the increased variability in the dark. 
Interestingly the duration of speed over 90mm/s showed that MPS IIIB mice spent 
significantly less time travelling  faster  than  90mm/s over 24 hours  (Genotype; 
F1,11=7.91,  p=0.01)   and   in   the   dark  (Genotype; F1,11=8.80,  p=0.01)  which is not  
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Figure 3-3 Home cage behaviour – activity 
At 8 months of age 6 WT (white squares) and 7 MPS IIIB (black squares) mice were placed in a cage 
260 x 365mm outlined in (A) that included a food bowl and nesting house containing water within it.  
After 24 hours of acclimatisation the home cage behaviour was recorded for 24 hours using infrared 
lights for night-time monitoring. The results of the home cage behaviour are presented as a 24 hour 
period with the average of every twenty minutes presented and as a bar chart of firstly the whole 24 
hours and secondly the light and dark periods separately. Error bars represent the SEM. p values 
were calculated by MANOVA repeated measure analysis and one way ANOVA. The mean average 
path length in meters (B), frequency of rapid exploratory behaviour (speed> 90mm/s) (C), duration 
of rapid exploratory behaviour in seconds (D), frequency of immobility (E) and duration of 
immobility (F) are presented. 
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consistent with the frequency, pathlength nor the results of the 1 hour open field 
test. 
The frequency (Figure 3-3E) and duration (Figure 3-3F) of immobility were also 
recorded over 24 hours. Both the frequency (Illumination; F1,11=54.24, p=0.00001) 
and duration (Illumination; F1,11=9.32, p=0.004) of immobility was significantly 
increased in darkness for all mice and overall MPS IIIB mice had increased 
frequency (Genotype; F1,11=4.42, p=0.047) and duration (Genotype; F1,11=9.69, 
p=0.005) of immobility. For duration of immobility we observed a significant 
genotype effect in light (Genotype; F1,11=9.32, p=0.011) and dark (Genotype; 
F1,11=4.67, p=0.054).  
In the 24 hour home cage test the overall frequency of entering the centre (Figure 
3-4A) was significantly higher in the dark (Illumination; F1,11=17.46, p=0.0015) and 
there was an overall increase in centre entries by MPS IIIB mice (Genotype; 
F1,11=6.96, p=0.015). In light there is also a significant effect (Genotype; F1,11=6.52, 
p=0.027). This parameter is consistent with the hyperactivity observed in the 24 
hour home cage test and 1 hour test. The distance travelled in the centre (Figure 3-
4B) is also consistent with hyperactivity as there is a significant overall increase in 
MPS IIIB path length in the centre (Genotype; F1,11=6.14, p=0.021) and in the light 
(Genotype; F1,11=5.21, p=0.043) but not in the dark (Genotype; F1,11=2.98, p=0.112). 
There is also increased activity for all mice in the dark compared to light 
(Illumination; F1,11=7.10, p=0.017). The speed in the centre is likewise consistent 
with hyperactivity with a significant overall genotype (Genotype; F1,11=5.71, 
p=0.026) and illumination effect (Illumination; F1,11=8.31, p=0.015). However the 
increased speed in the centre observed in MPS IIIB mice only occurs in the light 
(Genotype; F1,11=40.99, p=0.00005) and not in the dark (Genotype; F1,11=0.16, 
p=0.69). There is a significant illumination difference in the duration of time spent 
in the centre (Figure 3-4D) (Illumination; F1,11=12.69, p=0.0045) but no genotype 
difference. This suggests that there is no detectable difference in sense of danger 
between MPS IIIB and WT mice. 
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Figure 3-4 Home cage behaviour – centre 
At 8 months of age 6 WT (white squares) and 7 MPS IIIB (black squares) mice were placed in a cage 
outlined in Figure 3-3A, after 24 hours of acclimatisation the home cage behaviour was recorded for 
24 hours. The results of the home cage behaviour are presented as a 24 hour period with the 
average of every twenty minutes presented and as a bar chart of firstly the whole 24 hours and 
secondly the light and dark periods separately. Error bars represent the SEM. p values were 
calculated by MANOVA repeated measure analysis and one way ANOVA. The frequency of entering 
the centre (A), path length in the centre of the cage in meters (B), the speed in the centre in mm per 
second (C) and time spent in the centre in seconds (D) are presented. 
 
In order to assess loss of motor skills and muscle strength with time, we firstly used 
the inverted screen test over 120 seconds (Figure 3-5A) to assess the number of 
rear leg moves performed (Figure 3-5B) and the duration to fall over this period 
(Figure 3-5C). At 8 months of age, WT mice perform on average almost twice as 
many rear leg movements as MPS IIIB and also fall later than MPS IIIB mice, but 
neither effect is significant due to a large variability (Moves; F1,11=1.53, p=0.241, 
Time; F1,11=1.05, p=0.327). At 10 months of age the number of rear leg movements 
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(F1,5=5.80, p=0.06) and the time to fall from the screen (F1,5=5.86, p=0.06) were on 
the borderline of a significant decrease in MPS IIIB mice. Increased group size would 
therefore probably have shown a significant effect in both parameters at 10 
months. 
The horizontal bar test measures motor coordination and grip strength (Figure 3-
5D). At 8 months of age there is no significant difference between MPS IIIB and WT 
mice (F1,11=2.34, p=0.15) (Figure 3-5E), but by 10 months of age the MPS IIIB mice 
are significantly worse at crossing the bar than WT mice (F1,5=25.13, p=0.004). This 
is in agreement with the inverted screen test and suggests that the mice continue 
to display normal motor skills at 8 months, which are beginning to decline by 10 
months of age. 
 
Figure 3-5 Inverted screen and horizontal bar crossing 
At 8 months of age 4 WT and 5 MPS IIIB mice and at 10 months of age 3 WT and 4 MPS IIIB mice 
performed the inverted screed test (A). The number of rear leg moves on the inverted screen (B) and 
the time spent on the inverted screen (C) was recorded.  At 8 months of age 6 WT and 7 MPS IIIB 
mice and at 10 months of age 3 WT and 4 MPS IIIB mice performed the horizontal bar test (D). The 
horizontal bar score (E) is a measure of the time of the time taken to cross or fall from the bar. Error 
bars represent the SEM and p values were calculated by t test.  
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3.5 Discussion 
In this work we have been able to determine several behavioural parameters that 
allow analysis of treatment effects on the neurological deterioration seen in MPS 
IIIB mice.  
The 1 hour open field habituation test performed at the same time of day gives 
clear genotype separation at 10 minutes and to a greater extent at 1 hour.  Eight 
month old MPS IIIB mice show a significantly increased path length, frequency and 
duration of rapid exploratory behaviour and reduced frequency and duration of 
immobility all of which are consistent with a hyperactive phenotype. They also 
show significantly increased frequency of entry, path length and speed in the 
central area whilst duration in the centre was unchanged.  This suggests that these 
mice do not have a reduced sense of danger when measured in this test, although 
the relatively small size of the arena used in this study could have reduced this 
effect (Crawley 2007). The difference between WT and MPS IIIB mouse behaviour 
often appeared to diverge from a similar starting point in the first minute or two of 
the test which led to non-significant differences when observations were measured 
in the first 3 minutes of the test, as is used by some researchers in the field 
(Hemsley et al. 2005).  Although all parameters were significant when measured 
over the first 10 minutes of the test (with the exception of duration in centre) as is 
used by many researchers (Cressant et al. 2004), 7/8 parameters were more 
consistently significantly different when measured over the entire 1 hour test 
period.  
Fu et al.  performed a one hour open field test on 4.5 to 5 month old male and 
female mice, but did not report activity or anxiety differences except for a decrease 
in rearing in the second 30 minutes by male mice (Fu et al. 2007). It is possible that 
4.5 to 5 months of age is too early to detect differences in genotypes but it is also 
critical that the test is performed at the same time of day and this is not noted in 
the study. We did not observe differences in any type of rearing activity between 8 
month old MPS IIIB and WT mice, however this was only measured over the first 10 
minutes.  In a 10 minute open field test (Cressant et al. 2004), performed at 5 
weeks and 7 months of age, no significant genotype differences were observed at 5 
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weeks of age but significant hyperactivity was seen in MPS IIIB mice at 7 months, in 
line with the results presented here, which is also consistent with the patient 
phenotype (Cleary et al. 1993).  
MPS IIIB mice showed increased frequency of entry, path length and speed in the 
central area whilst duration in the centre was unchanged. These increases can all be 
explained by increased hyperactivity causing the mice to move faster and so 
entering the centre more frequently and travelling further in the same amount of 
time.  MPS IIIB mice have been demonstrated to be less anxious when using the 
elevated plus maze (Cressant et al. 2004), however significant changes were only 
seen in darkness, and no anxiety differences were seen in a 1 hour open field test in 
daylight (Fu et al. 2007).  These discrepancies could be because of the relatively 
small size of the open field used in our studies (Crawley 2007), or the effect seen in 
darkness could be an artefact (Cressant et al. 2004). To test this hypothesis a larger 
open field test arena would be required. 
In the 24 hour test we observed significant genotype effects in all parameters 
except duration in the centre, however significance was much less evident 
compared to the 1 hour test, and increases in immobility frequency and duration in 
MPS IIIB mice in the 24 hours test are not consistent with the hyperactive 
behaviour seen in the 1 hour open field test. Differences between MPS IIIB and WT 
mice appeared to be more evident in daylight than in darkness where few changes 
were seen.  This could be because mice are usually less active in daylight, thus 
hyperactive behaviour is more easily distinguished during a relatively inactive 
phase.  Interestingly, children with Sanfilippo are reported to have circadian rhythm 
disturbances, with difficulty in sleeping and frequent night waking and night 
wandering (Fraser et al. 2002; Fraser et al. 2005), which would be consistent with 
the phenotype observed here. In addition, significant periodicity was noted in MPS 
IIIB mice during the dark phase of the 24 hour test, which may have confounded the 
ability to distinguish genotypes in darkness. Similar MPS IIIB periodicity, and in 
particular, a late bout of activity at the transition between light and dark was 
previously observed by us in a circadian analysis of MPS IIIB mice (Canal et al. 2010). 
MPS IIIB mice show increased frequency and duration of all activity measures with 
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commensurate reductions in frequency and duration of immobility in the 1 hour 
open field, which is consistent with sustained hyperactive behaviour. However, in 
the home cage, although pathlength and frequency of rapid exploratory behaviour 
is increased, other measures such as duration of rapid activity are not. MPS IIIB 
mice also have increased frequency and duration of immobility in the home cage. 
This discrepancy could reflect the fact that there is a nesting box in the home cage 
where behaviour could not be measured, but this is unlikely as there is no change in 
the duration of time spent in this area between genotypes. It could instead reflect 
different types of hyperactive behaviour during exploratory behaviour while the 
mouse habituates to a novel environment in the 1 hour test compared to normal 
behaviour in the home cage. The 24 hour home cage behaviour suggests that the 
mouse is not able to sustain rapid activity over longer periods, and is compensating 
by spending more time immobile.  
The 24 hour data broadly supports the previous circadian analysis by Heldermon et 
al 2007 and ourselves (Heldermon et al. 2007; Canal et al. 2010; Heldermon et al. 
2010), but is less effective at separating the phenotypes and less convincingly 
demonstrates a hyperactive phenotype. Cressant et al. also performed a home cage 
test over a 24 hour period, however that study lacked a 24 hour acclimatisation 
period, so has an element of habituation (Cressant et al. 2004). They observed no 
difference between MPS IIIB and WT mice in the light but a significant increase in 
the time the MPS IIIB mice spent in motion in the dark at 4.5 months of age. The 
open field test could be more consistent than the 24 hour home cage test because 
the circadian time that testing was performed at (8:30am) is close to a peak of 
activity that we (Canal et al. 2010) have previously observed in MPS IIIB mice just 
before the lights were switched on in the early morning (7am). This peak can be 
seen in many of the 24 hour measures in these data as well. In contrast, WT mice 
are becoming less active as the lights come on. The inverted screen test did not 
show a significant effect at 8 or 10 months of age but there was a clear trend 
towards the MPS IIIB mice moving less and being less able to grip the inverted 
screen. A larger n number for this experiment may make this effect significant. 
There is a clear significant failure of MPS IIIB mice to complete the horizontal bar 
crossing test at 10 months of age but no changes at 8 months of age. Taken 
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together these changes suggest that motor skills are lost late by MPS IIIB mice at 10 
months of age, and that it can be variable between mice.  A rocking rotarod test 
was performed by Heldermon et al. which also measures motor skills and a 
significant defect in MPS IIIB mice was seen from 9 months onwards which supports 
the inverted screen and horizontal bar test results (Heldermon et al. 2007; 
Heldermon et al. 2010). An accelerating rotarod test was not reported to show a 
significant difference between WT and MPS IIIB mice at 5 months of age (Fu et al. 
2007; Fu et al. 2010) or from 1.5 to 13 months of age (Heldermon et al. 2007). In 
our hands motor skills do not deteriorate significantly until 9-10 months of age, 
thus the horizontal bar test and the inverted screen test only have utility for the 
long term evaluation of therapies when the mice are at least 9-10 months of age 
and group sizes are more than 6-7. In addition the observation of urinary retention 
in these mice from 8-10 months of age onwards (Malinowska et al. 2010) is clearly a 
limiting factor in their ability to perform motor tasks and as such the use of motor 
tests after 8-9 months of age are more likely to measure this effect than a central 
dysfunction in motor abilities. 
In our previous work on treating MPS IIIB mice with genistein we found similar 
hyperactivity increases in male MPS IIIB mice, although differences were less 
marked than females (Malinowska et al. 2010). Although this would suggest that 
female mice may be more consistent for behavioural testing, Fu et al 2007 reported 
vertical activity changes only observed in males (Fu et al. 2007). The ability to 
readily group house females makes them a more economic proposition than males. 
 
3.6 Conclusion 
We have demonstrated that it is possible to detect consistently increased 
hyperactivity and rapid exploratory behaviour in the mouse model of MPS IIIB at 8 
months of age using a 1 hour open field test and modest group sizes of 6-7, which is 
consistent with MPS IIIB patient behaviour. The minimum test time that we would 
recommend for open field behaviour is 10 minutes, with more consistent data 
obtained at 60 minutes, and it may be important that tests are carried out close to 
the time at which lights are switched on in the morning. Home cage behaviour by 
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contrast is a much less reliable distinguisher of phenotype in MPS IIIB mice and may 
reflect less sustained hyperactive behaviour. Finally, motor skill evaluations are not 
likely to yield useful data before 9-10 months of age and can be significantly 
influenced by gait impairment as a result of urinary retention. This simple protocol 
will allow the evaluation of potential therapies for MPS IIIB and could prove useful 
in the development of assessment protocols for other mouse models of 
neurodegenerative diseases.  
 
Supplementary Video 3-1 MPS IIIB one hour open field 
A segment of video recorded during the 1 hour open field test, which shows the median mouse from 
each group (MPS IIIB on the left, WT on the right) over the median 2 minutes of the test (minutes 
29-31).  The clip is shown at 4 times normal speed. Please see enclosed CD. 
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of Danger in the Open Field Test 
 
 
Published in Public Library of Science ONE (PLoS ONE) on 18th October 2011. 
The definitive version can be found at 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0025717 
and the published version can be found in the appendix. 
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4.1 Abstract 
Reliable behavioural tests in animal models of neurodegenerative diseases allow us 
to study the natural history of disease and evaluate the efficacy of novel therapies. 
Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo A), is a severe, 
neurodegenerative lysosomal storage disorder caused by a deficiency in the 
heparan sulphate catabolising enzyme, sulphamidase. Undegraded heparan 
sulphate accumulates, resulting in lysosomal enlargement and cellular dysfunction. 
Patients suffer a progressive loss of motor and cognitive function with severe 
behavioural manifestations and premature death. There is currently no treatment. 
A spontaneously occurring mouse model of the disease has been described, that 
has approximately 3% of normal enzyme activity. Behavioural phenotyping of the 
MPS IIIA mouse has been previously reported, but the results are conflicting and 
variable, even after full backcrossing to the C57BL/6 background. Therefore we 
have independently backcrossed the MPS IIIA model onto the C57BL/6J background 
and evaluated the behaviour of male and female MPS IIIA mice at 4, 6 and 8 months 
of age using the open field test, elevated plus maze, inverted screen and horizontal 
bar crossing at the same circadian time point. Using a 60 minute open field, we 
have demonstrated that female MPS IIIA mice are hyperactive, have a longer path 
length, display rapid exploratory behaviour and spend less time immobile than WT 
mice. Female MPS IIIA mice also display a reduced sense of danger and spend more 
time in the centre of the open field. There were no significant differences found 
between male WT and MPS IIIA mice and no differences in neuromuscular strength 
were seen with either sex.  The altered natural history of behaviour that we 
observe in the MPS IIIA mouse will allow more accurate evaluation of novel 
therapeutics for MPS IIIA and potentially other neurodegenerative disorders. 
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4.2 Introduction 
Mucopolysaccharidosis IIIA (MPS IIIA, OMIM #252900), or Sanfilippo Type A, is an 
autosomal recessive lysosomal storage disorder that affects 0.82 in 100,000 live 
births in the United Kingdom (Heron et al. 2011). The disease is characterised by 
severe and progressive loss of cognitive and motor functions, behavioural 
difficulties and eventually death in the second decade of life, although the severity 
and progression of the disease varies widely (Meyer et al. 2007; Valstar et al. 2010; 
Heron et al. 2011). MPS IIIA is caused by mutations in the SGSH gene that result in 
deficiency of the N-sulphoglucosamine sulphohydrolase enzyme (sulphamidase, EC 
3.10.1.1) and subsequent accumulation of undegraded heparan sulphate, lysosomal 
enlargement and cellular and organ dysfunction (Kresse et al. 1972; Kresse 1973; 
Scott et al. 1995; Valstar et al. 2008). Patients exhibit progressive 
neurodegeneration and behavioural problems including hyperactivity, a reduced 
sense of danger, aggression and sleep disturbances (Cleary et al. 1993; Bax et al. 
1995; Fraser et al. 2002; Fraser et al. 2005; Valstar et al. 2008; Malm et al. 2010). 
Although there are no current therapies, several strategies are in development for 
MPS IIIA or the phenotypically indistinguishable MPS IIIB disease, including 
substrate reduction therapy (Roberts et al. 2007; Malinowska et al. 2009; 
Malinowska et al. 2010), intrathecal enzyme replacement therapy (Gliddon et al. 
2004; Savas et al. 2004; Hemsley et al. 2007; Hemsley et al. 2008b; Hemsley et al. 
2009b) and gene therapy with lentiviral (McIntyre et al. 2010), adenoviral (Lau et al. 
2010b) or adeno-associated-viral (Fraldi et al. 2007) vectors. Most strategies make 
use of the ability of exogenous enzyme to complement affected cells, however the 
presence of the blood brain barrier limits efficient enzyme distribution. Biomarkers 
for MPS IIIA or related diseases are still in development (Langford-Smith et al. 2010; 
Langford-Smith et al. 2011c), thus the accurate evaluation of neurodegeneration 
using behavioural phenotyping in the mouse model of disease is paramount. A 
spontaneously occurring mouse model of MPS IIIA on a mixed 129SvJ, C57BL/6, SJL, 
and CD1 background has been previously described with around 3% of normal 
enzyme activity and exhibiting many of the features observed in patients (Bhaumik 
et al. 1999). The MPS IIIA mice exhibit severe neuropathology characterised by 
enlarged lysosomes, primary storage of HS, secondary storage of GM2 and GM3 
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gangliosides and cholesterol and chronic neuroinflammation (Bhaumik et al. 1999; 
McGlynn et al. 2004; Savas et al. 2004; Fraldi et al. 2007; Arfi et al. 2011). The MPS 
IIIA mice are euthanized between 9 and 12 months of age due to urine retention, a 
phenotype not seen in the patients but also seen in MPS IIIB mice (Gografe et al. 
2009). The MPS IIIA mouse model has been backcrossed to the C57BL/6 background 
by Professor John Hopwood’s Lysosomal Diseases Research Unit  (Crawley et al. 
2006) and to the C57BL/6J background by Jackson laboratories 
(Website)(Website)(Website)(Website)(Website)(Jackson Laboratories website). 
Although the behaviour of the MPS IIIA mouse model has been evaluated in the 
open field test at several ages, using different sexes, by several groups and on 
different strain backgrounds, there is a remarkable amount of variability in the 
outcome of the test as outlined in Table 4-1.  
Using the mixed background mouse, at many of the time points measured, no 
differences are observed between either male or female WT and MPS IIIA mice, 
with initial findings of hyperactivity and later hypoactivity in males (Hemsley et al. 
2005; Hemsley et al. 2007). After back crossing the MPS IIIA mice on to a C57BL/6 
background, the behaviour was extensively studied by Crawley et al. at different 
time points. Hyperactivity in males was observed at 12 weeks of age, and females at 
22 and 32 weeks of age, although these mice were not näively tested (Crawley et al. 
2006). At most time points, no differences were seen.  However male, but not 
female, MPS IIIA mice were shown to be hypoactive at some time points in the 
work of Lau et al (Lau et al. 2008) and male MPS IIIA mice were hypoactive at 15 
weeks of age in a more recent paper by Lau et al (Lau et al. 2010a). Hypoactivity in 
male mice was also observed at some time points in McIntyre et al. (McIntyre et al. 
2010). In columns 7, 8, 9 and 10 of Table 4-1 (marked as bold) we have also 
presented markedly variable outcomes of observations of locomotor behaviour of 
MPS IIIA and WT mice that received control intracranial injections (Fraldi et al. 
2007; Hemsley et al. 2007; Hemsley et al. 2009a; McIntyre et al. 2010). 
Patients with MPS IIIA are believed to have a reduced sense of danger, which can 
be inferred in mice by the amount of time spent in the centre of the open field test 
or by use of the elevated plus maze test, both of which can be used to measure 
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their tendency to avoid open spaces and remain close to cover (thigmotaxis). No 
difference in the time in centre of the open field was detected by Lau et al. (Lau et 
al. 2008), however this could be due to the small size of the open field used. In the 
elevated plus maze, male MPS IIIA mice were reported to display reduced anxiety 
with a greater proportion of their path length (distance travelled) spent in the open 
arms at some time points but not others (Lau et al. 2008; Lau et al. 2010a). 
Overall, there are discrepancies in behaviour of this mouse model that could be due 
to gender differences, the age of testing and the methodology used to perform the 
tests. Therefore we have attempted to perform a standardised analysis of MPS IIIA 
mice by first backcrossing them to the C57BL/6J background for over 10 
generations and subsequently testing a cohort of MPS IIIA and WT mice at the same 
circadian time point at 4, 6 and 8 months (16, 24 and 32 weeks) of age in the 60 
minute open field test, the elevated plus maze, as well as several other 
neuromuscular evaluations that we have previously shown to be effective for 
phenotyping MPS IIIB mice  (Langford-Smith et al. 2011b). The female MPS IIIA mice 
were hyperactivie, had a reducued sense of danger and no neuromuscular 
differences. The open field test performed at the same point in the circadian 
rhythm was a consistent, sensitive and reliable behavioural test for the evaluation 
of novel therapeutic strategies in MPS IIIA mice. 
  
Table 4-1 Summary of the significant differences in the open field activity of MPS IIIA mice in the literature 
Hemsley et al. Lau et al. McIntyre et al. * Hemsley et al. * Hemsley et al. * McIntyre  et al. * Fraldi et al.
2007 2010 2010 2007 2009 2010 2007
Mixed C57BL/6 C57BL/6 Mixed C57BL/6 C57BL/6 C57BL/6
Line Crossing Path Length Line crossing Line Crossing Path Length Line crossing Path Length
Male Female Male Male Female Male Male Male Female Male Male Male Male Male Female
3 Hyper Hyper NS NS
4 NS Hypo
5 NS NS
6 Hypo NS Hypo NS NS
8 NS NS NS* +Hypo*
10 NS NS Hypo NS NS NS NS*
12 Hyper NS NS* +Hypo* Hypo*
15 Hypo NS NS NS Hypo NS NS NS*
16 NS Hyper
18 Hypo NS NS NS Hypo* NS*
20 NS NS Hypo NS*
21 Hyper*
22 Hypo NS NS Hyper
24 NS NS* NS Hyper
25 NS NS
28 NS NS*
32 NS Hyper NS Some Hyper
40 NS NS NS NS
2006
Measure
Age (Weeks)
This Study
C57BL/6J
Path Length
Lau et al.
2008
C57BL/6
Zone Entries
Crawley et al.
Sex
Hemsley et al.
2005
Mixed
Line Crossing
C57BL/6
Line Crossing
Paper
Year
Background
 
Hyper indicates significant hyperactive behaviour and hypo indicates significant hypoactive behaviour in the open field test.  NS indicates no significant difference and * 
indicates mice that have recieved intracranial injections. Control injections contained: 2.5µl of 50mM sodium acetate, 100mM sodium chloride at pH 5.0 in Hemsley et al 2007, 
4µl 10mM sodium phosphate, 140mM sodium chloride pH 7.0 in Hemsley et al. 2009, 5µl 0.9% (w/v) sodium chloride in McIntyre et al. 2010 and 1µl GFP adeno-associated 
viral vector in Fraldi et al. 2007. The work of Hemsley et al. 2007 contained multiple control treated groups and where there were differences between groups, both have been 
shown. Where female mice are not mentioned or cells are blank no testing was performed. 
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4.3 Methods 
4.3.1 Mouse Maintenance 
The MPS IIIA mouse colony was maintained through heterozygous breeding at the 
University of Manchester, all procedures were ethically approved by the University 
of Manchester Ethical Review Process Committee and in accordance with the UK 
Home Office regulations under project licence PPL 40/3117. Mice were housed in 
individually ventilated cages, had access ad libitum to food and water and were in a 
12 hour light and dark cycle. Male mice were singly housed at 14 weeks of age due 
to aggressive tendencies but female mice remained housed in groups of 4-6.  The 
MPS IIIA mice have been backcrossed from the original mixed 129SvJ, C57BL/6, SJL, 
and CD1 background (Bhaumik et al. 1999) onto the C57BL/6J background by more 
than 10 generations of backcrossing with C57BL/6J mice (Harlan, UK) and were 
maintained by heterozygous breeding. WT and MPS IIIA littermates have been used 
in all behavioural experiments. 
4.3.2 Genotyping MPS IIIA mice 
MPS IIIA mice have a G to A mutation in the SGSH gene which removes a MspA1I 
restriction enzyme digestion site.  Genotyping is performed by PCR amplification of 
DNA followed by MspA1I digestion and observation of the size of DNA fragments 
produced.  Genomic DNA was extracted from ear punches using the GenElute 
Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich) following the 
manufacturer’s instructions and SGSH was amplified by PCR using the forward 
primer 5’ GTGTTCCCTGCCTGCTCAC 3’  and reverse primer 5’ 
CCAGTCCCCTCATCCCACTA 3’.  The DNA was digested with MspA1I (New England 
Biolabs, UK) and the DNA fragments were separated by 2% agarose gel 
electrophoresis. The genotype was determined from the pattern of DNA fragments; 
wild type (WT) reveals 199bp, 118bp and 78bp fragments, mutant (MUT) 317bp 
and 78 bp fragments and heterozygous (HET) 317bp, 199bp, 118bp and 78bp. 
4.3.3 Behavioural Testing 
At 4, 6 and 8 months (16, 24 and 32 weeks) of age, the same cohorts of 10 male WT 
and 10 male MPS IIIA mice and 10 female WT and female 11 MPS IIIA mice were 
Chapter 4 – MPS IIIA Behaviour 
 
[Page 135] 
analysed with the following behavioural tests. 1.5 hours into the 12 hour light 
phase the mice were dropped into the centre of an open field arena (width 450mm, 
depth 450mm, height 500mm) made of matt white acrylic (Figure 4-1A). The 
behaviour was recorded for 60 minutes using a digital camcorder (Sony) and 
analysed using Top Scan software (Clever Sys. Inc., USA). The path length, frequency 
(number of times) and duration of rapid exploratory behaviour (speed >100mm/s), 
frequency and duration of immobility (speed <5mm/s) and frequency of entering 
the centre and duration in the centre (75mm from each edge) was analysed. 
Rearing in the open field was analysed by counting the number of unsupported 
rears (front paws off the floor) and supported rears (front paws on the wall) in the 
first 10 minutes. The same researcher performed all experiments and was blinded 
to genotype. 
After a 30 minute rest, the mice were placed onto the end of an open arm of an 
elevated plus maze. The maze was constructed of matt white acrylic, comprised of 
four 500mm long by 100mm wide arms, two of which were enclosed by 500mm 
high walls, and was raised on a stand 500mm off the floor (Figure 4-5A).  Mice were 
placed so they faced towards the centre of the maze and were given 10 minutes to 
explore the maze before returning to a cage. The maze was cleaned using 70% 
ethanol. 30 minutes later the mice were tested for a second time, in the same 
manner. The results were analysed using Top Scan software (Clever Sys) to examine 
the amount of time spent on the open arm, the percentage of path length in the 
open arm, and the percentage of open arm entries. 
30 minutes later the inverted screen test was performed, as described previously 
(Figure 4-6A) (Langford-Smith et al. 2011b). In brief, at 4, 6 and 8 months of age the 
mouse was placed on a 470mm square with a 13mm square wire mesh. The screen 
was then rotated through 180° over 1-2 seconds. The mouse was then suspended 
upside down over a padded surface; the rear leg moves were counted and the 
duration suspended was recorded up to 2 minutes. 
One hour later the horizontal bar test was performed as described previously 
(Figure 4-6B) (Malinowska et al. 2010; Langford-Smith et al. 2011b). In brief, a 2mm 
diameter, 300mm long metal wire was secured between 2 posts, 320mm above a 
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padded surface. The mouse was allowed to grip the centre of the wire and the time 
taken to fall or to reach the side was recorded up to 2 minutes. The test was 
repeated three times as a training run followed by a 10 minute rest before three 
test runs.  The results were scored as follows: crossing the bar in x seconds was 
scored as 240-x, remaining on the bar was scored as 120 and falling off the bar after 
y seconds was recorded as y.  
4.3.4 Urine Retention 
Upon sacrifice 9 male WT, 8 male MPS IIIA, 7 female WT and 8 female MPS IIIA mice 
at 8 months (32 weeks) of age were dissected and the urine was removed from the 
bladder and volume measured using an insulin syringe (BD). 
4.3.5 Statistical Analysis 
Statistical analysis was performed using JMP software (SAS Institute Inc, Cary, NC, 
USA) and analysed by MANOVA with repeated measures for overall significances 
and by one or two way ANOVA, as appropriate, with Tukey post hoc tests at 
individual time points. Significance was set at p≤0.05. For the MANOVA analysis the 
Genotype significance determines if there is a difference between WT and MPS IIIA 
mice irrespective of the age of the mice, the Time significance determines if there is 
a change in the behaviour of the mice at different ages irrespective of the genotype 
and the Genotype*Time significance determines if MPS IIIA mouse behaviour 
changes over time in a different manner to WT mice. 
 
4.4 Results 
Cohorts of male and female, WT and MPS IIIA mice (n=10-11 per group) were 
monitored in a 60 minute open field test as outlined in Figure 4-1A.  The path 
length minute by minute over 60 minutes is shown at 4 months (16 weeks)  in 
Figure 4-1B, 6 months (24 weeks) in Figure 1C and at 8 months (32 weeks) in Figure 
1D. The behaviour in the first 3 minutes, 10 minutes and 60 minutes is presented to 
allow comparison against published data and to identify the minimum amount of 
time required for statistically significant analyses. At 4 months of age, female MPS 
IIIA mice were significantly hyperactive and travel almost twice as far as the WT 
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mice over 60 minutes (p=0.037; Figure 4-1B). Examining the behaviour over the first 
3 minutes showed no difference and no trend in female behaviour, but over 10 
minutes there was a non-significant trend towards hyperactivity. No difference was 
found in the path length of male WT or MPS IIIA mice at 4 months.  
At 6 months of age the same female MPS IIIA mice demonstrated increased path 
length with significant differences after 10 minutes (p=0.030) and  greater 
differences after 60 minutes (p=0.005; Figure 4-1C). No difference was detected 
between male WT and MPS IIIA mice (Figure 4-1C).  
At 8 months of age there was a trend for the female mice to be hyperactive but no 
significant differences were found after 3 (p=0.73), 10 (p=0.15) or 60 minutes 
(p=0.18; Figure 4-1D). Similarly, no significant differences were found with male 
mice after 3, 10 or 60 minutes. Overall, using MANOVA repeated measure analysis, 
a significant genotype difference (p=0.011), time difference (p=1.2x10-7) and a 
time*genotype difference (p=0.021) were found. This indicates that overall, MPS 
IIIA mice are significantly more hyperactive than WT mice, that this changes with 
time and that MPS IIIA and WT mice change their behaviour in a different manner 
over time. 
The number of unsupported rears (front paws off the floor), supported rears (front 
paws on a wall) and total rears were counted manually in the first 10 minutes of the 
open field test.  The only significant change observed was a decrease in the number 
of unsupported rears by female MPS IIIA mice at 6 months of age (Figure 4-1F). 
However, given that there were no other significant genotype effects, this may be 
just a chance occurrence (Figure 4-1E and G). MANOVA repeated measure analysis 
of the data showed no significant genotype effect in the three rearing measures, 
but there was a significant decline in all measures with time (unsupported; p=0.004, 
supported and total p=0.00003) irrespective of genotype. 
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Figure 4-1 Open field path length and rearing 
At 4, 6 and 8 months (16, 24 and 32 weeks) of age, 10 WT male (light grey squares), 10 MPS IIIA male 
(dark grey squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) mice were 
placed in the open field and the behaviour was recorded for 60 minutes (A). The results of the open 
field behaviour are presented as a 60 minute period with the average of every minute presented and 
as a bar chart of the first 3 minutes, first 10 minutes and the whole hour. Error bars represent the 
standard error of the mean (SEM). p values were calculated by 2 Way ANOVA. The mean average 
path length in metres at 4 (B), 6 (C) and 8 (D) months have been presented.  The number of 
unsupported, supported and total rears in the first 10 minutes at 4 (E), 6 (F) and 8 (G) months of age 
have also been presented. 
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Rapid exploratory motion was analysed by measuring the frequency and duration 
of speed over 100mm/s (Figure 4-2A-F). At 4 months of age, female MPS IIIA mice 
show significant increases in both the frequency (p=0.048; Figure 4-2A) and 
duration (p=0.05; Figure 4-2D) of rapid exploration over 60 minutes. However, no 
significant differences were observed after 3 or 10 minutes, although a trend was 
detected after 10 minutes (Figure 4-2A). No significant differences were found 
between male MPS IIIA or WT mice at 4 months of age. 
At 6 months of age, there was a trend towards increased frequency (Figure 4-2B) 
and duration (Figure 4-2E) of rapid exploratory motion after 3 minutes in the 
female MPS IIIA mice (p=0.23, p=0.10). After 10 (p=0.021, p=0.034) and 60 minutes 
(p=0.0003, p=0.0057), female MPS IIIA mice had significantly increased frequency 
(Figure 4-2B) and duration (Figure 4-2E) of rapid exploratory motion over 100mm/s. 
No significant differences were observed between male WT and MPS IIIA mice.  This 
rapid exploratory behaviour is visible in supplementary video 4-1 which shows the 
median female WT and MPS IIIA mouse at 6 months of age at 4 times normal 
speed. 
At 8 months of age, female MPS IIIA mice show a trend towards increased 
frequency of rapid exploratory motion over 60 minutes (p=0.18) (Figure 4-2C), with 
a trend to increase in duration after 10 minutes (p=0.083) and a significant increase 
after 60 minutes (p=0.02) (Figure 4-2F). Male MPS IIIA and WT mice were 
indistinguishable. Using MANOVA repeated measure analysis, there was a 
significant difference between WT and MPS IIIA mice over all three time points for 
frequency (Genotype; p=0.004) and duration (Genotype; p=0.013) of rapid 
exploratory motion. There was a significant decline in frequency (Time; p=9.7x10-15) 
and duration (Time, p=4.5x10-8) of rapid exploratory motion with time and also 
between genotypes over time for frequency (Time*Genotype p=0.00005) and 
duration (Time*Genotype, p=0.036). 
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Figure 4-2 Open field rapid exploratory behaviour 
At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey squares), 
10 WT female (white squares) and 11 MPS IIIA female (black squares) mice were placed in the open 
field and the behaviour was recorded for 60 minutes. The results of this test are presented as a 60 
minute period with the average of every minute presented and as a bar chart of the first 3 minutes, 
first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 
Way ANOVA. The frequency of moving faster than 100mm/s at 4 (A), 6 (B) and 8 (C) months and the 
duration spent moving faster than 100mm/s at 4 (D), 6 (E) and 8 (F) months of age have been 
presented. 
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The frequency and duration the mice spent immobile was also recorded (Figure 4-
3A-F). There were no significant differences in frequency of immobility between 
either male or female MPS IIIA and WT mice at any time point.  However, female 
WT mice had significantly increased duration of immobility over 60 minutes at 4 
(p=0.005) and 6 months (p=0.004) but not at 8 months (p=0.70). Male MPS IIIA or 
WT mice had indistinguishable duration of immobility at all time points measured. 
Using MANOVA repeated measures there was an overall increase in the frequency 
of WT immobility over MPS IIIA mice over the three time points (Genotype; 
p=0.027), but no change with time (Time; p=0.543), or genotype with time 
interaction (Genotype*Time; p=0.636). MANOVA repeated measures analysis of 
duration of immobility demonstrated a significant genotype effect over the three 
time points (Genotype; p=0.05), that changes significantly with time (Time; 
p=1.5x10-9) and changes differently with time between the two genotypes 
(Genotype*Time; p=0.030).  
Mice being a prey species tend to display thigmotaxis, remaining close to the sides 
of an open field arena. Increased frequency and duration of time spent in the 
centre of the open field test therefore demonstrates reduced thigmotaxis and this 
is commonly considered to be a measure of reduced anxiety or reduced sense of 
danger that the animal experiences (Simon et al. 1994). Male MPS IIIA and WT mice 
showed no significant differences in frequency of centre entries at any age (Figure 
4-4A, B and C). At 4 months of age, female MPS IIIA mice showed significantly 
increased centre entries at 60 minutes (p=0.0045). At 6 months female MPS IIIA 
mice entered the centre significantly more at 3, 10 and 60 minutes (p=0.057, 
p=0.023, p=0.0005; Figure 4-4B).  At 8 months of age female MPS IIIA showed no 
significant increases in centre entries (p=0.37) (Figure 4-4C). Using MANOVA MPS 
IIIA mice showed significantly increased centre entries (Genotype; p=0.003), which 
changed significantly over time (Time; p=2.3x10-11) and between genotypes over 
time (Genotype*Time; p=0.0013).   
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Figure 4-3 Open field immobile behaviour 
At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey squares), 
10 WT female (white squares) and 11 MPS IIIA female (black squares) mice were placed in the open 
field and the behaviour was recorded for 60 minutes. The results of this test are presented as a 60 
minute period with the average of every minute presented and as a bar chart of the first 3 minutes, 
first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 
Way ANOVA. The frequency of not moving at 4 (A), 6 (B) and 8 (C) months and the duration spent 
not moving at 4 (D), 6 (E) and 8 (F) months of age have been presented. 
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Figure 4-4 Open field sense of danger behaviour  
At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey squares), 
10 WT female (white squares) and 11 MPS IIIA female (black squares) mice were placed in the open 
field and the behaviour was recorded for 60 minutes. The results of this test are presented as a 60 
minute period with the average of every minute presented and as a bar chart of the first 3 minutes, 
first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 
Way ANOVA. The frequency of entering the centre at 4 (A), 6 (B) and 8 (C) months and the duration 
spent in the centre at 4 (D), 6 (E) and 8 (F) months of age have been presented. 
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The duration spent in the centre has also been analysed. At 4 months of age,  
female MPS IIIA mice spent significantly more time in the centre than WT, after 60 
minutes (p=0.012; Figure 4-4D). Males were not significantly different. At 6 months 
of age female MPS IIIA mice had increase duration in the centre after 60 minutes 
(p=0.012) and showed an almost significant trend in male mice (p=0.055; Figure 4-
4E).  At 8 months of age there are no significant differences between genotypes 
(Figure 4-4F). By MANOVA repeated measure analysis MPS IIIA mice spend 
significantly increased duration in the centre area (Genotype; p=0.001), this 
changes significantly over time (Time; p=2.5x10-6) and between genotypes over 
time (Time*Genotype; p=0.005). 
Thirty minutes after behavioural analysis in the open field, the same cohort of mice 
were tested on an elevated plus maze (Figure 4-5A) for ten minutes, followed by a 
30 minute rest and another 10 minute trial. Several parameters were measured 
(frequency of entering open arm, percentage of entries into the open arm, path 
length in open arm, percentage of path length in open arm and time in open arm) 
but none reached significance. Here we have presented the percentage of entries 
to the open arms, percentage of path length in the open arms and duration in the 
open arms as measure of anxiety (Figure 4-5B, C, D), which is representative of 
many of the other measures. At 4, 6 and 8 months of age there was no significant 
difference in male or female WT or MPS IIIA open arm entries (Figure 4-5B, C, D).  
At 4, 6 and 8 months there was no difference between WT and MPS IIIA mice in the 
repeat elevated plus maze and no difference between first and second elevated 
plus maze tests except that in the second test, all the mice performed fewer entries 
and had a shorter path length (Figure 4-6A-C). Statistical analysis by MANOVA 
showed no significant difference in genotype, or time but there was a significant 
difference in how the genotypes behaved over time in the percentage of path 
length in the open arm (p=0.019) as the MPS IIIA mouse path length decreased at 8 
months but the WT increased.  
The inverted screen test (Figure 4-7A) and horizontal bar crossing test (Figure 4-7B) 
were also performed. The inverted screen test measures neuromuscular strength 
and the bar crossing test measures both neuromuscular strength and motor 
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coordination.  The bar crossing test showed no significant differences between WT 
and MPS IIIA of either sex at 4, 6 or 8 months of age (Figure 4-7C-E). Over time, 
there was a significant decrease in the number of moves and time spent on the 
inverted screen (p=1.7x10-6, p=1.2x10-5), and a significant sex difference in the 
number of moves with females moving more (p=0.004). Bar crossing showed no 
genotype effect and no time effect but there was a significant Time*Sex effect 
(p=0.044), as the female score decreased over time but the male score increased at 
6 months and then decreased at 8 months.  
 
Figure 4-5 Elevated plus maze behaviour 
At 4, 6 and 8 months of age 7-11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT 
female (white bars) and MPS IIIA female (black bars) mice were placed on the elevated plus maze (A) 
and the behaviour was recorded for 10 minutes.  After a 30 minute rest, the test was repeated. The 
results of the first test are presented as the mean of each measure with error bars representing the 
SEM. p values were calculated by 2 Way ANOVA. The following measures have been presented; the 
percentage of total entries that were into the open arm, the percentage of the path length in the 
open arm and the duration spent on the open arm at 4 (B), 6 (C) and 8 (D) months of age. 
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Figure 4-6 Repeat elevated plus maze behaviour  
At 4, 6 and 8 months of age 7-11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT 
female (white bars) and MPS IIIA female (black bars) mice were placed on the elevated plus maze (A) 
and the behaviour was recorded for 10 minutes.  After a 30 minute rest, the test was repeated. The 
results of the repeat test are presented as the mean of each measure with error bars representing 
the SEM. p values were calculated by 2 Way ANOVA. The following measures have been presented; 
the percentage of total entries that were into the open arm, the percentage of the path length in the 
open arm and the duration spent on the open arm at 4 (A), 6 (B) and 8 (C) months of age. 
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Figure 4-7 Neuromuscular behaviour  
At 4, 6 and 8 months of age 8-11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT 
female (white bars) and MPS IIIA female (black bars) mice were placed on the inverted screen test 
(A) and horizontal bar crossing test (B). The number of rear leg moves, the time spent on the 
inverted screen and the bar crossing score are presented at 4 (C), 6 (D) and 8 (E) moths of age. Error 
bars represent the SEM and p values were calculated by 2 Way ANOVA. 
 
 
 Figure 4-8 Urine retention at 8 months 
At 8 months of age 9 WT male (light grey bars), 8 MPS IIIA male (dark grey bars), 7 WT female (white 
bars) and 8 MPS IIIA female (black bars) were sacrificed and the urine volume in the bladder 
measured. The results are presented as the mean with error bars representing the SEM. p values 
were calculated by 2 Way ANOVA. 
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4.5 Discussion  
We have backcrossed the mixed background MPS IIIA mouse model onto the 
C57BL/6J background and characterised a behavioural phenotype that can be used 
to accurately distinguish female MPS IIIA mice from WT littermates. Our findings 
clearly show that male mice show no significant difference to WT littermates in the 
open field test or elevated plus maze, whilst female MPS IIIA mice demonstrate 
characteristic hyperactive behaviour initially at 4 months (16 weeks) and more 
strongly at 6 months (24 weeks), which declines again at 8 months (32 weeks) of 
age. We also show that these mice have a reduced thigmotaxis at 4 and 6 months 
of age which would indicate a reduced sense of danger. Hyperactivity and a 
reduced sense of danger are observed in the behavioural phenotype of the MPS IIIA 
patients (Cleary et al. 1993; Bax et al. 1995; Valstar et al. 2008; Heron et al. 2011). 
In this study we observed no significant behavioural differences between WT and 
MPS IIIA male mice. This is in contrast to Hemsley et al. 2005 where hyperactivity 
was initially observed at 3 weeks, hypoactivity at 6 and 15 weeks and no changes at 
10, 20 and 40 weeks in male mixed background  mice (Hemsley et al. 2005). Lau et 
al. 2008 used male MPS IIIA mice that had been back crossed onto the C57BL/6 
background and observed no differences at 3, 5 and 15 weeks, with significant 
hypoactivity at 10, 18 and 22 weeks (Lau et al. 2008) but subsequently observed 
hypoactivity in 15 week old male mice (Lau et al. 2010b). Crawley et al., using male 
MPS IIIA mice on the same C57BL/6 background, found no changes at 4, 6, 8, 10, 15, 
18, 22, 25, 32 and 40 weeks and only observed hyperactivity at 12 weeks (Crawley 
et al. 2006). Finally, using male mice independently crossed onto the C57BL/6J 
background by Jackson laboratories, hypoactivity was observed in MPS IIIA  mice at 
20 weeks of age by McIntyre et al. but no difference was found at 24 or 32 weeks 
(McIntyre et al. 2008). Clearly, it is hard to obtain consistent behavioural readouts 
from male mice in this context and it is always difficult to know if hypoactivity could 
be confounded by any parameter affecting the mouse’s physical ability to move.  
We find male MPS IIIA mice to be very aggressive and are unable to keep them 
group housed, which is likely to change their behaviour. Singly housing male 
C57BL/6 mice has been shown to increase locomotor activity and reduce anxiety 
(Voikar et al. 2005) or alternatively in other researchers hands to have no effect 
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(Arndt et al. 2009). At the very least, it certainly leads to weight gains, which will 
restrict movement, and this may confound reliable open field measures.  
Additionally we find that all MPS IIIA mice retain urine over time, with male mice 
retaining significantly more urine at 8 months of age and urine retention is the 
humane endpoint (Figure 4-8). Clearly urinary retention could be restricting 
movement which would confound behavioural measures. Lastly, it is worth pointing 
out that many male mouse studies are on mixed, C57BL/6 or C57BL/6J 
backgrounds, some of which have been performed in different laboratories, which 
could lead to inconsistencies in outcomes. Overall, we would argue that 
comparisons of male MPS IIIA mice with WT are not appropriate (or easy to 
perform) for determination of treatment responses. 
Several studies analysed behaviour of male MPS IIIA mice following control 
intracranial injections. Fraldi et al. tested male mice and found that the MPS IIIA 
mice were hyperactive at 21 weeks of age but not prior to this, but these mice had 
received intracranial injections and this may have adversely affected the mouse’s 
behaviour (Fraldi et al. 2007). Other studies where intracranial injections have been 
given to MPS IIIA mice all used male mice and generally observed either no changes 
or hypoactivity (Hemsley et al. 2007; Hemsley et al. 2009a; McIntyre et al. 2010). It 
is worth considering that intracranial injections could have altered the natural 
behaviour of the mouse and this may be why hypoactivity is observed. 
We found female MPS IIIA mice to be hyperactive, having a significantly increased 
path length, frequency and duration of rapid exploratory behaviour and reduced 
duration of immobility at 4 and 6 months of age, (16 and 24 weeks) whilst duration 
of rapid exploratory behaviour was significantly increased at 8 months (32 weeks). 
At 4 months of age differences are only significant after 60 minutes, but at 6 
months they are all significant after both 10 and 60 minutes. This indicates that the 
60 minute test is a more sensitive test to identify hyperactivity than the 10 or 3 
minutes tests. No significant differences were observed over the first 3 minutes at 
any time point, thus we would suggest that studies such as that of Crawley et al. 
2006 where this short test has been used are not likely to yield significant 
differences (Crawley et al. 2006).  
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Our hyperactivity findings in females are supported by Crawley et al, where 
hyperactivity was observed at 22 and 32 weeks of age in a 3 minute test with 
female MPS IIIA C57BL/6 mice, however no difference was observed at any point 
prior to 18 weeks or at 25 or 40 weeks of age (Crawley et al. 2006). They also 
observed hypoactivity in females at 4 weeks of age but we do not have comparative 
data to comment on this.  The longer testing time utilised in our study may have 
meant that we were better able to detect behavioural changes in the mice that 
were not detectable with the 3 minute test.   
On the mixed background, female MPS IIIA mice were hyperactive at 3 weeks of age 
but at subsequent ages no differences were observed at 6, 10, 15, 20, 30 or 40 
weeks of age (Hemsley et al. 2005).  In the work of Lau et al., using the C57BL/6 
backcross, no differences were observed between female WT and MPS IIIA C57BL/6 
mice between 3-22 weeks of age (Lau et al. 2008).  
MPS IIIB is a phenotypically indistinguishable disease to MPS IIIA. In the mouse 
model of MPS IIIB, hyperactivity has been observed in a 10 minute open field test 
(Cressant et al. 2004) but hypoactivity in an 8 minute open field test performed half 
in the light half in the dark (Li et al. 1999). A 60 minute open field test did not 
report differences in path length in male or female mice (Fu et al. 2007), but a 60 
minute open field test that we performed on female mice at the same circadian 
time as this study observed hyperactivity at 8 months of age (Langford-Smith et al. 
2011b), which is consistent with our findings here. We also observed significant 
increases in hyperactivity in male MPS IIIB mice at 8 months of age, although they 
were less significant differences than those observed in females (Malinowska et al. 
2010). The MPS IIIB mouse is a complete knockout and thus may be slightly more 
severe than the MPS IIIA mouse with ~3% residual enzyme activity. This may explain 
why we were able to detect significant genotype differences at 8 months of age in 
MPS IIIB in all parameters but only some in MPS IIIA. We believe that the 60 minute 
open field test is still measuring habituation behaviour due to the profiles of activity 
observed in both MPS IIIA mice in this paper and in MPS IIIB mice (Langford-Smith 
et al. 2011b) over time. We found that differences in behaviour between MPS IIIB 
and WT mice (Langford-Smith et al. 2011b) and MPS IIIA and WT mice (Figure 4-1B 
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and C) became more pronounced from 3 to 10 to 60 minutes and diverged in the 
first few minutes from a similar initial response. When we compared MPS IIIB and 
WT mice over a 24 hour period following 24 hours of habituation (Langford-Smith 
et al. 2011b) the differences were significantly muted and over 14 days there was 
no significant difference (Canal et al. 2010). This suggests that a 60 minute open 
field test does not reflect home cage behaviour but instead probably measures 
extended habituation to a novel environment. 
A significant decrease in the number of unsupported rears by female MPS IIIA mice 
was observed at 6 months of age, however, there was no difference in the overall 
number of rears, or supported rears, at this or any other time point. No consistent 
trend in the number of rears with female mice is apparent in the literature, Crawley 
et al. reported that female MPS IIIA mice reared less at 15 and 25 weeks of age but 
there were no significant differences at 9 other time points (Crawley et al. 2006).  
No significant differences in rearing were observed in Lau et al. who also used 
backcrossed mice (Lau et al. 2008), or Hemsley et al who used mixed background 
mice (Hemsley et al. 2005).  A more consistent trend is observed in male mice with 
MPS IIIA rearing less (Hemsley et al. 2005; Crawley et al. 2006; Hemsley et al. 2007; 
Lau et al. 2008; Hemsley et al. 2009a), but increased rearing has been observed at 3 
weeks (Hemsley et al. 2005). However, at most time points no significant difference 
is observed.  Manual measurement of rears can be subjective and there may be 
variations in the rearing behaviour, such as amount of time per rear that cannot be 
measured by simply counting the number of rears. This is why we examined the 
number of supported and unsupported rears (Benjamini et al. 2010; Langford-Smith 
et al. 2011b). In the MPS IIIB mouse model, no difference in rearing was observed in 
the first 10 minutes of an open field test with female mice at 8 months of age 
(Langford-Smith et al. 2011b) and no difference in the first 30 minutes but a 
significant decrease in the number of rears by 4.5 - 5 month old male MPS IIIB mice 
in the second 30 minutes of a 60 minute open field test (Fu et al. 2007). Our 
conclusion is that rearing is too variable an outcome in MPS IIIA and IIIB mice and is 
therefore not a valuable informative test. 
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At 4 and 6 months of age the MPS IIIA female mice had a reduced sense of danger 
and spent a greater proportion of time in the centre of the open field, this measure 
was significant after 60 minutes but not after 3 or 10 minutes. This is supported by 
the patients with MPS IIIA which are believed to have a reduced sense of danger 
(Heron et al. 2011). No difference in the time in centre was detected by Lau et al. in 
both male and female mice (Lau et al. 2008), however this could be because the 
open field was larger in our study and therefore more sensitive to thigmotaxis 
(Crawley 2007; Benjamini et al. 2010). In the MPS IIIB mouse model no differences 
were observed in the duration spent in the centre of the open field (Langford-Smith 
et al. 2011b) but the open field used in that study was also smaller than the one 
used in this study. 
The elevated plus maze did not demonstrate a decrease in anxiety or sense of 
danger in the MPS IIIA mice. There were also no differences between repeat tests, 
and both WT and MPS IIIA mice appeared to habituate equally. Lau et al. 2010, 
observed no significant differences with male mice at 6.5  months (26 weeks) of age 
with a 5 minute elevated plus maze test, but there was a trend towards reduced 
anxiety (Lau et al. 2010a). However in Lau et al. 2008  a significant increase in the 
time the male MPS IIIA mice spent in the open arms at 18 weeks of age, the 
percentage of the path length on the open arms at 15 and 18 weeks and the 
percentage of entries into the open arms at 20 weeks was observed (Lau et al. 
2008). Additionally they observed significant differences between repeats of the 
elevated plus maze, male MPS IIIA mice had a significantly longer path length in the 
repeat elevated plus maze test while WT mice remained unchanged (Lau et al. 
2008). We did not observe decreased anxiety or a change in behaviour between 
repeat elevated plus maze tests. The width of the arms could be affecting this test 
as this study used 10 cm wide arms and Lau et al., used 7cm wide arms. It has been 
demonstrated that when using 5, 7 or 9 cm wide arms, NMRI mice spent more time 
in the wider open arms compared to C57BL/10J mice that showed no difference 
(Lamberty et al. 1996). Ten minutes on the elevated plus maze may also be too 
short a time to detect the sense of danger differences in the MPS IIIA mice as the 
only centre measure on open field that is significant after 10 minutes is the number 
of centre entries in female mice at 6 months of age (p=0.023). A lack of difference 
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in the elevated plus maze performed in daylight is supported by MPS IIIB mice 
which showed no difference in the light but were less anxious in the dark (Cressant 
et al. 2004). The increased number of centre entries and duration in the open field 
could perhaps reflect increased but undirected anxiety whereby mice are actually 
more agitated but have lost the ability to determine what is dangerous. A more 
pragmatic explanation could be due to the mice not being naively tested as they 
only received a 30 minute break after the open field test before starting the 
elevated plus maze test. Prior behavioural tests can affect the result of elevated 
plus maze tests with C57BL/6J mice that have previously been tested in an open 
field test (Voikar et al. 2004). 
No significant differences were observed in the inverted screen or bar crossing tests 
which is consistent with the work of Crawley et al. who observed no difference in 
neuromuscular strength with back crossed MPS IIIA mice (Crawley et al. 2006). 
However on the mixed background strain, there was a significant decrease in 
neuromuscular strength with MPS IIIA mice being unable to grip the inverted screen 
for as long as the WT mice from 20 weeks of age (Hemsley et al. 2005). The work in 
our study is supported by work with the MPS IIIB mouse model that does not show 
a decline in motor function at 5 months of age by accelerating rotarod  (Fu et al. 
2007; Fu et al. 2010) but does by a rocking rotarod test from 9 months onwards 
(Heldermon et al. 2007; Heldermon et al. 2010). The decline in motor function 
could relate to the presence of increasing urine retention in the MPS IIIA and B 
mouse models (Bhaumik et al. 1999; Gografe et al. 2009; Malinowska et al. 2010). 
Our own tests in the MPS IIIB mouse model found that neuromuscular decline only 
occurred at 10 months of age (40 weeks) (Malinowska et al. 2010; Langford-Smith 
et al. 2011b).  Given that the MPS IIIA mouse has residual enzyme activity, it is 
possible that progression of MPS IIIA disease is slightly less rapid than in MPS IIIB 
which would explain why we did not see a trend to changes in motor function at 8 
months in MPS IIIA mice.  
Standardisation of tests is a very important aspect of behavioural test design that 
may have affected comparison of our tests to those of other laboratories. In this 
study the size of the open field was larger than that described in many studies and 
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the behaviour was observed for much longer (60 minutes compared to 3 minutes). 
The increased size and time of the test allows better spatial and temporal 
resolution of the mouse behaviour and so makes the test more sensitive (Benjamini 
et al. 2010). Video analysis software was used which has been shown to be more 
sensitive than line crossing determined by an observer or beam breaks (Kafkafi et 
al. 2003). In this study, the mouse was placed in the centre of the open field rather 
than in the corner and the test was carried out at the same time point of circadian 
rhythm for all mice as there is a known peak in activity in the similar MPS IIIB mouse 
model (Canal et al. 2010). The mice in this study were also housed differently; 
females were group housed and male mice were singly housed from 14 weeks of 
age. The background of the mice can affect the behavioural phenotype, therefore 
we backcrossed the MPS IIIA mice in this study onto the C57BL/6J background for 
more than 10 generations. Other groups have used MPS IIIA mice on a mixed 
background (Hemsley et al. 2005; Hemsley et al. 2007), or on a C57BL/6 (Crawley et 
al. 2006; Fraldi et al. 2007; Lau et al. 2008; Lau et al. 2010a) or C57BL/6J (McIntyre 
et al. 2010) background. Strain specific differences can also significantly affect 
behavioural outcomes (Gerlai 1996).  
 
4.6 Conclusion 
We have demonstrated that we can reliably detect differences in the behaviour of 
female but not male MPS IIIA mice at 4 and 6 months (16 and 24 weeks) of age and 
these differences match the patient phenotype. Male mice were singly housed due 
to their aggression which may change comparative behavioural responses. Female 
MPS IIIA mice are hyperactive, with a longer path length, increased frequency and 
duration of rapid exploratory behaviour, and spend less time immobile. They also 
show a trend to this behaviour at 8 months of age with significantly increased 
duration of rapid exploratory behaviour. Female MPS IIIA mice demonstrate a 
reduced sense of danger with a greater proportion of the time spent in the centre 
of the open field with a greater number of centre entries. These two time points 
and multiple measures are ideal to evaluate novel therapies for MPS IIIA as the 
effect of a therapy can be sensitively determined using multiple measures. This 
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behavioural phenotype is supported by both the phenotype of the patients and our 
recent similar observations in the MPS IIIB mouse model (Malinowska et al. 2010; 
Langford-Smith et al. 2011b). The increased size of the open field,  the increased 
length of the test, the use of video analysis software and performing the test at 
consistent point in the circadian rhythm have produced a sensitive and robust test 
to evaluate the effect of therapies on female MPS IIIA mice.  
 
Supplementary Video 4-1 MPS IIIA open field behaviour video  
A video running at 4 times the normal speed showing the median female WT and MPS IIIA mouse at 
6 months of age. The MPS IIIA mouse is on the left and the WT mouse is on the right. Please see 
enclosed CD. 
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5.1 Abstract  
Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo disease) is a 
neurodegenerative disorder caused by a deficiency in the lysosomal enzyme 
sulphamidase (SGSH), catabolising heparan sulphate (HS). Affected children present 
with severe behavioural abnormalities, sleep disturbances and progressive 
neurodegeneration, leading to death in their second decade. MPS I, a similar 
neurodegenerative disease accumulating HS, is treated successfully with 
haematopoietic stem cell transplantation (HSCT) but this treatment is ineffectual 
for MPS IIIA. We compared HSCT in MPS IIIA mice using donor cells transduced ex 
vivo with lentiviral vector expressing SGSH (LV-WT-HSCT) versus wild-type donor 
cell transplant (WT-HSCT) or autologous transduction (LV-IIIA-HSCT). LV-WT-HSCT 
results in 10% of normal brain enzyme activity, near normalisation of brain HS and 
GM2 gangliosides, significant improvements in neuroinflammation and complete 
behavioural correction. Both WT-HSCT and LV-IIIA-HSCT mediated improvements in 
GM2 gangliosides and neuroinflammation but were less effective at reducing HS or 
in ameliorating abnormal HS sulphation observed in MPS IIIA mice, and had no 
significant effect on behaviour. This suggests that HS has a more significant role in 
neuropathology than either neuroinflammation or GM2 gangliosides. These data 
provide compelling evidence for the efficacy of lentiviral mediated HSCT for 
neurological correction of MPS IIIA where conventional transplant is ineffectual. 
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5.2 Introduction  
Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo type A) is a neurodegenerative 
lysosomal storage disease resulting from a deficiency in the enzyme sulphamidase 
(N-sulphoglucosamine sulphohydrolase, SGSH, EC 3.10.1.1), caused by mutations in 
the SGSH gene (Valstar et al. 2008). The enzyme deficiency leads to accumulation of 
heparan sulphate (HS) in cells, leading to cellular and organ dysfunction, particularly 
in the brain (Valstar et al. 2008). Patients present with progressive failure to 
achieve developmental milestones, severe behavioural changes including 
hyperactivity and sleep disturbances, later cognitive and motor function decline 
and a markedly shortened lifespan (Meyer et al. 2007; Valstar et al. 2008; Heron et 
al. 2011). The age of presentation and severity of symptoms varies significantly. 
Disease neuropathology is poorly understood, with several factors probably 
contributing to the onset of disease including primary HS storage in the brain, 
secondary storage of GM gangliosides, amongst other lipids (Bhaumik et al. 1999; 
McGlynn et al. 2004) and severe neuroinflammation (Savas et al. 2004; Fraldi et al. 
2007; Arfi et al. 2011). There are no current treatments for MPS III. 
Intravenous enzyme replacement therapy (ERT) is a successful treatment for 
attenuated MPS diseases storing HS, such as MPS I Hurler-Scheie, which has limited 
neurological involvement due to residual enzyme activity in the brain. In this case, 
delivered recombinant enzyme is taken up by mannose-6-phosphate receptors and 
cross corrects residual enzyme deficient recipient cells. Since enzyme is unable to 
cross the blood brain barrier, intravenous ERT is ineffective in neuronopathic MPS 
diseases including MPS I Hurler (IH) and MPS IIIA.  
Patients with MPS IH usually receive haematopoietic stem cell transplantation 
(HSCT) (Boelens et al. 2009; Wynn et al. 2009b). Donor cells repopulate the 
recipient’s haematopoietic system and engrafted donor leukocytes secrete enzyme 
that can cross-correct cells in the periphery. In addition, monocytes traffic from the 
bone marrow into the brain where they differentiate into microglial cells and 
mediate cross correction in the recipient central nervous system (CNS) (Krivit et al. 
1995). As long as treatment is delivered early in life, this results in significant 
beneficial effects on cognitive outcomes, lifespan, and peripheral bone and joint 
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disease in MPS IH patients (Shapiro et al. 1995; Boelens et al. 2009; Wynn et al. 
2009b).   
In contrast, MPS IIIA patients show increased lifespan but no significant 
neurological improvements after HSCT, despite storage of very similar substrates in 
the brain (Shapiro et al. 1995; Sivakumur et al. 1999; Prasad et al. 2008). Following 
unrelated cord blood transplants, one year patient survival rates are similar (77% 
MPS IH, 79% MPS III) but 3 year patient survival is markedly different (75% MPS IH, 
56% MPS III), suggesting that engraftment is successful but that transplant is not 
curative for MPS III (Prasad et al. 2008).  We have recently reported that metabolic 
correction, (expressed as reduction of glycosaminoglycan substrate), of MPS I 
patients receiving transplants from heterozygote donors with one enzyme gene 
copy, is less complete than those receiving unrelated transplants from homozygous 
donors with two enzyme gene copies (Wynn et al. 2009b). HSCT failure in MPS IIIA 
patients could therefore be due to insufficient enzyme being produced by donor-
derived microglia in the brain (Shapiro et al. 1995; Sivakumur et al. 1999), whilst 
gene therapy could be an approach to increase secreted enzyme in the brain 
beyond that achieved by wild type transplantation.  
A clinically relevant gene therapy approach for MPS IIIA and the clinically 
indistinguishable MPS IIIB, is direct brain delivery of AAV (Cressant et al. 2004; 
Fraldi et al. 2007; Heldermon et al. 2010). However, this approach is very invasive 
and has potential scale-up issues with limited distribution of vector from the 
injection sites in the brain (Wang et al. 2003; Taymans et al. 2007), as well as the 
potential for immune responses in patients exposed directly to vector or enzyme 
(Worgall et al. 2008). 
The alternative approach of ex vivo gene delivery to HSCs, using a lentiviral vector 
(LV-HSCT), has become progressively more clinically achievable for 
neurodegenerative metabolic diseases in recent years. This is due to vastly 
improved HSCT survival rates, of over 90% for MPS IH (Boelens et al. 2009), and 
several studies showing the potential for correction of neurodegenerative diseases 
via HSC modification (Biffi et al. 2006; Cartier et al. 2009; Gentner et al. 2010; 
Visigalli et al. 2010). Ex vivo LV-HSCT was used to replace the arylsulphatase A 
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enzyme in a mouse model of metachromatic leukodystrophy, and achieved 10% of 
normal brain enzyme and neuronal correction (Biffi et al. 2006), which has resulted 
in an ongoing clinical trial. In MPS I, erythroid specific LV-HSCT resulted in 
neurological correction of mice (Wang et al. 2009), whilst another LV-HSCT 
approach has resulted in 5 fold increases in brain enzyme and significant 
improvements in peripheral disease in MPS I mice (Visigalli et al. 2010). In mouse 
models of MPS IIIA and IIIB, HSCT alone is unable to correct the neurological 
phenotype (Heldermon et al. 2010; Lau et al. 2010a). However, a retroviral HSCT 
approach in MPS IIIB mice resulted in 25% of normal brain enzyme activity in two 
cases; although copy numbers were not stated and behavioural analysis was not 
performed (Zheng et al. 2004). No data are published on LV-HSCT in MPS IIIA. 
To evaluate the efficacy of LV-HSCT against normal HSCT in MPS IIIA mice we 
compared MPS IIIA mice receiving either WT or MPS IIIA cells that were ex vivo 
transduced with an SGSH expressing lentiviral vector, against mice receiving normal 
HSCT. We have demonstrated that LV-HSCT can significantly increase the SGSH 
enzyme activity in the brain, normalise brain HS, reduce secondary pathology and 
correct behaviour of MPS IIIA mice where normal HSCT fails.  
 
5.3 Methods 
5.3.1 Construction and Testing of SGSH Lentiviral Vector 
The lentiviral vector plasmid pHR’SIN-cPPT-SEW (Demaison et al. 2002) was 
modified by replacing the eGFP gene with a Gateway conversion cassette 
(Invitrogen Life Technologies #11828-019) containing two attB sites flanking a ccdB 
positive selection gene, producing pHRsin.SFFV.Gateway.   This produced a lentiviral 
backbone that could act as a Gateway destination vector so that genes could be 
cloned in directly using recombination technology. The human SGSH cDNA 
sequence including 5’ and 3’ UTR from image clone #5226903 (Geneservice) was 
Gateway cloned into a donor vector (pDonor221) containing attP sites as described 
(Hartley et al. 2000) with BP Clonase (Invitrogen). This resulted in SGSH cDNA being 
flanked by attL sites enabling Gateway cloning of SGSH cDNA into the lentiviral 
Chapter 5 – Stem Cell Gene Therapy For MPS IIIA 
[Page 161] 
vector using LR Clonase to create pHRsin.SFFV.hSGSH.att.wpre. To confirm the 
ability of microglia to produce active enzyme from the construct, the human 
microglial cell line CHME3 was transfected with pHRsin.SFFV.hSGSH.att.wpre using 
Fugene 6 as per manufacturer’s instructions (Roche). Three days later, media and 
cells were analysed for SGSH activity. 
5.3.2 Lentiviral Vector Production and Titration 
HEK 293T cells were seeded in 15cm tissue culture plates (Corning) in 
DMEM/10%FCS/2mM L-glutamine, (Lonza) and cultured overnight at 37°C until 40-
70% confluent. VSV-G pseudo-typed lentiviral vector was produced by the transient 
transfection of HEK 293T cells with pHRsin.SFFV.hSGSH.att.wpre, pMD2G and 
p∆8.91gag/pol (Bigger et al. 2006) in a 3:1:2 ratio using a total of 15µg of plasmid 
DNA per dish, 44.5µl of Fugene 6 (Roche) in Optimem (Gibco) as per manufacturer’s 
instructions. The media was replaced 4 hours and 24 hours after transduction and 
harvested at 36 and 60 hours. Cells were removed by centrifugation at 262g for 15 
minutes at 4°C, and filtered through a 0.45µm low protein binding filter (Nalgene). 
Lentiviral vector particles were concentrated by centrifugation at 21,191g for 150 
minutes at 4°C, resuspended in PBS and stored at -80°C. Lentiviral vector was titred 
using a similar method to Kutner et al. (Kutner et al. 2009). 1x105 murine lymphoma 
(EL4) cells (ATCC Number TIB-39, Sigma) were cultured in RPMI 1640 (Lonza)/10% 
FCS/2mM L-glutamine and transduced with 5 dilutions of concentrated lentiviral 
vector. Four days later, genomic DNA was extracted from the cells using the 
GenElute Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich) and analysed by 
Quantitative Real Time PCR (QPCR) to determine the number of integrated lentiviral 
genomes per cell. The infectious titre was calculated as the number of cells at 
transduction multiplied by the number of lentiviral copies per cell divided by the 
volume of lentiviral vector added. Titres of 1.1x109TU/ml (integrated transducing 
units) were normally reached. 
5.3.3 QPCR Copy Number Determination 
The WPRE copy number of lentiviral vectors in genomic DNA from murine cell lines, 
bone marrow, blood and spleen samples was determined by QPCR using the 
Applied Biosystems 7500 Real Time PCR System.  A primer and probe set against 
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wpre (TAMRA) were used as previously described (Lizee et al. 2003) and 
standardised against rodent gapdh primer and probe set (VIC) (Applied 
Biosystems). Samples were run in duplicate 25µl reactions using the cycling 
parameters 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. The copy number was determined using a standard 
curve generated by dilutions of genomic DNA from an EL4 cell line clone (ALS EL4 
eGFP 2,2) containing 2 integrated copies/cell of pHRsin.SFFV.eGFP.att.wpre. The 
EL4 cell clone (ALS EL4 eGFP 2,2) was made by transducing EL4 cells with the 
pHRsin.SFFV.eGFP.att.wpre lentiviral vector expressing eGFP, followed by two 
consecutive rounds of single cell cloning. The lentiviral copy number per cell was 
determined by Southern blot of whole genomic DNA as previously described 
(Themis et al. 2005).    
5.3.4 Mice and Transplant Procedures 
All in vivo procedures were ethically approved in accordance with UK Home Office 
regulations. MPS IIIA mice (Bhaumik et al. 1999) were backcrossed for 10 
generations onto the C57BL/6J background (B6.Cg-Sgshmps3a/6J), maintained by 
heterozygote breeding and genotyped as previously described (Langford-Smith et 
al. 2011a). Littermate controls were used throughout. MPS IIIA mice were also 
backcrossed onto the PEP3 CD45.1 congenic background (B6.SJL-PtprcaPepcb/BoyJ) 
to distinguish donor and recipient cells. 
Total bone marrow mononuclear cells were isolated from femur, tibia, and ilium of 
WT CD45.1 or MPS IIIA/CD45.1 mice and lineage depleted using the murine 
hematopoietic progenitor enrichment cocktail (Stem Cell Technologies) according 
to manufacturer’s instructions. Cells were resuspended in X-Vivo10 (BioWhittaker) 
and transduced as previously described (Siapati et al. 2005). 
6-8 week old mice housed in individually ventilated cages were myeloablated with 
125mg/kg Busulfan (Busilvex; Pierre Fabre) in 5 daily doses via intra-peritoneal 
injection. 1 week prior to myeloablation and for a further 7 weeks, mice received 
acidified water (pH 2.8), irradiated food, mash and sugar free jelly to prevent 
gastrointestinal infections and to encourage fluid uptake. Within 24 hours of the 
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final injection of Busulfan, 1.5-2.5x105 lineage depleted transduced (LV-SGSH) or 
un-transduced haematopoietic stem cells were delivered intravenously. 
5.3.5 Flow Cytometry   
Haematopoietic engraftment was assessed at 6-16 weeks post-transplant in 
peripheral blood by staining with anti-mouse CD45.1-PE or CD45.2-FITC (BD 
Pharmingen) in a 5% solution of ToPro3 Iodide (Molecular Probes) on a BD FACS 
Canto II flow cytometer. 
5.3.6 Behaviour 
At 4 and 6 months (16 and 24 weeks) of age 10 female  mice were assessed for 
open field behaviour over 60 minutes at the same circadian time point as previously 
described (Malinowska et al. 2010; Langford-Smith et al. 2011a; Langford-Smith et 
al. 2011b)  and data analysed using  TopScan suite software version 2.0 (Clever Sys. 
Inc). 
5.3.7 Sample Processing 
At 8 months of age, anesthetised mice were trans-cardially perfused with 37°C 
Tyrode’s. Brains were removed; one hemisphere frozen at –80°C and one fixed in 
4% paraformaldehyde for 24 hours then 30% sucrose 2mM MgCl2/PBS for 48 hours 
before freezing at –80°C. For biochemical assays the snap frozen hemisphere was 
homogenized so that all assays represent an average of each hemisphere. Liver and 
spleen were frozen at –80°C. For SGSH and GAG assays, samples of brain, liver or 
spleen were homogenized and sonicated in homogenisation buffer (0.5M NaCl, 
0.02M Tris pH 7-7.5), then centrifuged at 2,200g for 15 minutes at 4°C and the 
supernatant collected. Protein concentration was determined using the BCA 
(Thermo Scientific) assay according to manufacturer’s instructions. 
5.3.8 SGSH Enzyme Activity  
SGSH enzyme activity was measured in a two-step protocol using a fluorescent 
substrate MU-αGlcNS (Moscerdam) as per manufacturer’s instructions (Karpova et 
al. 1996) with minor modifications. The amount of starting material was 
standardised to 40µg of total protein for liver and spleen and 60µg for brain.  
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5.3.9 Blyscan for Total Sulphated Glycosaminoglycans 
The total amount of sulphated glycosaminoglycans (GAG) in 100µg of liver and 
brain was determined using the Blyscan Kit (Biocolor Ltd.) (Malinowska et al. 2009).  
Actinase E (200µg) was added to the sample, incubated at 55°C for 20 hours before 
heating at 100°C for 5 minutes and centrifuging at 3,000g for 10 minutes. The 
supernatant was incubated with 1,9-dimethymethylene blue for 30 minutes with 
vigorous shaking. After centrifuging at 10,000g for 15 minutes at 4°C the pellet was 
incubated with dye dissociation reagent for 15 minutes and the colour quantified 
using a spectrophotometer at 656nm. The quantity was determined against a 
known concentration GAG standard.  
5.3.10 AMAC-labelled Disaccharide Analysis of Heparan Sulphate 
Analysis of the quantity and sulphation state of HS was determined as previously 
described (Holley et al. 2011). Total HS was calculated by summing the peak area 
and applying a labelling efficiency correction factor as described (Holley et al. 2011). 
Three randomly assigned mice from each group were analysed. 
5.3.11 Immunohistochemistry 
Four brain sections per mouse taken from bregma 0.26, -0.46, -1.18 and -1.94mm  
were stained for Isolectin B4 and GM2 gangliosides and quantified as previously 
described (Canal et al. 2010; Malinowska et al. 2010). Isolectin B4 stained sections 
were counterstained with Mayer’s haematoxylin before mounting. A section from -
0.84mm relative to bregma (2 mice per group) was stained for lysosomal associated 
membrane protein 2 (LAMP2) to demonstrate the size of the lysosomal 
compartment. Sections were blocked in 5% goat serum, 1mg/ml BSA 0.1% Triton X-
100 in TBS for 1 hour and incubated overnight at 4°C with rat anti-LAMP2 IgG 
(2μg/ml; developed by August, JT, Developmental Studies Hybridoma Bank, 
University of Iowa, USA) in blocking solution, washed 4x in TBS and stained with 
Alexa 488 goat anti-rat IgG (1:1000, Invitrogen) in blocking solution for 1 hour in the 
dark. After washing with TBS, sections were counterstained with 300nM DAPI 
(Invitrogen) for 15 minutes. Sections were mounted using ProLong Gold Anti-fade 
mounting medium (Invitrogen). Representative sections from cortex layer IV/V have 
been displayed. 
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5.3.12 Statistical Analysis 
JMP software version 8 (SAS Institute Inc.) was used with one way ANOVA and 
Tukey post hoc test to analyse data. Data were log transformed where they failed 
normality tests. Significance was assumed for probabilities of 0.05 or lower. Survival 
analysis was performed in SPSS version 19 (IBM) using Kaplan-Meier analysis with 
Mantel-Cox log rank pairwise comparisons.  
5.4 Results 
5.4.1 Lentiviral HSCT Results in Significant Expression, Transduction and Donor 
Chimerism 
In order to evaluate if ex vivo transduction of HSCs using a lentiviral vector 
expressing SGSH (LV-SGSH) could improve treatment outcomes in MPS IIIA mice, 
we constructed a LV-SGSH vector driven by the spleen focus forming virus (SFFV) 
promoter (Figure 5-1A). 
To confirm that microglia could over express SGSH without toxicity, the human 
microglial cell line, CHME3, was transfected with the lentiviral plasmid containing 
SGSH. A 4.5 fold increase in cellular SGSH activity (Figure 5-1B) and an 18 fold 
increase in secreted SGSH activity (Figure 5-1C) were observed without cellular 
toxicity.  
WT or MPS IIIA lin- bone marrow was either un-transduced or transduced with LV-
SGSH before transplant into Busulfan myeloablated 6-8 week old MPS IIIA mice 
(n=16 per group) (Figure 5-1A). Age matched control groups of WT to WT 
transplant, un-transplanted WT and MPS IIIA were used for comparison (n=16 per 
group). At 16 weeks post-transplant, peripheral blood chimerism was 88%, 89% and 
90% in the LV-WT-HSCT, LV-IIIA-HSCT and WT-HSCT groups respectively (Figure 5-
1D). The average copy number was 0.27 integrations per white blood cell for LV-
WT-HSCT and 0.22 integrations for LV-IIIA-HSCT groups (Figure 5-1E), however the 
copy number for the LV-IIIA-HSCT biochemistry/histology group was only 0.11 
copies/cell and for the LV-IIIA-HSCT survival group was 0.34. No adverse events or 
leukemic blasts have been observed on blood smears from all mice including the 
survival cohort, kept for over one year post-transplant (n=6 per group).  
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Figure 5-1 Lentiviral SGSH transduced microglia have improved SGSH activity 
(A) Lineage depleted bone marrow was transduced or untransduced with a lentiviral vector 
expressing human SGSH under the SFFV promoter and transplanted into Busulfan conditioned 
recipients at 2 months (8 weeks) of age. Groups were; WT to WT transplant, WT untreated, MPS IIIA 
untreated, WT donor cells transduced with LV-SGSH into MPS IIIA recipients (LV-WT-HSCT), MPS IIIA 
donor cells transduced with LV-SGSH into MPS IIIA recipients (LV-IIIA-HSCT) and WT to MPS IIIA (WT-
HSCT) (n=16 per group).  An open field behavioural test was performed at 4 and 6 months (16 and 
24 weeks) of age, chimerism and copy number were determined at 6 months of age, and at 8 
months of age (32 weeks of age, 24 weeks post transplant), mice were sacrificed for biochemical and 
histological analysis and a cohort was kept for survival and sacrificed at their humane endpoint. (B) 
The human microglial cell line CHME3 was transfected or mock-transfected with LV-SGSH and 
enzyme activity measured in cells and, (C) media. (D) Donor chimerism was determined using flow 
cytometry at 16 weeks post-transplant. (E) Lentiviral vector copy number in white blood cells was 
determined by QPCR at 16 weeks post-transplant. Error bars represent the standard error of the 
mean (SEM) and significant difference is demonstrated with *= p<0.05, **= p<0.01 and ***= 
p<0.001.  
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5.4.2 LV-WT-HSCT Increases Brain SGSH and Normalises HS Storage in the MPS 
IIIA Brain 
To determine the outcome of therapy on primary neuropathology, 5 mice per 
group were sacrificed at 8 months of age and perfused with Tyrode’s to flush blood 
from organs. SGSH enzyme activity was measured in the spleen, liver and brain 
(Figure 5-2A-C). Untreated MPS IIIA mice expressed approximately 3% of WT 
activity (Bhaumik et al. 1999). All treatments significantly increased SGSH activity in 
the spleen to 87%, 77% and 53% of WT activity by LV-WT-HSCT, LV-IIIA-HSCT and 
WT-HSCT respectively. In the liver, SGSH activity was significantly increased to 46%, 
32% and 37% of WT activity by LV-WT-HSCT, LV-IIIA-HSCT and WT-HSCT 
respectively. In the brain, SGSH activity was significantly increased to 10% of WT 
activity (p=0.007) by LV-WT-HSCT and 7% of WT activity (p=0.05) by LV-IIIA-HSCT. 
WT-HSCT increased activity to 6% of WT activity, but this was not significantly 
elevated over residual MPS IIIA brain enzyme activity of 3%.  
Total sulphated glycosaminoglycans (GAGs), including HS, were measured in the 
liver and brain (Figure 5-2D,E). In the liver, GAGs were normalised to WT levels by 
LV-WT-HSCT and WT-HSCT, with near normalisation by LV-IIIA-HSCT. In the brain, 
LV-WT-HSCT and LV-IIIA-HSCT both normalised GAGs to WT levels, whilst WT-HSCT 
significantly reduced GAG levels. Total brain HS levels were measured following 
AMAC-labelled disaccharide analysis (Figure 5-2F), revealing that all transplants 
significantly decreased total brain HS. WT-HSCT and LV-IIIA-HSCT both decreased HS 
storage by 51%, whereas LV-WT-HSCT normalised brain HS levels to those of WT 
with a 77% reduction.  
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Figure 5-2 LV-WT-SGSH improves enzyme activity and reduces primary storage in MPS IIIA mice 
SGSH enzymatic activity was measured in (A) spleen, (B) liver and (C) brain. The level of sulphated 
glycosaminoglycans was determined using the Blyscan assay in the (D) liver and (E) brain. (F) The 
level of HS storage in the brain was determined by AMAC. (G) The different HS disaccharides were 
quantified. (H) The relative proportion of HS that was N-acetylated (NAc), N-sulphated (NS), 6-O-
sulphated (6S) and 2-O-sulphated (2S) was also determined by AMAC. Error bars represent the SEM.  
Significant difference to MPS IIIA is demonstrated with *= p<0.05, **= p<0.01 and ***= p<0.001.  
Where treatments result in significant improvement to MPS IIIA and there is no significant difference 
to WT, this is shown by a line and ns. 
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5.4.3 HS Sulphation is Significantly Increased in MPS IIIA and Normalised by LV-
WT-HSCT 
Six characteristic disaccharides are revealed by AMAC analysis (Figure 5-2G). 
Overall, MPS IIIA mouse brains displayed significant increases in the four most 
highly sulphated disaccharides HexA(2S)-GlcNS(6S) (p=5.6x10-7) and HexA(2S)-GlcNS 
(p=7.8x10-5), and commensurate reductions in HexA-GlcNS (p=1.2x10-5) and HexA-
GlcNAc (p=2.7x10-5). This led to overall significant increases in N- (p=0.00002), 2-O- 
(p=4.3x10-7) and 6-O-sulphation (p=0.0007) and a commensurate reduction in N-
acetylated (unsulphated, p=0.00002) regions over WT (Figure 5-2H). LV-IIIA-HSCT 
was unable to change this abnormal profile, whilst WT-HSCT significantly improved 
outcomes in 3 out of 4 abnormal disaccharides (p<0.03-0.00001) and LV-WT-HSCT 
further improved all 4 abnormal disaccharide profiles (p<0.01-1x10-6) and 
normalised HexA(2S)-GlcNS(6S) and HexA-GlcNAc to WT proportions (Figure 5-2G). 
Both WT-HSCT and LV-WT-HSCT significantly improved abnormal HS sulphation 
patterning towards normal WT levels, but only LV-WT-HSCT was able to fully 
normalise this in the case of NAc, N- and 6-O-sulphation to WT levels (p=0.0001, 
p=0.0001, p=0.0006, Figure 5-2H). 2-O-sulphation remained significantly increased 
over WT (p=0.002). LV-IIIA-HSCT had no significant effect on HS sulphation 
patterning.  
5.4.4 LV-WT-HSCT and WT-HSCT Reduce Secondary Storage and 
Neuroinflammation Equally 
In order to determine if treatment had an effect on lysosomal swelling, we stained 
the cerebral cortex for LAMP2 (green) and a nuclear stain, DAPI (blue) (Figure 5-3A).  
MPS IIIA mice exhibited cells with large, dense LAMP2 staining around the nucleus, 
whilst WT mice displayed discrete punctate LAMP2 staining in a perinuclear 
location. LV-IIIA-HSCT did not appear to have an effect on abnormal MPS IIIA 
lysosomal morphology whilst WT-HSCT was able to reduce some of this pathology 
and LV-WT-HSCT resulted in cells with substantial reduction of abnormal LAMP2 
staining. 
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Severe neuroinflammation in MPS IIIA mice is measurable by the significant 
infiltration of Isolectin B4 positive microglial cells into the cerebral cortex (Figure 5-
3B,D). WT mice have virtually no microglia in this location. Microglial numbers were 
significantly reduced by 61% in LV-WT-HSCT (p=1x10-7), 50% in LV-IIIA-HSCT 
(p=3x10-6) and 61% in WT-HSCT (p=1x10-7), but there was no significant difference 
between treatments and all remained significantly elevated above WT. 
MPS IIIA mouse brains also displayed significant secondary storage of GM2 
gangliosides, particularly in lamina II/III and V/VI of the primary motor, 
somatosensory and parietal areas of the cerebral cortex (Figure 5-3C,E) whilst no 
staining was detected in these areas in WT mice (McGlynn et al. 2004). A significant 
decrease in GM2 gangliosides of 76% (p=0.02) was detected after LV-WT-HSCT and 
78% (p=0.02) after WT-HSCT, normalising GM2 gangliosides to WT levels. 
Treatment with LV-IIIA-HSCT did not significantly reduce GM2 gangliosides but 
resulted in an average of 10% reduction. However, there was significant variability 
between mice with some almost completely corrected and others hardly corrected 
at all (Figure 5-3C). More effective GM2 ganglioside clearance correlated with 
higher lentiviral copy number. GM2 ganglioside storage was observed in the 
amygdala, but did not appear to be reduced by any treatment (Figure 5-4). 
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Figure 5-3 Neuropathology is improved by all treatments  
(A) Representative sections of brain cortex (layer IV/V) from -0.84mm relative to bregma were 
stained with LAMP2 (green) to demonstrate lysosomal compartment size and DAPI (blue) to 
highlight nuclei. (Bar=50µm). (B) Representative images of cerebral cortex layer IV/V from around -
0.46mm relative to bregma showing isolectin B4-positive microglia (brown) and nuclei (blue) and (C) 
GM2 gangliosides (black). Two images of LV-IIIA HSCT are shown, one with a high copy and one with 
a low copy to demonstrate the variable response in this group (Bar=50µm). (D) The number of 
microglia were counted and, (E) GM2 ganglioside storage was quantified using Image J from 2 fields 
of view (x20 objective) per brain section, 4 sections per mouse (n=5 mice per group). Error bars 
represent the SEM.  Significant difference to MPS IIIA is demonstrated with *= p<0.05, **= p<0.01 
and ***= p<0.001. Where treatments result in significant improvement to MPS IIIA and there is no 
significant difference to WT this is shown by a line and ns. 
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Figure 5-4 GM2 ganglioside storage in whole brain. 
Brain sections from approximately -1.18  to -1.94mm relative to bregma stained for GM2 ganglioside 
(black).  The cortex (C), amygdala (A) and retrosplenial granular cortex (RSD) are marked. Bar = 
1000µm 
 
5.4.5 MPS IIIA Behaviour is Fully Corrected by LV-WT but Unchanged by WT or 
LV-IIIA -HSCT 
At 4 and 6 months of age a 60 minute open field test was performed to determine 
the effect of treatment on mouse behaviour (Langford-Smith et al. 2011b). In order 
to control for the effect of Busulfan conditioning we initially compared age matched 
untransplanted WT mice with WT to WT transplanted mice, and found their 
behaviour to be indistinguishable (data not shown). In our hands, MPS IIIA mice 
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present a phenotype of hyperactive behaviour with increased path length, duration 
and frequency of rapid exploratory behaviour, whilst immobility time is reduced. 
MPS IIIA mice also displayed reduced thigmotaxis which we interpret as a reduced 
sense of danger, with increased frequency and duration of centre entries (Langford-
Smith et al. 2011a). At 4 months of age, MPS IIIA mice showed increased 
hyperactive behaviour with significantly increased path length (p=0.034, Figure 5-
4A) but no significant change in duration or frequency of rapid exploratory 
behaviour or immobility (Figure 5-5 B,C,D). Frequency and duration of centre 
entries are significantly increased at 4 months (p=0.02, p=0.03, Figure 5-5E,F). 
Although no significant reductions are seen with any treatment at this age, LV-IIIA-
HSCT and WT-HSCT appear to have little effect on behaviour whilst LV-WT-HSCT 
shows a clear trend towards normalisation of every parameter to WT levels except 
centre entry duration. 
At 6 months of age, MPS IIIA behaviour diverges further from the WT control mice 
to give highly significant differences in path length (Figure 5-5G, p=0.002), duration 
(Figure 5-5H, p=0.001), and frequency of speed over 100mm/s (Figure 5-4I, 
p=0.002), immobility time (Figure 5-5J, p=0.02), frequency (Figure 5-5K, p=0.001), 
and duration of centre entries (Figure 5-5L, p=0.04). These behaviours can be 
observed in Supplementary Video 5-1 and strongly suggest increases in 
hyperactivity and a reduced sense of danger.  
Neither LV-IIIA-HSCT nor WT-HSCT were able to significantly improve any of these 
abnormal behaviours, although WT-HSCT did show a non-significant trend towards 
normalisation in sense of danger measures (frequency and duration of centre 
entries, Figure 5-5K,L). Hyperactivity in particular, was not corrected by either 
treatment. 
In contrast LV-WT-HSCT significantly improved path length (Figure 5-5G, p=0.01), 
duration (Figure 5-5H, p=0.004), and frequency of speed over 100mm/s (Figure 5-5I, 
p=0.009), immobility time (Figure 5-5J,  p=0.04), and frequency of centre entries 
(Figure 5-5K, p=0.007), with a non-significant trend to reduction of centre entries 
(Figure 5-5L, p=0.11). All behaviours were normalised to WT levels and none were 
significantly different from the WT group. 
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Figure 5-5 Behavioural correction and survival 
The open field behaviour test was performed for one hour at the same point of the circadian rhythm 
at 4 and 6 months (16 and 24 weeks) of age (n=10 female mice per group). The measures of 
hyperactivity at 4 months were, (A) path length, (B) duration spent moving over 100mm/s, (C) 
frequency spent moving over 100mm/s, (D) duration immobile, whilst (E) frequency of centre 
entries and (F) duration in centre measures thigmotaxis and may be a measure of sense of danger. 
The same parameters, (G-L) were also measured at 6 months of age.  (M)  A cohort of 6-10 mice 
from each group were kept to 92 weeks of age. Mice were sacrificed when they reached their 
humane end point, frequently caused due to urine retention. The median survival in weeks (w) for 
each group is shown at the bottom of the curve. Error bars represent the SEM.  Significant difference 
to MPS IIIA is demonstrated with *= p<0.05, **= p<0.01 and ***= p<0.001. Where treatments result 
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in significant improvement to MPS IIIA and there is no significant difference to WT this is shown by a 
line and ns. 
 
A cohort of 5-10 randomly selected mice per group were kept to assess the effect of 
treatment on longevity (Figure 5-5M). WT and WT-WT transplanted groups were 
pooled as survival is not significantly affected in this group. Two WT mice reached 
the humane end point by week 92, the end of the study. Untreated MPS IIIA mice 
all died between weeks 42-54. WT-HSCT treated mice also began to die in week 42 
but had increased survival range to 71 weeks (p=0.03). LV-WT-HSCT delayed death 
to weeks 51-63 (p=0.01) with one mouse from this group still surviving at week 92. 
Interestingly, LV-IIIA-HSCT delayed death to weeks 57-75 (p=0.0002) with one 
mouse still surviving from this group at week 76. The lentiviral copy number of 
these LV-IIIA-HSCT mice was found to be significantly higher (0.34 copies/cell) than 
that of mice analysed by histology and biochemistry (0.11 copies/cell). 
 
5.5 Discussion 
This study is the first to compare a lentiviral vector based HSCT gene therapy 
approach against normal transplantation in Sanfilippo disease. Our data shows that 
although WT-HSCT is able to significantly improve many pathological markers in the 
brain of MPS IIIA mice it was unable to significantly improve brain enzyme activity 
or correct abnormal behaviour. In contrast, augmentation of brain enzyme delivery 
by transduction of WT HSCs with a lentiviral vector expressing the SGSH gene prior 
to transplant (LV-WT-HSCT), improved all pathological markers as well as, or better 
than WT-HSCT and normalised most of these markers to WT levels. In particular, LV-
WT-HSCT was able to significantly improve brain enzyme activity to 10% of normal 
and fully correct behaviour of MPS IIIA mice. We also transduced MPS IIIA HSCs 
with a lentiviral vector expressing the SGSH gene (LV-IIIA-HSCT) and observed a 
phenotype somewhere between WT-HSCT and LV-WT-HSCT treatments. 
HSCT in MPS IIIA patients was discontinued in the UK more than a decade ago as it 
was found to have no significant effect on neurological outcomes, despite some 
improvement in lifespan (Shapiro et al. 1995; Sivakumur et al. 1999). Our data on 
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WT-HSCT failure in MPS IIIA mice are consistent with these clinical observations and 
are also consistent with similar data obtained after whole bone marrow transplant 
of irradiated MPS IIIA mice (Lau et al. 2010a). More recently, cord blood 
transplantation has been performed in 19 MPS IIIA and IIIB patients (Prasad et al. 
2008), of which 12 survived and 9 had disease stabilisation, but there was limited 
impact on cognitive function. In 2 patients that were transplanted before 2 years of 
age, modest gains in cognitive functions have been reported. Overall the 
transplanted patients appear to sleep better and have fewer behavioural problems, 
but behaviour is not corrected and this treatment remains controversial.  
Our lentiviral vector is capable of effective gene expression in human microglial 
cells and we have previously shown it to be expressed in all murine and human 
hematopoietic lineages (Siapati et al. 2005) producing therapeutic protein for over 
a year in mice (Bigger et al. 2006). In the periphery, very significant improvements 
in normal enzyme activity are clearly present, but in the perfused brain only LV-WT-
HSCT (10%) and LV-IIIA-HSCT (7%), were able to significantly increase enzyme 
activity above baseline activity of 3%, suggesting that SGSH activity from donor WT 
microglial cells is probably only around 3%, whilst gene therapy is providing around 
4% for copy numbers of 0.11-0.27.  
Total HS and HS composition were significantly altered in MPS IIIA mouse brains. 
We have recently shown that similar increases in amount of HS and sulphation 
composition, particularly in 2-O sulphation of HS are also present in MPS I (Holley et 
al. 2011). In the same work we also show that HS is present in significant excess in 
non-lysosomal and extracellular locations (Holley et al. 2011), and in unpublished 
work, show a functional role for abnormal HS sulphation in altered cell to cell 
signalling. Only LV-WT-HSCT was able to normalise both the amount of HS and the 
NAc, N- and 6-O-S sulphation patterning. Despite significant reductions in 2-O 
sulphation of HS by LV-WT-HSCT this was not normalised, suggesting that treatment 
could probably be improved further.  
LV-IIIA-HSCT significantly reduced total HS but did not alter composition. This was 
the most variable treatment and this discrepancy could just reflect variable copy 
numbers between mice. This was particularly evident in GM2 ganglioside analysis 
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where some mice were corrected by LV-IIIA-HSCT and others uncorrected (Figure 5-
3C). This correlated with copy number.  
Both LV-WT-HSCT and WT-HSCT reduced the number of infiltrating microglial cells 
in the cortex by similar amounts, whilst only LV-WT-HSCT was able to correct 
behaviour. Microglial pathology was probably the least well corrected of all of the 
measured markers. This could suggest a relatively minor role for microglial 
infiltration in neuropathology. This is supported by work demonstrating that early 
neurodegeneration occurs independently of neuroinflammation in MPS IIIB mice 
(Ausseil et al. 2008).  However, if microglial infiltration is a downstream event to 
primary pathology as seems likely, the inability to fully correct this marker could 
just reflect a failure of the brain to clear microglia after significant 
neuroinflammatory insult. Aspirin treatment of MPS IIIA mice has been shown to 
reduce the expression of neuroinflammatory and oxidative stress genes (Arfi et al. 
2011), but unfortunately neither behaviour nor other markers of disease pathology 
such as microglial infiltration, were examined in this study, thus it is hard to know if 
reduction of neuroinflammation alone would significantly improve neuropathology. 
It has been proposed that GM2 and GM3 gangliosides could have significant roles in 
neurodegeneration in MPS IIIA as they are components of lipid rafts and 
glycosynaptic microdomains, whilst increased GM2 gangliosides may affect 
signalling, adhesion, motility and growth in the brain (McGlynn et al. 2004). 
However, the ability to clear GM2 ganglioside storage whilst LAMP2 lysosomal 
storage and behaviour remain uncorrected, suggests that GM2 ganglioside may be 
less important than HS in neuropathology. It is also possible that there are other, as 
yet unidentified storage products that are playing a more substantial role in 
neuropathology. GM2 and GM3 gangliosides are stored in different vesicular 
compartments to HS for example (McGlynn et al. 2004) and HS storage is not 
restricted to the lysosome but is also present in the Golgi and extracellular regions 
(Holley et al. 2011). HS is probably the best indicator of pathology that we currently 
have but other markers such as SCMAS (Subunit c of Mitochondrial ATP Synthase) 
and Tau have also been proposed (Ryazantsev et al. 2007; Ohmi et al. 2009). 
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Neither WT-HSCT nor LV-IIIA-HSCT were able to improve behaviour overall. 
Although LV-WT-HSCT fully corrected behaviour, the copy number achieved was 
low (0.27 copies per cell) and could be improved significantly. LV-IIIA-HSCT had a 
variable outcome and this likely reflects the relatively variable copy number (0.08-
0.55, average 0.22). This problem is most evident in the survival curves, where, 
against all expectation, the biggest improvement in survival was observed in the LV-
IIIA-HSCT group, followed by LV-WT-HSCT and then WT-HSCT. The average copy 
number in the randomly selected LV-IIIA-HSCT survival cohort was 0.34, compared 
to 0.11 for the biochemistry cohort. This suggests that for clinical efficacy we would 
either require lentiviral transduction of unrelated cord blood or improved copy 
number in autologous transplant of MPS IIIA cells and at least 60% transduction of 
cells to eliminate “patchiness” in the brain. Given the improved clinical outcomes of 
HSCT in MPS IH with 1 year survival at 93% in our centre (Wynn et al. 2009a) and 
91% in several European centres (Boelens et al. 2009), a clinical approach using 
unrelated CD34+ cord blood donor cells as the cell source for lentiviral transduction 
is potentially feasible. As we have already seen in MPS IH patients receiving HSCT 
from unrelated homozygote donors, there is improved metabolic correction over 
those receiving HSCT from related heterozygote donors (Wynn et al. 2009b).  
The LV-HSCT approach has been applied to several other mouse models of disease. 
In an almost identical outcome to our own, 10% of normal ARSA brain expression 
was achieved in the mouse model of metachromatic leukodystrophy (MLD), which 
was associated with behavioural correction at 6 months of age (Biffi et al. 2006). A 
clinical trial has now begun using this approach. In the mouse model of MPS I, up to 
450% of normal brain enzyme activity were achieved and approximately 200% was 
associated with brain and peripheral disease correction (Visigalli et al. 2010). In 
globoid cell leukodystrophy (GLD) approximately 16% of normal brain enzyme 
activity were achieved which improved survival of the mice, however comparing 
the mice that had less than 16% and those that had 16-25% reveals that better 
survival is achieved with higher enzyme activity (Gentner et al. 2010). It is 
interesting to note the difference in achievable enzyme expression in the brain in 
MPS I against MLD, MPS IIIA and GLD. The difference between the level of enzyme 
produced and the level required for correction in the brain for different enzymes 
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could be due to the different normal expression levels, the amount that is actually 
required to fulfil normal catabolism and the amount of storage. SGSH enzyme 
activity could be improved by co-expressing the sulphatase modifying factor 1 
(SUMF1) gene from the vector. SUMF1 modifies sulphatases by producing a formyl-
glycine residue that is required for sulphatase activity, and over expression of 
SUMF1 alongside SGSH increases enzymatic activity (Fraldi et al. 2007). There have 
been reports that the level of SUMF1 expression is critical to achieve significantly 
improved SGSH expression but codon optimisation of SGSH could also improve 
expression. 
MPS IIIA still lacks any clinically approved treatment but there are three approaches 
in clinical development of significance. Intrathecal ERT is currently being evaluated 
in the clinic having shown efficacy in MPS IIIA mice (Hemsley et al. 2008b) and dogs 
(Crawley et al. 2011). This therapy is based on the premise that the spinal CSF can 
distribute drug throughout the central nervous system. It may be hampered by a 
requirement for repeated, long-term delivery and the normal flow of CSF which is 
from the brain down the spine, against the flow of any delivered enzyme. Another 
approach is direct injection of an AAV vector co-expressing SUMF1 and SGSH, 
successfully evaluated in mice (Fraldi et al. 2007), and now in clinical trial. It is 
unclear how well this treatment will scale from the 0.5cm3 mouse brain to a 
1500cm3 human brain. Finally, we have recently shown that a substrate reduction 
therapy approach using high dose genistein in MPS IIIB mice was able to improve 
neuropathology and behaviour (Malinowska et al. 2010). Any of these approaches 
could potentially be used in combination with LV-HSCT to improve disease 
outcomes. 
A clinical trial for LV-HSCT in MPS IIIA will need to evaluate the potential benefit of 
the therapy against the potential clinical risks. Retroviral mediated HSCT has been 
utilised in two clinical trials for X-SCID, which resulted in the successful treatment of 
19 out of 20 patients using a retroviral vector. 5 patients in these two trials 
developed acute T cell lymphoblastic leukaemia as a result of retroviral insertional 
mutagenesis and one died (Hacein-Bey-Abina et al. 2008). However, 4 of the 
patients surviving leukaemia recovered T cell diversity and numbers following 
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chemotherapy.  30 patients have been treated for ADA deficiency worldwide using 
a similar approach and 67% show a clear clinical benefit with no evidence of clonal 
dominance (Aiuti et al. 2009; Gaspar et al. 2011b). 
Since these trials, retroviral vectors have been improved by the removal of 
retroviral enhancer elements, which should help reduce the risk of proto-oncogene 
transactivation (Thornhill et al. 2008). Lentiviral vectors may have an improved 
safety profile over retroviral vectors as they tend to integrate into transcriptional 
units rather than promoter regions (Schroder et al. 2002; Wu et al. 2003). A recent 
trial for adrenoleukodystrophy using a LV-HSCT approach has shown significant 
delay in neurodegenerative disease progression in two patients treated so far 
(Cartier et al. 2009). Our proposed approach using LV-WT-HSCT in MPS IIIA may 
have a slightly increased risk from allogeneic transplant, but this may be offset by 
the ability to achieve neuropathological and behavioural correction using average 
copy numbers as low as 0.27 per cell, which will help to mitigate the risk of proto-
oncogene transactivation. 
In summary the LV-WT-HSCT approach significantly improved brain SGSH activity to 
10% of normal activity, normalising HS storage, N-, 6-O sulphation and unsulphated 
HS composition, GM2 ganglioside storage and behaviour in mice with MPS IIIA. LV-
WT-HSCT significantly reduces 2S HS composition and neuroinflammation with 
improved survival. Although both WT-HSCT and LV-IIIA-HSCT showed 
improvements in many of these parameters, neither treatment was able to 
significantly change abnormal behaviour. Given the unmet clinical need, we believe 
lentiviral mediated haematopoietic stem cell gene therapy is a clinically relevant 
and viable approach to treat MPS IIIA and similar neurodegenerative disorders. 
 
Supplementary Video 5-1 Behavioural correction of MPS IIIA mice by LV-WT-HSCT 
but not other treatments 
A video running at 4 times normal speed showing the median 2 minutes of video from the median 
mouse from the WT (top left), MPS IIIA (top right), WT-HSCT (bottom left) and LV-WT-HSCT (bottom 
right) groups at 6 months of age. Please see enclosed CD. 
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The behaviour of MPS IIIA and IIIB mice in the literature is conflicting, therefore the 
first aim of this thesis was to characterise the behaviour of the mouse models of 
MPS IIIB and MPS IIIA in order to develop tests to assess the efficacy of novel 
therapeutics. The second aim was to evaluate a lentiviral vector based 
haematopoietic stem cell gene therapy for MPS IIIA. 
 
6.1 Comparing MPS IIIA and MPS IIIB Mouse Behaviour 
When comparing the MPS IIIA and IIIB data it is important to consider the 
differences between these experiments. Changes were made to the open field 
apparatus between the MPS IIIB and MPS IIIA behavioural studies. The arena was 
increased in size to make it more sensitive to thigmotaxis differences (Simon et al. 
1994; Crawley 2007), and the flooring was changed to make the video analysis of 
the mice easier, the different flooring could also affect behaviour, as having a 
sawdust flooring has been shown to facilitate running in a T maze (Contet et al. 
2001b). The lighting was also different as the experiments were performed in a 
different mouse facility. We have now standardised the lighting to avoid this 
problem in future. Additionally the MPS IIIA mice were housed in individually 
ventilated cages and the MPS IIIB mice were not, any differences between housing 
and experimental environments can potentially affect the outcome of behavioural 
studies (Crabbe et al. 1999; Deacon 2006; Kallnik et al. 2007). Therefore it was not 
possible to make a direct comparison of the behaviour between MPS IIIA and B 
mice in the open field, but behavioural similarities were observed. 
6.1.1 Hyperactivity 
Overall hyperactivity was observed in both mouse models. The MPS IIIA mice are 
hyperactive at 4 and 6 months of age but at 8 months, there is a trend but they are 
only significantly hyperactive in the duration of motion faster than 100mm/s. 
Similarly the MPS IIIB mice are hyperactive but were only tested at of 8 months of 
age.  
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While the MPS IIIA and IIIB patient groups are indistinguishable there are some 
differences in the mice that may affect their behaviour (Heron et al. 2011). The MPS 
IIIB mice have no residual NAGLU activity while the MPS IIIA mice have 
approximately 3% of normal SGSH activity (Bhaumik et al. 1999; Li et al. 1999; 
Crawley et al. 2006).  An ongoing study in this laboratory by Ai Yin Liao is currently 
analysing the behaviour of the MPS IIIB mice at 6 months of age in the same open 
field that we used for the MPS IIIA behaviour, so we will be able to make a direct 
comparison in the future. It would be interesting to compare the activity of the MPS 
IIIA and MPS IIIB mice in the same open field set up at different time points as the 
low level of residual enzyme activity in MPS IIIA mice may cause a delayed onset or 
a less pronounced hyperactive phenotype. The sense of danger in the open field 
may also be affected. However, work by (Hemsley et al. 2005) suggests that the 
behaviour phenotype could be present from 3 weeks of age in MPS IIIA, although 
the behaviour of the MPS IIIA mice is conflicting in the literature.  
Further work could be performed on the timing of the one hour open field. Is it 
important that it is performed during a peak of activity identified in the circadian 
rhythm? Or is the consistency in the circadian time point important (Kopp 2001)? 
Previous studies that utilised a one hour open field test did not observe 
hyperactivity but they were performed at different points in the circadian rhythm 
and were also measured differently (Fu et al. 2007). If the circadian time point has 
an effect this may have an impact on the use of open field tests in the wider 
behavioural research field. However, previously it has been shown that social 
behaviours are not affected by testing in the light or the dark phase (Yang et al. 
2008).  
6.1.2 Reduced Sense of Danger? 
The MPS IIIA mice demonstrated a reduced sense of danger at 4 and 6 months but 
not at 8 months as measured by the centre duration in the open field. This is 
consistent with the MPS IIIB mice which were examined at 8 months of age and no 
difference was observed. However a small open field was used with the MPS IIIB 
mice which may be less sensitive to sense of danger (thigmotaxis) differences 
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(Crawley 2007). No difference was also observed by Lau et al. with MPS IIIA mice 
that also used a small open field (Lau et al. 2008).  
The elevated plus maze was also used to assess the sense of danger in MPS IIIA 
mice but no differences were observed at 4, 6 and 8 months of age. The elevated 
plus maze has previously yielded conflicting results in MPS IIIB mice, a reduced 
sense of danger (increased entry to open arms) was observed when the test was 
performed in the dark (Cressant et al. 2004) but not in the light (Fu et al. 2007). In 
the MPS IIIA mice a reduced sense of danger has been observed at some time 
points but not others (Lau et al. 2008) and in some papers no difference is observed 
(Lau et al. 2010a). 
The discrepancy in the reduced sense of danger in the open field but not in the 
elevated plus maze could have been because the elevated plus maze was 
performed 30 minutes after the open field and previous behavioural tests can affect 
the results of subsequent tests (Voikar et al. 2004). The width of the elevated plus 
maze arms in this study are wider than in some other studies (Lau et al. 2008), 
which has been shown to have an effect on some strains of mice but not others 
(Lamberty et al. 1996). However narrower arms can make it harder to place the 
mice consistently into the maze and to clean it adequately (Deacon et al. 2006). 
Therefore to clarify if MPS IIIA and IIIB mice demonstrate a reduced sense of danger 
or reduced anxiety, the elevated plus maze should be repeated on näively tested 
mice. If we do not observe a reduced sense of danger in the test the elevated zero 
maze, elevated platform or 3D spatial maze could be tested (Crawley 2007; 
Michalikova et al. 2010). Alternatively the mice may have a reduced sense of 
danger in the open field because they have reduced thigmotaxis, but they have a 
normal or heightened response to the transition from the dark enclosed arms to 
the brightly lit open arms, this could be evaluated in a light-dark exploration test 
(Crawley et al. 1980). This may explain why increased MPS IIIB entries into the open 
arms of the elevated plus maze have been observed in the dark (Cressant et al. 
2004) but not in the light (Fu et al. 2007).  
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6.1.3 Neuromuscular Strength 
In MPS IIIB mice the inverted screen and horizontal bar crossing tests that measure 
neuromuscular strength and motor coordination, showed no significant differences 
at 8 months of age and a significant (horizontal bar crossing) or close to significant 
(inverted screen) decline in MPS IIIB mice at 10 months of age. This suggests that 
the neuromuscular strength tests only have utility after 8 months of age. The 
decline in motor function coincides with urine retention in the mice which may 
impact on their ability to perform these tests (Bhaumik et al. 1999; Gografe et al. 
2009; Malinowska et al. 2010). The lack of neuromuscular changes in MPS IIIB mice 
suggests that the open field behaviour observed is due to neurological aspects of 
disease and not somatic aspects. Likewise in MPS IIIA at 4, 6 and 8 months of age no 
neuromuscular strength or coordination differences in male or female mice were 
detected. In MPS IIIB mice there was a trend towards reduced neuromuscular 
strength and coordination but not at 8 months with the MPS IIIA mice, this could be 
because of the residual enzyme activity in the MPS IIIA mice delaying onset of 
disease. Therefore the neuromuscular behaviour of the MPS IIIA mice at later time 
points could be examined to determine if a delay is observed but it would not be of 
practical use in testing novel therapeutics unless long-term experiments were 
performed.  
A decline in motor function after 8 months of age in MPS III is supported by most of 
the literature (Crawley et al. 2006; Fu et al. 2007; Heldermon et al. 2007; Fu et al. 
2010; Heldermon et al. 2010) except (Hemsley et al. 2005). 
A factor that needs to be addressed is the question of what a behavioural assay is 
actually measuring. A recent paper using MPS IIIB mice suggested that it had 
demonstrated “correction of cognitive and motor function” using an accelerating 
Rotarod test at 5-5.5 months of age (Fu et al. 2011). This test has previously shown 
no differences at this or later ages and it seems a stretch to say that is measuring 
cognitive function as most consider it measures neuromuscular strength and 
coordination. Therefore it is advantageous to have correction of a range of complex 
behaviours such as hyperactivity and anxiety rather than just motor function. It 
would also be interesting to correct the somatic disease and then examine the 
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behaviour of the mice to confirm that the behavioural test is measuring effects on 
neurological function. Peripheral correction could be achieved with intravenous 
delivery of lentiviral vector or hydrodynamic delivery of plasmid to produce high 
activity of enzyme that is unlikely to cross the blood brain barrier.  
6.1.4 Memory and Learning 
We have not performed any analysis of learning and memory in the MPS IIIA or IIIB 
mice as these tests are very time consuming to perform so are not ideal for testing 
a large number of mice to assess therapeutic effect. The MPS IIIA and IIIB mice are 
reported to have a reduced spatial learning ability. For MPS IIIB, a Morris water 
maze (Fu et al. 2007) and a hidden Morris water maze (platform is not visible) (Fu et 
al. 2010) have been performed. In the standard Morris water maze over three days 
4.5-5 month old WT mice improve in finding the platform from about 22s to about 
4s, the MPS IIIB mice perform significantly worse but do improve from about 39 
seconds to about 19 seconds (Fu et al. 2007). However the WT mice swim at 17 
cm/s but the MPS IIIB mice only swim at around 9 cm/s, therefore the MPS IIIB mice 
may have a reduced memory but their reduced swim speed is confounding the 
analysis; it might take them longer to get there because swimming is more difficult. 
A hidden platform Morris water maze was performed at 5-5.5 months of age, this 
controls for different visual acuity between WT and MPS IIIB mice, there was a 
much smaller decrease in time to platform by WT mice, (~35s to  ~28s) but it was 
significantly different from MPS IIIB (~44s to 42s) (Fu et al. 2010). With this test 
there was still a significantly slower swim speed in the MPS IIIB mice but the 
difference was not as great (0.97cm/s for WT and 0.83cm/s for MPS IIIB) and the 
speed was much slower than previously reported (17cm/s and 9cm/s). Therefore in 
the hidden water maze, where the mouse cannot see the platform, there is less 
difference between WT and MPS IIIB mice but the test is still affected by differences 
in swim speed.  
In MPS IIIA, a different protocol was performed for the hidden Morris water maze. 
In a 5 day acquisition phase, after the first day, the WT mice reached the platform 
faster on each day in one study (Gliddon et al. 2004) but only on one day in another 
(Crawley et al. 2006). After the acquisition phase the platform was removed and 
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the time spent in the correct quadrant was measured. A significant difference was 
detected between WT and MPS IIIA in both papers but in one, the difference 
quoted in the text could not have been significantly different and did not match the 
figures (Crawley et al. 2006). A relearning phase was then carried out after the 
probe phase and in both papers MPS IIIA mice performed significantly worse. These 
papers did not report any differences in swim speed. Another study in MPS IIIA was 
performed slightly differently. For two days before the acquisition phase the mice 
could see the platform and no difference between WT and MPS IIIA was observed. 
In the 5 day acquisition phase MPS IIIA mice were slower in only two days (Fraldi et 
al. 2007). In the probe phase the difference between WT and MPS IIIA was not 
statistically analysed but there was a definite trend towards a reduction in time 
spent in the correct quadrant by MPS IIIA mice. This paper did not present the swim 
speeds but reported that they were not significantly different.  
It appears that MPS IIIA and IIIB mice have a reduction in spatial learning and 
memory but differences in visual acuity or swim ability may confound the results. 
Consequently it needs to be determined whether MPS IIIA and B mice have a 
reduced swimming ability, if they do then the Morris water maze should not be 
used (Crawley 2007). The Morris water maze could still be used if the distance 
travelled in getting to the platform was analysed rather than the time but using 
alternative memory tests would be better (Contet et al. 2001a). 
An alternative to the Morris water maze is the Barnes maze (Barnes 1979). In this 
test the mouse is placed in the centre of a brightly lit table with holes around the 
edge and one of these holes is an escape to a dark compartment. However the 
hyperactivity and possible reduced sense of danger in the MPS IIIA and IIIB mice 
may affect this learning test. Therefore a better test for learning and memory in the 
MPS mice may be the radial maze or T maze, where the order of arm entries and 
the arms entered are recorded (Deacon et al. 2006). WT mice tend to explore each 
area and remember where they have explored; therefore the amount of time the 
mouse takes is not relevant so the hyperactive behaviour or reduced sense of 
danger should not confound the results.  
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6.1.5 Optimisation of Behavioural Testing 
The open field analysis in MPS IIIA was improved by using a larger open field, 
performing the test for longer (60 minutes compared to 3 minutes) at the same 
point of circadian rhythm and by using video analysis software which provides 
better spatial and temporal resolution (Kafkafi et al. 2003; Benjamini et al. 2010). 
This should make this open field set up more reliable than previously used in the 
literature and offer a more sensitive assessment of therapeutic effect. Previous 
studies in MPS IIIA only measured the behaviour in the open field in the first three 
minutes, in our hands the first three minutes was not indicative of the behaviour 
over 60 minutes. Consequently some of the variability in the literature could be 
caused by different operators putting the mice in the open field in different ways, 
over only 3 minutes this could have a large impact on the results.  
At the start of the study it was not known which sex would produce consistent 
behaviour outcomes and if transplant alone would affect behaviour, therefore 10 
groups of mice with 10 per group were transplanted. In addition untreated control 
groups (WT and MPS IIIA, male and female n=10) were also tested. All mice were 
put through all the behavioural tests at 4, 6 and 8 months of age. The behaviour of 
WT mice that received a transplant of WT cells was not different to un-transplanted 
WT controls and therefore was not included in the results. The male mice showed 
no behaviour differences, although they almost significantly spent more time in the 
centre of the open field at 6 months (p=0.055). Hence we did not analyse these 
mice in the long term study of lentiviral enhanced stem cell gene therapy and only 
analysed the female mice. The differences in behaviour between sex could be due 
to the fact that the male mice were singly housed due to aggressive behaviour 
while the females were group housed (Voikar et al. 2005; Arndt et al. 2009).   
In the future, to evaluate novel therapies in MPS IIIA we will only use female mice 
as they display the behavioural changes and are more economical to house. 
Additionally WT to WT transplants or the WT to MPS IIIA transplants will not need 
to be performed. The behaviour will only need to be assessed at 6 months of age 
and rather than perform the open field test, repeated elevated plus maze, bar 
crossing and inverted screen test, only the one hour open field test will be 
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performed. This will speed up and simplify the assessment of therapies in the MPS 
IIIA mice in our lab.  
6.1.6 MPS III Mouse and Patient Behavioural Similarities 
The MPS III patient’s behavioural problems include hyperactivity, a reduced sense 
of danger, aggression and sleep disturbances (Cleary et al. 1993; Bax et al. 1995; 
Fraser et al. 2002; Fraser et al. 2005; Valstar et al. 2008; Malm et al. 2010). The 
results of these mouse behaviour papers concur with the patient phenotype. 
Hyperactivity is observed in MPS IIIA and IIIB mice and, with a larger open field, a 
reduced sense of danger is observed in MPS IIIA mice.  Aggression in male MPS IIIA 
mice has been observed and resulted in singly housing the male mice but this has 
not been quantified (Gliddon et al. 2004). Changes in the circadian rhythm have 
also been observed in MPS IIIB mice (Canal et al. 2010). Therefore in terms of 
hyperactivity, a reduced sense of danger, aggression and sleep disturbances the 
MPS III mouse models appear to be a good model of patient disease. 
Professor Elsa Shapiro is undertaking a natural history study of MPS IIIA patients 
funded by Shire Human Genetic Therapies, Inc. (NCT01047306).  At the MPS III 
Research & Treatment Workshop in 2011 she presented preliminary data 
speculating that MPS IIIA has similarities with Klüver–Bucy syndrome where loss or 
damage of the amygdala results in behavioural changes.  Klüver–Bucy syndrome 
was first identified by making large resections in the temporal lobes of rhesus 
monkeys (Klüver et al. 1937). Patients have visual agnosia (the inability to recognise 
familiar objects or faces), hyperorality (an urge to examine objects with the mouth), 
hypermetamorphosis (the impulse to notice and react to everything within sight), 
docility, loss of the normal fear or anger response, hypersexuality and dietary 
changes. Also reported is aphasia (impairment of language), memory disturbance, 
seizures, aggression, uncontrolled screaming and hyperactivity (Cohen et al. 2010), 
although patients may not exhibit all of the symptoms listed. Some of these 
behaviours, such as the reduced fear, aggression and hyperactivity have been 
observed in the MPS III patients and mice but many including hypersexuality have 
not been reported (Cleary et al. 1993; Bax et al. 1995; Fraser et al. 2002; Fraser et 
al. 2005; Valstar et al. 2008; Malm et al. 2010; Wegrzyn et al. 2010).  
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The amygdala is involved in emotional responses and so can be measured by a 
contextual or cued fear experiment (Phillips et al. 1992). A mouse is given a mild 
shock in a novel environment after a noise has been made. The next day the mouse 
is reintroduced to the environment without the sound and the freezing behaviour is 
measured, this is contextually conditioned fear. The next day the mouse is placed in 
a new environment and the noise is made and the freezing behaviour is recorded, 
this is cued or tonal conditioning (Crawley 2007).  This test has been performed on 
2.5 and 4.5 month old MPS IIIB mice; no difference in contextual fear was observed 
and no difference in tone fear at 2.5 months but a reduced tone fear response was 
observed at 4.5 months. However the lack of tonal fear at 4.5 months could be due 
to hearing deficits observed in MPS IIIB mice (Li et al. 1999). Therefore the MPS IIIB 
mice do not present with contextual fear differences that you would expect from 
amygdala damage in Klüver–Bucy syndrome.  
To further examine the behavioural similarities to Klüver–Bucy syndrome the 
aggression of MPS IIIA and B mice could be quantified using the resident intruder 
test (Thurmond 1975). Alongside this the social interactions of the mice could be 
examined with novel mice or cage mates.  
The amygdala may play a role in the MPS III behavioural phenotype and we and 
others have observed accumulation of GM2 in this area (McGlynn et al. 2004; Lau 
et al. 2010a) but GM2 storage is also present throughout the brain and the patients 
and mice do not appear to present with all behavioural aspects. Therefore as there 
is global accumulation of HS, extensive neuroinflammation and widespread 
accumulation of GM2 gangliosides it is possibly too restrictive to consider the 
amygdala storage of GM2 gangliosides as the cause of the behaviour phenotype. 
Any theories of the cause of the behaviour of MPS III patients will need to explain 
the differences in behaviour between MPS I and III patients (Wegrzyn et al. 2010). 
While MPS III patients are reported to be hyperactive, aggressive and have a 
reduced sense of danger, MPS I patients have little behavioural problems other 
than learning difficulties despite both storing HS (Pitt et al. 2009; Wegrzyn et al. 
2010).  
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In preliminary data from Dr Michael Potegal, MPS I and MPS III patients spent time 
in a “risk-room” with their mother and their exploratory behaviour and behaviour 
when their mother left was examined. The MPS I patients explored less than the 
MPS III patients and the MPS III patients were not as concerned by the absence of 
their mother (Potegal et al. 2011). These behavioural differences are despite both 
MPS I and MPS III storing HS. Therefore the behaviour of the mouse models of MPS 
I and III could be examined further to try and corroborate this observation however, 
the more complex behaviours observed in the patients may not be quantifiable in 
mice. However it is hard to compare behaviour of MPS I and MPS III mice as the 
MPS I mice have more severe somatic and skeletal manifestations. 
6.1.7 MPS III Mouse vs. Patient Disease Pathology and Response to Treatment 
In our laboratory Dr Fiona Wilkinson has recently examined the neuropathology of 
MPS I, IIIA and IIIB mice at 4 and 9 months of age (Wilkinson, Submitted PLoS ONE 
September 2011). An increase in the size of the lysosomal compartment in MPS IIIB 
compared to MPS I and increasing storage from 4 to 9 months was observed. GM2 
ganglioside storage was observed throughout the brain but more intense storage 
was observed in several brain regions including the amygdala in both MPS I and III. 
The storage of GM2 ganglioside in the cerebral cortex was quantified and there was 
no significant difference between MPS types or from 4 to 9 months of age.  
Neuroinflammation in terms of activated astrocytes (GFAP positive) and microglia 
(isolectin B4 positive) was significantly increased in MPS IIIA and B in comparison to 
MPS I but this parameter also does not progress from 4 to 9 months of age. No 
significant neuronal cell loss or reduction in cortical thickness was detected but a 
trend towards a reduction was observed. The combination of no changes in GM2 
gangliosides and neuroinflammation from 4-9 months suggests these factors are 
less important in neurodegeneration and behavioural phenotype, and primary 
storage that increases with time is more important. Previously neurodegeneration 
has been shown to occur independently to neuroinflammation in MPS IIIB mice and 
that anti-inflammatory administration to MPS IIIA mice had no effect of the 
expression of apoptosis genes (Ausseil et al. 2008; Arfi et al. 2011).  
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The study of lentiviral vector stem cell gene therapy in chapter 5 suggests that GM2 
gangliosides and neuroinflammation are not important in determining the 
behaviour of MPS IIIA mice as the LV-WT-HSCT and WT-HSCT treatments had the 
same effect on GM2 gangliosides and neuroinflammation in the cortex but LV-WT-
HSCT corrected the behaviour and WT-HSCT did not (Table 6-1). There appeared to 
be little or no effect on GM2 ganglioside storage in the amygdala by both 
treatments (Figure 5-4). The difference between these treatment groups was that 
there was less HS storage in LV-WT-HSCT and the HS was less sulphated. The 
amount of HS and the sulphation state of HS is important in many cellular process 
including cell signalling and growth factor signalling and gradients (Merry et al. 
2002; Bishop et al. 2007; Turnbull et al. 2010).  In the work of Dr Wilkinson in our 
lab it was also found that the HS in MPS IIIA and IIIB is more sulphated than in MPS I 
or WT. The difference between WT-HSCT and LV-WT-HSCT could be further 
analysed to examine the differences in GM2 and GM3 gangliosides by thin layer 
chromatography but we have currently been unable to do so. Examination of 
VAMP2 and synaptophysin, proteins involved in neuronal synapses or cholesterol 
that is also found to be elevated in MPS could also be examined in different regions 
of the brain, including the amygdala.   
Brain WT LV-WT-HSCT LV-IIIA-HSCT WT-HSCT MPS IIIA 
SGSH Activity, % WT 100 10 7 6 3 
Total GAGs, Fold WT 1 1.1 0.7 1.2 1.6 
Total HS, Fold WT 1 5 9 9 17 
%HS Un sulphated  58 52 39 48 38 
%HS NS 42 48 61 52 62 
% HS 6S 21 22 29 23 31 
% HS 2S 20 32 48 38 52 
Cortex Microglia Number 8 62 76 61 143 
Cortex GM2 gangliosides, Fold WT 1 28 99 25 110 
Hyperactive Behaviour  
(Path length, m) 4 months 
110 119 155 186 195 
Hyperactive Behaviour  
(Path length, m) 6 months 
77 79 151 118 181 
Sense of danger  
(Centre entries) 4 months 
168 204 248 329 300 
Sense of danger  
(Centre entries) 6 months 
99 107 250 164 273 
Table 6-1 Comparison of treatment results from chapter 5  
A summary of the biochemistry and histology results in the brain and behavioural outcomes. The 
path length and centre entries are indicative of the other activity and sense of danger measures 
respectively. This table highlights the different behavioural outcomes in comparison to biochemical 
and histology results. 
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MPS IIIB is also thought to be a tauopathy like Alzheimer’s disease; 
hyperphosphorylated tau was detected in the medial entorhinal cortex and in older 
mice in the dentate gyrus, which are regions involved in memory and memory and 
navigation respectively, but the mechanism of storage is not clear (Ohmi et al. 
2009). However it is not clear if hyperphosphorylated tau in this very limited region 
of the brain involved in memory is relevant to the clinical pathology or treatment of 
MPS III. Additionally some of the antibodies against hyperphosphorylated tau used 
in Alzheimer’s disease did not work in MPS IIIB (Ohmi et al. 2009) and two prior 
studies did not observe hyperphosphorylated tau (Ginsberg et al. 1999; Hamano et 
al. 2008). Therefore it seems unlikely that the very limited distribution of 
hyperphosphorylated tau that one group has observed is the most important factor 
in MPS III.  The brains of the treated and untreated mice in this study could be 
examined to see if the treatment has had any effect on tau expression.  
We propose that the behaviour of MPS III is most likely to be related to the amount 
and sulphation of HS rather than the presence of GM2 gangliosides, 
neuroinflammation and hyperphosphorylated tau in specific regions of the brain 
but more work is needed to confirm this hypothesis. 
6.1.8 Impact of Behavioural Papers 
The results of these behavioural studies probably does not have broad applicability 
to other MPS diseases or LSDs, as MPS III is unusual in having a primarily neuronal 
phenotype with mild somatic effects. Mice with significant skeletal pathology may 
have impaired movement and so in the open field test hypoactivity may be 
observed where hyperactivity is expected. Therefore this test would not measure 
correction of neurological behaviour but effect on the body.   
The behaviour of MPS I and MPS VII mice has been described in the literature but 
there are inconsistencies. MPS I mice (Clarke et al. 1997) are either hypoactive (Pan 
et al. 2008) or show no difference in path length (Reolon et al. 2006), and no 
difference in centre time (Reolon et al. 2006; Pan et al. 2008) in the open field test. 
No differences in anxiety were observed in the elevated zero maze or marble 
burying tests (Pan et al. 2008). Some groups have observed no difference in spatial 
memory in the Morris water maze (Pan et al. 2008) but others show a decrease 
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(Wolf et al. 2011). Other memory tests such as novel object recognition have been 
used which show that MPS I mice spend more time examining a novel object when 
it is reintroduced at 8 months of age (Pan et al. 2008) but not younger (Reolon et al. 
2006; Pan et al. 2008). Further memory tests have been performed which show no 
difference in short term inhibitory avoidance but a reduction in long term inhibitory 
avoidance (Reolon et al. 2006).  
Since there is no clear behavioural phenotype in MPS I patients or the mice, 5 
minute open field tests were performed 3 times separated by 30 minute gaps. The 
WT mice were 55% less active in the third than first trial but the MPS I mice were 
only 31% less active (Pan et al. 2008). This suggests that the MPS I mice habituate 
to a novel environment more slowly or are hyperactive compared to WT when 
measured in this way but not in a long open field test (up to 90 minutes has been 
analysed) where the somatic manifestations may be more limiting. This repeat 
open field test is frequently used in MPS I mice (Hartung et al. 2004; Pan et al. 
2008; Wang et al. 2009; Visigalli et al. 2010) but has not been tested in MPS III. By 
using a repeat test the effect of any neuromuscular affects on behaviour can be 
controlled although it has not been determined if neuromuscular strength and 
coordination defects are present in MPS I mice. 
MPS VII mice have not been examined by the open field test but they are 
hypoactive in home cage activity and have circadian rhythm changes (Ross et al. 
2000). They also spend less time grooming, which is thought to be caused by 
skeletal problems (Chang et al. 1993; Bastedo et al. 1994). MPS VII mice have a 
reduced swimming ability (Chang et al. 1993) that could affect the reduced spatial 
memory in MPS VII mice in the Morris water maze (Chang et al. 1993; Bastedo et al. 
1994; O'Connor et al. 1998; Sakurai et al. 2004). However the MPS VII mice also 
have impaired novel object recognition (Fukuhara et al. 2006) and in a repeated 
acquisition and performance chamber appear to have memory problems (Brooks et 
al. 2002).  
The behaviour of MPS II mouse models has not been evaluated (Garcia et al. 2007; 
Jung et al. 2010) and the behaviour papers from this study may influence the 
characterisation of these mice. The behavioural measures identified in this study 
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will be used to characterise the MPS IIIC mouse model that has recently been made 
in Dr Alexei Pshezhetsky’s laboratory. 
6.1.9 Novel Mouse Model Behavioural Testing Strategy 
Assessing the behaviour of MPS IIIA and IIIB mice and reviewing the literature has 
led me to devise a plan for testing a novel MPS mouse model. Firstly the 
neuromuscular strength and coordination of the mice should be analysed as 
subsequent tests can be affected by neuromuscular problems. A simple way to do 
this is to use the bar crossing and inverted screen test (Jeyakumar et al. 1999) or 
use an accelerative or rocking Rotarod. The open field or repeated open field test (if 
the mice have neuromuscular problems) is also a simple test that is easy to perform 
that can be used to examine the activity and habituation of the mice and also 
indicates if the mice have an altered sense of danger (or anxiety) by the amount of 
time spent in the centre. The time of day the open field test is performed could also 
be important so a study of the circadian rhythm activity may also be beneficial. If 
the open field test suggests that there are anxiety differences this can be confirmed 
with elevated plus or zero mazes. If the researcher has observed neuromuscular 
strength differences or hypo or hyper activity differences they should consider how 
these may impact on the analysis of these mazes. It may be most appropriate to 
examine the number of entries into the open as a percentage of all arm entries, but 
multiple parameters should be considered (distance, time, entries, percentage of 
distance, percentage of entries) to make an informed assessment of the results.  
Tests of cognitive function and memory are very time consuming to perform so are 
not ideal for testing novel therapeutics; however they are useful in characterising a 
mouse model. The most commonly used spatial memory test is the Morris water 
maze, however the swimming ability must be assessed and the eyesight of the mice 
should be tested if visual cues are going to be used. If the swimming ability is 
significantly reduced the distance travelled to the platform or the proportion of the 
path length in the correct quadrant could be measured using video tracking 
software, however it may be more appropriate to perform alternative memory 
tests such as the barns, radial or T maze. The radial or T maze may be most 
applicable if there are activity level differences. Other memory tests such as the 
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contextual or tonal fear tests can also be performed, but the visual and auditory 
acuity should be examined to confirm that the results are caused by memory 
defects not an inability to recognise the surroundings or hear the sound.  
Aggression and social behaviours could also be examined using resident intruder 
tests and other behaviour test dependent on the patient phenotype and any 
anomalies in the other tests.  
 
6.2 Lentiviral Vector Enhanced Haematopoietic Stem Cell Gene Therapy 
for MPS IIIA  
Having optimised the analysis of behaviour in MPS IIIA mice the effect of lentiviral 
vector based haematopoietic stem cell gene therapy for MPS IIIA in the mouse 
model was assessed.  There are two potential approaches to clinically treat MPS IIIA 
patients with lentiviral vector based haematopoietic stem cell gene therapy. Firstly 
donor bone marrow or cord blood could be transduced with the lentiviral vector, 
which we have modelled as the LV-WT-HSCT, or an autologous transplant where 
the patient’s own bone marrow is gene modified before being returned to the 
patient; modelled using MPS IIIA bone marrow (LV-IIIA-HSCT).  These approaches 
have been compared to a donor transplant with cells expressing normal SGSH 
activity (WT-HSCT), which has been shown to be ineffective in improving 
neurological function in patients although it may stabilise the peripheral disease 
(Vellodi et al. 1992; Shapiro et al. 1995; Sivakumur et al. 1999; Lau et al. 2010a).  
For evaluation of the lentiviral enhanced stem cell gene therapy in the MPS IIIA 
mice a number of experiments had to be optimised: the transplantation of MPS IIIA 
mice with low numbers of lineage depleted haematopoietic stem cells, the 
production and titration of the SGSH lentiviral vector. Titration of the vector 
involved setting up QPCR and designing and testing different primer and probe sets 
and producing a known copy number standard. The SGSH enzyme activity assay was 
optimised further and the MPS IIIA mice were backcrossed onto the C57BL/6 
background so that the behavioural testing and analysis could be optimised and 
performed.  
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6.2.1 The LV-IIIA-HSCT or LV-WT-HSCT Approach in the Clinic 
The LV-WT-HSCT transplant was the most successful but with higher copy numbers 
or enhanced expression of SGSH the LV-IIIA approach would be indistinguishable 
from the LV-WT approach. The LV-WT approach has the advantage that lower copy 
numbers would be required because of the endogenous expression of SGSH which 
would make it safer from an insertional mutagenesis stand point. However the LV-
IIIA approach would involve a safer conditioning regimen with less immune 
suppression required and no risk of graft vs. host disease. It should also be 
considered that despite the risks there are currently no treatments for MPS IIIA and 
patients die on average at 15 years of age (Meyer et al. 2007; Heron et al. 2011).  
In some diseases such as X-SCID, the transplanted transduced autologous cells have 
a selective advantage over the resident HSCs therefore little or no conditioning is 
required (Qasim et al. 2009). However in MPS IIIA where there is little or no 
selective pressure, myeloablative conditioning may still be required. Immune 
suppression may also be necessary to prevent a response against the transgene 
(Cartier et al. 2009; Grez et al. 2011). Therefore even in an autologous transplant, a 
high level of myeloablation and immune suppression may be required. In ongoing 
work in our laboratory Kia Langford-Smith has been working on reduced intensity 
transplant conditioning regimens in WT and MPS I mice that may also be applicable 
in MPS III. 
This study cannot advise which approach is most appropriate for the clinic but it 
does strongly suggest that the lentiviral vector haematopoietic stem cell gene 
therapy approach is an efficacious treatment for MPS IIIA and potentially other 
neuropathic lysosomal storage disorders with secreted enzymes.   
Additionally, this study also cannot advise on the best time to treat patients and 
whether MPS IIIA disease is reversible. Although MPS IIIA mice at 8 weeks of age 
are considered symptomatic (Crawley et al. 2006) there is no significant neuronal 
loss in the mice at 9 months of age although there is a trend (Dr Fiona Wilkinson 
unpublished data). In advanced patients LV-HSCT may just stabilise the disease like 
a normal transplant and not improve the quality of life. The younger MPS I patients 
are transplanted the better the outcome and this is likely to be the case for MPS III 
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(Boelens et al. 2007; Boelens et al. 2009). There is no newborn screening program 
for MPS IIIA and given the rarity of the condition there is unlikely to be one. 
However pre-symptomatic patients are identified where a sibling or other family 
member has already been diagnosed.  
6.2.2 Clinical Development of Lentiviral HSCT 
The lentiviral vector backbone used in this study would not gain regulatory approval 
from the gene therapy advisory committee (GTAC) since it contains a viral 
promoter. The vector backbone has now been modified in this lab by Ana 
Sergijenko who has changed the backbone to one that is currently in use in the 
clinical trial in Italy for MLD by Dr A. Biffi and Professor L. Naldini. This vector uses a 
human PGK or human CD11b promoter for the SGSH gene rather than the viral SFFV 
promoter; this reduces the chance that the promoter will cause transcription to 
start at neighbouring genes to the integration site. The wpre sequence has also 
been mutated to stop the production of the X protein that has been implicated in 
oncogenesis (Schambach et al. 2006). The SGSH gene sequence has now been 
codon optimised to enhance expression of SGSH, and the length of the transgene 
has been shortened by removing the untranslated region to enhance transduction. 
Co-expressing the sulphatase modifying factor 1 (SUMF1) gene which modifies 
sulphatases by producing a formyl-glycine residue that is required for sulphatase 
activity could also increase SGSH activity (Fraldi et al. 2007). 
The safety and efficacy of this vector is being examined in the laboratory by Ana 
Sergijenko in vitro in haematopoietic stem cells and in vivo. The Modlich assay will 
be performed to look at the rate of oncogenic transformation with the lentiviral 
vector in vitro (Modlich et al. 2006). This is a requirement for regulatory approval 
from GTAC and the Medicines and Healthcare products Regulatory Agency (MHRA). 
In vivo efficacy of this therapy will be assessed in MPS IIIA mice to establish if higher 
copy numbers and higher activity of SGSH are achieved in the brain with a greater 
reduction in HS. The incidence of leukaemia in vivo will also be examined. 
Integration site analysis will be performed to determine if there are common 
integration sites, or common integrations into genes within common integration 
sites (Biffi et al. 2011). 
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6.2.3 Other Therapies in Development 
There are two main alternative therapeutic approaches that are currently in or 
starting soon in clinical trial, intrathecal enzyme replacement therapy (IT-ERT) or 
intracranial AAV gene therapy.  
IT-ERT is currently in clinical trial in Manchester by Shire Human Genetic Therapies 
Ltd for MPS IIIA (NCT01299727, NCT01155778).  Recombinant human SGSH is being 
delivered by intrathecal drug delivery ports monthly in the first cohort but rising to 
fortnightly in another. However there is a risk that the port can become infected 
(Boviatsis et al. 2004) and the behavioural problems of MPS IIIA children makes it 
hard to get them to cooperate for the injections. This therapy will require lifelong 
repeated injections if it is successful. Preclinical work in MPS IIIA mice (Savas et al. 
2004; Hemsley et al. 2007; Hemsley et al. 2008a) and dogs (Hemsley et al. 2009b; 
Crawley et al. 2011) is promising but higher doses are required for therapeutic 
effect in the dog than are being used in the clinical trial. This may also be a very 
expensive way to treat patients as the production of recombinant enzyme is 
expensive and repeat delivery for life will be necessary.  
Lysogene announced in June 2011 that authorization for a phase I/II clinical trial 
(SAF-301) of direct injection of AAV had been approved by the French Agency for 
the Safety of Health Products (AFSSAPS) and that the clinical trial began in 
September 2011. This approach has varying results in preclinical testing with 
apparent success in some areas but is limited by the spread of AAV so that no 
overall reduction in HS was observed (Fraldi et al. 2007). However in short term 
preclinical testing of intrastriatal delivery of the GMP clinical vector in MPS IIIA mice 
performed in this laboratory for Lysogene, we have seen higher activity of SGSH 
expression although this decreases further from the injection site. Direct injection 
of AAV into MPS IIIB mice was more successful (Fu et al. 2002; Fu et al. 2007; 
Heldermon et al. 2010). It is currently unclear how well this treatment will scale 
from the 0.5cm3 mouse brain to a 1500cm3 human brain and how many injection 
sites will be required. However a clinical trial for late infantile neuronal ceroid 
lipofuscinosis (NCT00151216) has shown some success in reducing the rate of 
decline but, an antibody response was raised against the vector capsid and it is not 
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clear if the adverse events that occurred in the trial were caused by the disease, the 
vector or surgery (Worgall et al. 2008). A new clinical trial is now underway with an 
AAV serotype that has a better distribution and expression in the brain 
(NCT01161576).  
In both these approaches the somatic manifestation, although mild, will also 
require treatment through gene therapy or enzyme replacement therapy. There is 
also the concern in both of these treatments that an immune response will limit the 
efficacy of the enzyme or cause neuroinflammation. An immune response against 
the enzyme will not occur in LV-HSCT as the immune system is replaced with one 
that expresses SGSH, therefore the immune system will be tolerant to SGSH.  
We have recently shown that a substrate reduction therapy approach using high 
dose genistein in MPS IIIB mice was able to improve neuropathology and behaviour 
(Malinowska et al. 2009; Malinowska et al. 2010) and a clinical trial in MPS III is 
being planned. Any of these approaches could ideally be used in combination with 
LV-HSCT to provide a source of the deficient enzyme to improve disease outcomes. 
 
6.3 Conclusions 
This thesis set out to firstly to evaluate the behaviour of MPS IIIA and IIIB mice and 
relate this to the patient phenotype and to determine a behavioural test and the 
appropriate age to evaluate novel therapies in MPS IIIA.  
The behavioural testing has allowed us to establish that both MPS IIIA and IIIB mice 
share behavioural similarities with the MPS III patients; they are hyperactive and at 
least in the MPS IIIA mice exhibit a reduced sense of danger in the open field. These 
two supporting papers have allowed us to identify a robust assay with multiple 
parameters to evaluate the effect of lentiviral vector enhanced haematopoietic 
stem cell gene therapy on the neurodegeneration in MPS IIIA mice. 
The second aim was to over express SGSH in haematopoietic stem cells using a 
lentiviral vector and transplant these cells into MPS IIIA mice. The third aim was to 
perform a long-term comparison of lentiviral vectors expressing SGSH in 
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transplanted MPS IIIA HSCs compared to transplants of transduced normal cells and 
normal cells alone into MPS IIIA mice, to determine the effect on enzyme activity, 
GAG and HS storage levels, HS sulphation, GM2 ganglioside secondary storage, 
neuroinflammation and behaviour. 
This thesis has demonstrated that the lentiviral enhanced haematopoietic stem cell 
gene therapy approach to treat a mouse model of MPS IIIA is viable, and warrants 
further in vitro investigation before being taken forward into clinical trial. 
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Mucopolysaccharidosis IIIB (MPS IIIB) is a lysosomal
storage disorder characterized by severe behavioural dis-
turbances and progressive loss of cognitive and motor
function. There is no effective treatment, but behavioural
testing is a valuable tool to assess neurodegeneration
and the effect of novel therapies in mouse models of dis-
ease. Several groups have evaluated behaviour in this
model, but the data are inconsistent, often conflicting
with patient natural history. We hypothesize that this
discrepancy could be due to differences in open field
habituation and home cage behaviour. Eight-month-
old wild-type and MPS IIIB mice were tested in a 1-h
open field test, performed 1.5 h after lights on, and a
24-h home cage behaviour test performed after 24 h
of acclimatization. In the 1-h test, MPS IIIB mice were
hyperactive, with increased rapid exploratory behaviour
and reduced immobility time. No differences in anxi-
ety were seen. Over the course of the test, differences
became more pronounced with maximal effects at 1 h.
The 24-hour home cage test was less reliable. There was
evidence of increased hyperactivity in MPS IIIB mice,
however, immobility was also increased, suggesting a
level of inconsistency in this test. Performance of open
field analysis within 1–2 h after lights on is probably
critical to achieving maximal success as MPS IIIB mice
have a peak in activity around this time. The open field
test effectively identifies hyperactive behaviour in MPS
IIIB mice and is a significant tool for evaluating effects of
therapy on neurodegeneration.
Keywords: Behaviour, lysosomal storage disease, MPS IIIB,
mucopolysaccharidosis, neurodegenerative disease, open
field, Sanfilippo syndrome
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Mucopolysaccharidosis type IIIB (MPS IIIB, OMIM #252920),
or Sanfilippo syndrome, is caused by a deficiency in the
lysosomal enzyme, α-N-acetylglucosaminidase, as a result
of mutations in the NAGLU gene (O’Brien 1972; Zhao
et al. 1996). NAGLU deficiency impairs lysosomal degra-
dation of heparan sulphate in the brain, resulting in enlarged
lysosomes, secondary storage of gangliosides and choles-
terol (Constantopoulos et al. 1978; McGlynn et al. 2004),
severe neuroinflammation (Canal et al. 2010; Ohmi et al.
2003) and progressive cellular and organ dysfunction (Valstar
et al. 2008). Patients present with severe behavioural prob-
lems including aggression, hyperactivity, a decreased sense
of danger and sleep disturbances (Cleary & Wraith 1993;
Fraser et al. 2005; Moog et al. 2007) leading to progres-
sive neurodegeneration and death in the second decade of
life, although the phenotype varies considerably (Heron et al.
2011; Meyer et al. 2007).
There is currently no effective therapy for MPS IIIB, but
substrate reduction therapy (Malinowska et al. 2009, 2010),
enzyme replacement therapy (Yu et al. 2000), and gene
therapy and stem cell therapy approaches (reviewed in
Valstar et al. 2008) have been evaluated. Surrogate clinical
biomarkers for MPS IIIB have only recently been forthcoming
and are still in development (Langford-Smith et al. 2010,
2011); therefore, the behavioural phenotype of the mouse
model remains an important tool for measurement of
treatment effect on the severe neurodegenerative phenotype
seen in both mice and patients.
The mouse model of MPS IIIB has previously been reported
to show alterations in circadian rhythms as measured in the
home cage, including increased activity in the light (Canal
et al. 2010; Heldermon et al. 2007) or dark (Cressant et al.
2004). Interestingly, none of these studies, including our
own, showed overall increases in activity of MPS IIIB mice.
In contrast, an 8-min open field analysis of the MPS IIIB
mouse model, half in light, half in dark, showed reductions
in activity in both light and dark phases (Li et al. 1999), whilst
a separate study observed reduced rearing in the second
30 min of a 1-hour open field test (Fu et al. 2007). This
contrasts with observations of hyperactivity in MPS IIIB mice
in a 10-min open field test (Cressant et al. 2004).
MPS IIIB mice also show a reduced sense of danger in
some situations. Fear conditioning was normal in the con-
textual fear test but reduced in tone fear test (Li et al. 1999)
which could be caused by differences in sensory function,
© 2011 The Authors 673
Genes, Brain and Behavior © 2011 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society
Langford-Smith et al.
whilst no changes in the acoustic startle response have
been observed (Fu et al. 2007). A reduced sense of danger
(increased entry to open arms) has been observed in the ele-
vated plus maze test when performed in the dark (Cressant
et al. 2004) but not in the light (Fu et al. 2007). Therefore,
again it is not clear if the MPS IIIB mice mimic the pathology
seen in patients where they have a reduced sense of danger.
These disparities may reflect different testing conditions,
and require definitive characterization in both the home cage
and open field to determine a reliable phenotype.
Methods
Mouse maintenance
MPS IIIB mice (Li et al. 1999) were maintained by heterozygous
breeding as described (Canal et al. 2010) on a C57BL/6J background
with occasional backcrossing to the C57BL/6J line (Harlan, Bicester,
UK) to maintain the background. Wild-type (WT) and MPS IIIB knock-
out (KO) female littermates were used for all behavioural analysis.
All procedures were ethically approved and in accordance with the
UK Home Office and European Union (2010/63/EU) regulations. Mice
had access ad libitum to food and water and were housed under a
12-h light–dark cycle.
Behavioural testing
The 1-h open field test was performed as described previously
(Malinowska et al. 2009, 2010). In brief, 8-month-old female mice
(n = 6 WT, n = 6 MPS IIIB) were dropped into the centre of an arena
(260 × 365 mm) containing corn cob flooring and the behaviour was
recorded with a digital camera (Sony, Tokyo, Japan) for 60 min. The
open field test was performed 1.5 h after the lights were turned on in
a randomized blinded fashion. The behaviour was analysed using Top
Scan software version 2.0 (Clever Sys. Inc., Reston, VA, USA). The
path length, rapid exploratory behaviour (speed >90 mm/second),
immobility (speed <0.05 mm/second) and frequency, path length,
duration and speed in the central 25% of the cage were analysed.
Rearing was manually counted by an observer blinded to the
genotype of the mice. The number of supported rears (using the side
of the cage) and unsupported rears were counted for the first 10 min
of the 1-h open field.
In the 24-h home cage test, a mouse (n = 6 WT, n = 7 MPS IIIB)
was placed in a cage (260 × 365 mm) with food and a plastic water
tower where water is accessible and the mice can nest underneath
(Fig. 3a). Behaviour in this area could not be analysed as it is hidden
from view. The mice were allowed to acclimatize for 24 h before
24 h of filming. When the lights were turned off, infra red lights
automatically turned on to illuminate the mice for the night-vision-
enabled camera. Behaviour was analysed as for the 1-h open field
using the same measures and Top Scan Suite software (Cleversys
Inc., Reston, VA, USA).
The inverted screen test was performed at 8 months (n = 4 WT,
n = 5 MPS IIIB) and 10 months (n = 3 WT, n = 4 MPS IIIB) of age
by placing the mouse on a 470-mm square screen covered with
a 13-mm square wire mesh and rotating the screen through 180◦
over 1–2 seconds. The mouse was suspended upside down above
a padded surface and the number of rear leg moves was counted
and the amount of time spent suspended up to a maximum of 2 min
was recorded.
The horizontal bar test was performed as described previously
(Malinowska et al. 2010) at 8 months (n = 6 WT, n = 7 MPS IIIB)
and 10 months (n = 3 WT, n = 4 MPS IIIB) of age. In brief, a 300-mm
metal wire, 2 mm in diameter, was secured between two posts
320 mm above a padded surface. The mouse was allowed to grip
the centre of the wire and the time to fall or reach the side was
recorded, and after 2 min the test was stopped. Crossing the bar in x
seconds was scored as 240−x, remaining on the bar was scored as
120, and falling off the bar after y seconds was recorded as the value
of y. The test was repeated three times as a practice run followed
by a 10-min rest prior to three tests where the score was recorded.
Statistical analysis
Data were analysed using JMP software version 8 (SAS Institute
Inc., Cary, NC, USA) and multivariant analysis of variance (MANOVA)
repeated-measure analysis and one-way ANOVAs were used, where
appropriate, to determine differences between groups (Genotype)
and within groups (Illumination). The F value is given for each
comparison, together with degrees of freedom and the probability of
error. Significance is assumed at probabilities of less than 0.05.
Results
To test the hypothesis that MPS IIIB mice, like patients,
are more hyperactive and have a reduced sense of danger,
groups of 6–7, 8-month-old female WT and MPS IIIB mice
were monitored for 1 h for habituation behaviour in the open
field. To check the reliability of the home cage test, following
24 h of acclimatization, we monitored the same mice in
the home cage environment for a further 24 h. We also
performed tests of motor function at 8 and 10 months of age
to monitor motor decline.
To compare the open field test (Fig. 1a) to previous studies
and to determine the minimum time required to achieve
consistent significance, we have presented the data as per
minute activity graphs and analysed the first 3 and 10 min
of the test as well as the total 60 min for significance,
using a student’s t-test (Cressant et al. 2004; Hemsley &
Hopwood 2005). MPS IIIB mice travel more than three
times as far as WT mice over the duration of the trial
(Fig. 1b) with significant differences observed in the first 3
(F1,10 = 13.63, P = 0.004), 10 (F1,10 = 19.69, P = 0.001) and
60 min (F1,10 = 20.70, P = 0.001) of the trial.
Rapid exploratory behaviour was monitored by the
frequency (Fig. 1c) and duration (Fig. 1d) of speed over
90 mm/second. Highly significant increases in both of
these parameters were observed in MPS IIIB mice at 3,
10 and 60 min after commencement of the test (F1,10 =
17.98–33.11, P = 0.002–0.0002). Video S1 shows the
median mouse from each group over the median 2 min of the
open field test (minutes 29–31), running at four times normal
speed, in which many of these behaviours can be observed.
We also monitored frequency (Fig. 1e) and duration (Fig. 1f)
of immobility over the period of the test. MPS IIIB mice had
a consistently reduced frequency and duration of immobility
but this was only significant when measured at 10 and 60 min
(F1,10 = 16.67–60.24, P = 0.008 to <0.0001) and was not
significant at 3 min (F1,10 = 2.99–1.97, P = 0.11–0.19). In
these cases, the groups became more significantly different
as the analysis period was extended. Interestingly, this
appears to be because of an initial similarity in the behaviour
of the two groups when the mice were first placed in the
cage, which rapidly diverges over time (Fig. 1e,f).
As a prey species, mice tend to display thigmotaxis (Simon
et al. 1994), and thus show a reduced tendency to enter the
central part of an open field arena. In Fig. 2a the frequency
of entries into the centre of the open field was recorded
every minute for 1 h. Figure 2b shows the path length in the
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Figure 1: One-hour open field – activity. At 8 months of age six WT (white squares) and six MPS IIIB (black squares) mice were
placed in the centre of a cage 260 × 365 mm outlined in (a) and the behaviour was recorded for 1 h. The results of the open field
behaviour are presented as a 1-h period with the average of every minute presented and as a bar chart of the first 3 min, first 10 min
and whole hour. Error bars represent the standard error of the mean (SEM). P values were calculated by t-test. The mean average
path length in meters (b), frequency of rapid exploratory behaviour (speed >90 mm/second) (c), duration of rapid exploratory behaviour
(speed >90 mm/second) (d), frequency of immobility (e) and duration of immobility (f) are presented.
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Figure 2: One-hour open field – centre and rearing. At 8 months of age six WT (white squares) and six MPS IIIB (black squares)
mice were placed in a cage outlined in Fig. 1a and the behaviour was recorded for 1 h. The results of the open field behaviour are
presented as a 1-h period with the average of every minute presented and as a bar chart of the first 3 min, first 10 min and whole hour.
Error bars represent the SEM. P values were calculated by t-test. The frequency of entering the centre (a), path length in the centre of
the cage in meters (b), the speed in the centre in millimetre per second (c), time spent in the centre in seconds (d), and the frequency
of rearing (e) are presented.
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central area and shows a very similar pattern. In the first
minute, the WT and MPS IIIB mice are indistinguishable,
but diverge in subsequent minutes with the MPS IIIB
mice entering the centre more frequently and travelling
further. This results in no significant differences between
WT and MPS IIIB mice in the first 3 min (F1,10 = 4.63–2.33,
P = 0.57–0.16) but a significant increase in MPS IIIB centre
entries and path length after 10 min (F1,10 = 8.29–9.04,
P = 0.02–0.01) and a greater significant difference after
60 min (F1,10 = 21.19–23.45, P = 0.001–0.0007). MPS IIIB
travel at significantly higher speeds in the central area
(Fig. 2c) with improving significance from 3 (F1,10 = 13.52,
P = 0.0043) to 10 (F1,10 = 22.50, P = 0.0008) to 60 minutes
(F1,10 = 78.65, P = 0.000005). This parameter is consistent
with the overall rapid exploratory behaviour and may not be
related to a reduced sense of danger. Figure 2d shows that
there is no clear difference in the duration spent in the centre
of the open field, after 3 min there is no significant difference
(F1,10 = 2.58, P = 0.140), at 10 minutes the WT mice
spent significantly more time in the centre (F1,10 = 10.03,
P = 0.010); however, after 60 min there is no significant
difference (F1,10 = 1.48, P = 0.251). Both groups of mice
spent significantly more time in the sides of the test area than
in the centre (not shown) (F1,10 = 296.36, P = 9 × 10−9);
thus, they both display a tendency to thigmotaxis. Overall
these data suggest that although MPS IIIB mice enter the
central area more frequently and travel further and more
rapidly in this area, there is no significant reduction in the
sense of danger in MPS IIIB mice in this test in terms of the
duration spent within the central area.
Finally, we measured rearing activity of mice over the first
10 min of the open field test (Fig. 2e). This is not measurable
using our automated system and was therefore scored by
hand. No significant difference was identified in the number
of unsupported rears (F1,10 = 1.51, P = 0.247), supported
rears using the side of the cage (F1,10 = 0.256, P = 0.624)
and total rears (F1,10 = 1.21, P = 0.297) between MPS IIIB
or WT mice.
The same groups of female mice were acclimatized in
the same test arena as the open field for 24 h by supplying
bedding, a house, food and water ad libitum (Fig. 3a). Home
cage behaviour was then monitored for the subsequent 24 h.
Figure 3b shows the average path length travelled by
groups of six to seven WT or MPS IIIB mice in 20-min
intervals over 24 h, split into two equal 12-h light or dark
periods. All mice have significantly increased path length in
darkness than in light (Illumination; F1,11 = 15.46, P = 0.002)
and over 24 h, MPS IIIB mice have a significant increase
in path length over their WT counterparts, travelling on
average 656 m compared to 298 m for WT mice (Genotype;
F1,11 = 5.29, P = 0.03). However, there are no significant
differences between MPS IIIB and WT when measured
only in darkness (Genotype; F1,11 = 2.56, P = 0.138) or light
(Genotype; F1,11 = 3.22, P = 0.100). This suggests that a
minimum of 24 h observation in the home cage is required
to show significant differences in path length.
Rapid exploratory behaviour is measured as frequency
(Fig. 3c) and duration (Fig. 3d) of speed over 90 mm/second
as before. All mice have an increased frequency of
speed over 90 mm/second in darkness compared to light
(Illumination; F1,11 = 9.23, P = 0.013). MPS IIIB mice have
a borderline significantly increased frequency of speed
over 90 mm/second over the entire 24-h period (Genotype;
F1,11 = 4.05, P = 0.057) and an almost significant difference
between genotypes when this is measured in light
(Genotype; F1,11 = 4.27, P = 0.063) but not in darkness
(Genotype; F1,11 = 2.48, P = 0.144) alone, because of the
increased variability in the dark. Interestingly the duration of
speed over 90 mm/second showed that MPS IIIB mice spent
significantly less time travelling faster than 90 mm/second
over 24 h (Genotype; F1,11 = 7.91, P = 0.01) and in the
dark (Genotype; F1,11 = 8.80, P = 0.01), which is neither
consistent with the frequency and the path length nor the
results of the 1-h open field test.
The frequency (Fig. 3e) and duration (Fig. 3f) of immobility
were also recorded over 24 h. Both the frequency (Illumina-
tion; F1,11 = 54.24, P = 0.00001) and duration (Illumination;
F1,11 = 9.32, P = 0.004) of immobility were significantly
increased in darkness for all mice and overall MPS IIIB mice
had increased frequency (Genotype; F1,11 = 4.42, P = 0.047)
and duration (Genotype; F1,11 = 9.69, P = 0.005) of immo-
bility. For duration of immobility we observed a significant
genotype effect in light (Genotype; F1,11 = 9.32, P = 0.011)
and dark (Genotype; F1,11 = 4.67, P = 0.054).
In the 24-h home cage test the overall frequency of
entering the centre (Fig. 4a) was significantly higher in the
dark (Illumination; F1,11 = 17.46, P = 0.0015) and there was
an overall increase in centre entries by MPS IIIB mice
(Genotype; F1,11 = 6.96, P = 0.015). In light there is also
a significant effect (Genotype; F1,11 = 6.52, P = 0.027). This
parameter is consistent with the hyperactivity observed in
the 24-h home cage test and 1-h test. The distance travelled
in the centre (Fig. 4b) is also consistent with hyperactivity
as there is a significant overall increase in MPS IIIB path
length in the centre (Genotype; F1,11 = 6.14, P = 0.021)
and in the light (Genotype; F1,11 = 5.21, P = 0.043) but not
in the dark (Genotype; F1,11 = 2.98, P = 0.112). There is
also increased activity for all mice in the dark compared
to light (Illumination; F1,11 = 7.10, P = 0.017). The speed
in the centre is likewise consistent with hyperactivity
with a significant overall genotype (Genotype; F1,11 = 5.71,
P = 0.026) and illumination effect (Illumination; F1,11 = 8.31,
P = 0.015). However, the increased speed in the centre
observed in MPS IIIB mice only occurs in the light (Genotype;
F1,11 = 40.99, P = 0.00005) and not in the dark (Genotype;
F1,11 = 0.16, P = 0.69). There is a significant illumination
difference in the duration of time spent in the centre (Fig. 4d)
(Illumination; F1,11 = 12.69, P = 0.0045) but no genotype
difference. This suggests that there is no detectable
difference in sense of danger between MPS IIIB and WT
mice.
To assess loss of motor skills and muscle strength with
time, we firstly used the inverted screen test over 120
seconds (Fig. 5a) to assess the number of rear leg moves
performed (Fig. 5b) and the duration to fall over this period
(Fig. 5c). At 8 months of age, WT mice perform on average
almost twice as many rear leg movements as MPS IIIB and
also fall later than MPS IIIB mice, but neither effect is signif-
icant because of a large variability (Moves: F1,11 = 1.53, P =
0.241; Time: F1,11 = 1.05, P = 0.327). At 10 months of age
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Figure 3: Home cage behaviour – activity. At 8 months of age six WT (white squares) and seven MPS IIIB (black squares) mice
were placed in a cage 260 × 365 mm outlined in (a) that included a food bowl and nesting house containing water within it. After
24 h of acclimatization the home cage behaviour was recorded for 24 h using infrared lights for night-time monitoring. The results
of the home cage behaviour are presented as a 24-h period with the average of every 20 min presented and as a bar chart of
firstly the whole 24 h and secondly the light and dark periods separately. Error bars represent the SEM. P values were calculated by
MANOVA repeated-measure analysis and one-way ANOVA. The mean average path length in meters (b), frequency of rapid exploratory
behaviour (speed >90 mm/second) (c), duration of rapid exploratory behaviour in seconds (d), frequency of immobility (e) and duration
of immobility (f) are presented.
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Figure 4: Home cage behaviour – centre. At 8 months of age six WT (white squares) and seven MPS IIIB (black squares) mice were
placed in a cage outlined in Fig. 3a, after 24 h of acclimatization the home cage behaviour was recorded for 24 h. The results of the
home cage behaviour are presented as a 24-h period with the average of every 20 min presented and as a bar chart of firstly the
whole 24 h and secondly the light and dark periods separately. Error bars represent the SEM. P values were calculated by MANOVA
repeated-measure analysis and one-way ANOVA. The frequency of entering the centre (a), path length in the centre of the cage in
meters (b), the speed in the centre in millimetre per second (c) and time spent in the centre in seconds (d) are presented.
the number of rear leg movements (F1,5 = 5.80, P = 0.06)
and the time to fall from the screen (F1,5 = 5.86, P = 0.06)
were on the borderline of a significant decrease in MPS IIIB
mice. Increased group size would therefore probably have
shown a significant effect in both parameters at 10 months.
The horizontal bar test measures motor co-ordination
and grip strength (Fig. 5d). At 8 months of age there is
no significant difference between MPS IIIB and WT mice
(F1,11 = 2.34, P = 0.15) (Fig. 5e), but by 10 months of age
the MPS IIIB mice are significantly worse at crossing the bar
than WT mice (F1,5 = 25.13, P = 0.004). This is in agreement
with the inverted screen test and suggests that the mice
continue to display normal motor skills at 8 months, which
are beginning to decline by 10 months of age.
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Figure 5: Inverted screen and horizontal bar crossing. At
8 months of age four WT and five MPS IIIB mice and at
10 months of age three WT and four MPS IIIB mice performed
the inverted screed test (a). The number of rear leg moves on
the inverted screen (b) and the time spent on the inverted screen
(c) were recorded. At 8 months of age six WT and seven MPS
IIIB mice and at 10 months of age three WT and four MPS IIIB
mice performed the horizontal bar test (d). The horizontal bar
score (e) is a measure of the time of the time taken to cross
or fall from the bar. Error bars represent the SEM and P values
were calculated by t-test.
Discussion
In this work we have been able to determine several
behavioural parameters that allow analysis of treatment
effects on the neurological deterioration seen in MPS IIIB
mice.
The 1-h open field habituation test performed at the same
time of day gives clear genotype separation at 10 min
and to a greater extent at 1 h. Eight-month-old MPS IIIB
mice show a significantly increased path length, frequency
and duration of rapid exploratory behaviour and reduced
frequency and duration of immobility, all of which are
consistent with a hyperactive phenotype. They also show
significantly increased frequency of entry, path length and
speed in the central area whilst duration in the centre was
unchanged. This suggests that these mice do not have
a reduced sense of danger when measured in this test,
although the relatively small size of the arena used in this
study could have reduced this effect (Crawley 2007). The
difference between WT and MPS IIIB mouse behaviour
often appeared to diverge from a similar starting point in the
first minute or two of the tests which led to non-significant
differences when observations were measured in the first
3 min of the test, as is used by some researchers in the
field (Hemsley & Hopwood 2005). Although all parameters
were significant when measured over the first 10 min of the
test (with the exception of duration in centre) as is used
by many researchers (Cressant et al. 2004), seven of eight
parameters were more consistently significantly different
when measured over the entire 1-h test period.
Fu et al. performed a 1-h open field test on 4.5–5-month-
old male and female mice, but did not report activity or
anxiety differences except for a decrease in rearing in the
second 30 min by male mice (Fu et al. 2007). It is possible
that 4.5–5 months of age is too early to detect differences
in genotypes but it is also critical that the test is performed
at the same time of day and this is not noted in the study.
We did not observe differences in any type of rearing activity
between 8-month-old MPS IIIB and WT mice; however, this
was only measured over the first 10 min. In a 10-min open
field test (Cressant et al. 2004), performed at 5 weeks and
7 months of age, no significant genotype differences were
observed at 5 weeks of age but significant hyperactivity was
seen in MPS IIIB mice at 7 months, in line with the results
presented here, which is also consistent with the patient
phenotype (Cleary & Wraith 1993).
MPS IIIB mice showed increased frequency of entry, path
length and speed in the central area whilst duration in the
centre was unchanged. These increases can all be explained
by increased hyperactivity causing the mice to move faster
and so entering the centre more frequently and travelling
further in the same amount of time. MPS IIIB mice have been
showed to be less anxious when using the elevated plus
maze (Cressant et al. 2004); however, significant changes
were only seen in darkness, and no anxiety differences were
seen in a 1-h open field test in daylight (Fu et al. 2007). These
discrepancies could be because of the relatively small size
of the open field used in our studies (Crawley 2007), or the
effect seen in darkness could be an artefact (Cressant et al.
2004). To test this hypothesis a larger open field test arena
would be required.
In the 24-h test we observed significant genotype effects
in all parameters except duration in the centre; however,
significance was much less evident compared to the 1-h
test, and increases in immobility frequency and duration
in MPS IIIB mice in the 24-h test are not consistent with
the hyperactive behaviour seen in the 1-h open field test.
Differences between MPS IIIB and WT mice appeared
to be more evident in daylight than in darkness where
few changes were seen. This could be because mice are
usually less active in daylight; thus, hyperactive behaviour is
more easily distinguished during a relatively inactive phase.
Interestingly, children with Sanfilippo are reported to have
circadian rhythm disturbances, with difficulty in sleeping and
frequent night waking and night wandering (Fraser et al.
2002, 2005), which would be consistent with the phenotype
observed here. In addition, significant periodicity was noted
in MPS IIIB mice during the dark phase of the 24-h test, which
may have confounded the ability to distinguish genotypes in
darkness. Similar MPS IIIB periodicity, and, in particular, a
late bout of activity at the transition between light and dark
were previously observed by us in a circadian analysis of
MPS IIIB mice (Canal et al. 2010). MPS IIIB mice show
increased frequency and duration of all activity measures
with commensurate reductions in frequency and duration
of immobility in the 1-h open field, which is consistent
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with sustained hyperactive behaviour. However, in the home
cage, although path length and frequency of rapid exploratory
behaviour are increased, other measures such as duration
of rapid activity are not. MPS IIIB mice also have increased
frequency and duration of immobility in the home cage. This
discrepancy could reflect the fact that there is a nesting box in
the home cage where behaviour could not be measured, but
this is unlikely as there is no change in the duration of time
spent in this area between genotypes. It could instead reflect
different types of hyperactive behaviour during exploratory
behaviour while the mouse habituates to a novel environment
in the 1-h test compared to normal behaviour in the home
cage. The 24-h home cage behaviour suggests that the
mouse is not able to sustain rapid activity over longer periods,
and is compensating by spending more time immobile.
The 24-h data broadly support the previous circadian
analysis by Heldermon et al. and ourselves (Canal et al.
2010; Heldermon et al. 2007, 2010), but is less effective
at separating the phenotypes and less convincingly shows
a hyperactive phenotype. Cressant et al. also performed
a home cage test over a 24-hour period; however, that
study lacked a 24-hour acclimatization period, so has an
element of habituation (Cressant et al. 2004). They observed
no difference between MPS IIIB and WT mice in the light but
a significant increase in the time the MPS IIIB mice spent
in motion in the dark at 4.5 months of age. The open field
test could be more consistent than the 24-h home cage test
because the circadian time that testing was performed at
(0830 h) is close to a peak of activity that we (Canal et al.
2010) have previously observed in MPS IIIB mice just before
the lights were switched on in the early morning (0700 h).
This peak can be seen in many of the 24-h measures in these
data as well. In contrast, WT mice are becoming less active
as the lights come on. The inverted screen test did not show
a significant effect at 8 or 10 months of age but there was
a clear trend towards the MPS IIIB mice moving less and
being less able to grip the inverted screen. A larger n number
for this experiment may make this effect significant. There
is a clear significant failure of MPS IIIB mice to complete
the horizontal bar crossing test at 10 months of age but no
changes at 8 months of age. Taken together these changes
suggest that motor skills are lost late by MPS IIIB mice at
10 months of age, and that it can be variable between mice.
A rocking rotarod test was performed by Heldermon et al.
which also measures motor skills, and a significant defect
in MPS IIIB mice was seen from 9 months onwards which
supports the inverted screen and horizontal bar test results
(Heldermon et al. 2007, 2010). An accelerating rotarod test
was not reported to show a significant difference between
WT and MPS IIIB mice at 5 months of age (Fu et al.
2007, 2010) or from 1.5 to 13 months of age (Heldermon
et al. 2007). In our hands motor skills do not deteriorate
significantly until 9–10 months of age; thus, the horizontal
bar test and the inverted screen test only have utility for the
long-term evaluation of therapies when the mice are at least
9–10 months of age and group sizes are more than 6–7. In
addition, the observation of urinary retention in these mice
from 8 to 10 months of age onwards (Malinowska et al. 2010)
is clearly a limiting factor in their ability to perform motor tasks
and as such the use of motor tests after 8–9 months of age is
more likely to measure this effect than a central dysfunction
in motor abilities.
In our previous work on treating MPS IIIB mice with
genistein we found similar hyperactivity increases in male
MPS IIIB mice, although differences were less marked
than females (Malinowska et al. 2010). Although this would
suggest that female mice may be more consistent for
behavioural testing, Fu et al. (2007) reported vertical activity
changes only observed in males (Fu et al. 2007). The ability to
readily group house females makes them a more economic
proposition than males.
Conclusion
We have showed that it is possible to detect consistently
increased hyperactivity and rapid exploratory behaviour in
the mouse model of MPS IIIB at 8 months of age using a
1-h open field test and modest group sizes of 6–7, which
is consistent with MPS IIIB patient behaviour. The minimum
test time that we would recommend for open field behaviour
is 10 min, with more consistent data obtained at 60 min, and
it may be important that tests are carried out close to the time
at which lights are switched on in the morning. Home cage
behaviour by contrast is a much less reliable distinguisher of
phenotype in MPS IIIB mice and may reflect less sustained
hyperactive behaviour. Finally, motor skill evaluations are
not likely to yield useful data before 9–10 months of age
and can be significantly influenced by gait impairment as a
result of urinary retention. This simple protocol will allow the
evaluation of potential therapies for MPS IIIB and could prove
useful in the development of assessment protocols for other
mouse models of neurodegenerative diseases.
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Abstract
Reliable behavioural tests in animal models of neurodegenerative diseases allow us to study the natural history of disease
and evaluate the efficacy of novel therapies. Mucopolysaccharidosis IIIA (MPS IIIA or Sanfilippo A), is a severe,
neurodegenerative lysosomal storage disorder caused by a deficiency in the heparan sulphate catabolising enzyme,
sulfamidase. Undegraded heparan sulphate accumulates, resulting in lysosomal enlargement and cellular dysfunction.
Patients suffer a progressive loss of motor and cognitive function with severe behavioural manifestations and premature
death. There is currently no treatment. A spontaneously occurring mouse model of the disease has been described, that has
approximately 3% of normal enzyme activity levels. Behavioural phenotyping of the MPS IIIA mouse has been previously
reported, but the results are conflicting and variable, even after full backcrossing to the C57BL/6 background. Therefore we
have independently backcrossed the MPS IIIA model onto the C57BL/6J background and evaluated the behaviour of male
and female MPS IIIA mice at 4, 6 and 8 months of age using the open field test, elevated plus maze, inverted screen and
horizontal bar crossing at the same circadian time point. Using a 60 minute open field, we have demonstrated that female
MPS IIIA mice are hyperactive, have a longer path length, display rapid exploratory behaviour and spend less time immobile
than WT mice. Female MPS IIIA mice also display a reduced sense of danger and spend more time in the centre of the open
field. There were no significant differences found between male WT and MPS IIIA mice and no differences in neuromuscular
strength were seen with either sex. The altered natural history of behaviour that we observe in the MPS IIIA mouse will allow
more accurate evaluation of novel therapeutics for MPS IIIA and potentially other neurodegenerative disorders.
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Introduction
Mucopolysaccharidosis IIIA (MPS IIIA, OMIM #252900), or
Sanfilippo Type A, is an autosomal recessive lysosomal storage
disorder that affects 0.82 in 100,000 live births in the United
Kingdom [1]. The disease is characterised by severe and
progressive loss of cognitive and motor functions, behavioural
difficulties and eventually death in the second decade of life,
although the severity and progression of the disease varies widely
[1,2,3]. MPS IIIA is caused by mutations in the SGSH gene that
result in deficiency of the N-sulfoglucosamine sulfohydrolase
enzyme (sulfamidase, EC 3.10.1.1) and subsequent accumulation
of undegraded heparan sulphate, lysosomal enlargement and
cellular and organ dysfunction [4,5,6,7]. Patients exhibit progres-
sive neurodegeneration and behavioural problems including
hyperactivity, a reduced sense of danger, aggression and sleep
disturbances [7,8,9,10,11,12].
Although there are no current therapies, several strategies are
in development for MPS IIIA or the phenotypically indistin-
guishable MPS IIIB disease, including substrate reduction
therapy [13,14,15], intrathecal enzyme replacement therapy
[16,17,18,19,20] and gene therapy with lentiviral [21], adenoviral
[22] or adeno-associated-viral [23] vectors. Most strategies make
use of the ability of exogenous enzyme to complement affected
cells, however the presence of the blood brain barrier limits
efficient enzyme distribution. Biomarkers for MPS IIIA or related
diseases are still in development [24,25], thus the accurate
evaluation of neurodegeneration using behavioural phenotyping
in the mouse model of disease is paramount. A spontaneously
occurring mouse model of MPS IIIA on a mixed 129SvJ,
C57BL/6, SJL, and CD1 background has been previously
described with around 3% of normal enzyme activity and
exhibiting many of the features observed in patients [26]. The
MPS IIIA mice exhibit severe neuropathology characterised by
enlarged lysosomes, primary storage of HS, secondary storage of
GM2 and GM3 gangliosides and cholesterol and chronic
neuroinflammation [19,23,26,27,28]. The MPS IIIA mice are
euthanized between 9 and 12 months of age due to urine
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retention, a phenotype not seen in the patients but also seen in
MPS IIIB mice [29]. The MPS IIIA mouse model has been
backcrossed to the C57BL/6 background by Professor John
Hopwood’s Lysosomal Diseases Research Unit [30] and to the
C57BL/6J background by Jackson laboratories [31].
Although the behaviour of the MPS IIIA mouse model has been
evaluated in the open field test at several ages, using different
sexes, by several groups and on different strain backgrounds, there
is a remarkable amount of variability in the outcome of the test as
outlined in Table 1.
Using the mixed background mouse, at many of the time points
measured, no differences are observed between either male or
female WT and MPS IIIA mice, with initial findings of
hyperactivity and later hypoactivity in males [18,32]. After back
crossing the MPS IIIA mice on to a C57BL/6 background, the
behaviour was extensively studied by Crawley et al. at different
time points. Hyperactivity in males was observed at 12 weeks of
age, and females at 22 and 32 weeks of age, although these mice
were not naively tested [30]. At most time points, no differences
were seen. However male, but not female, MPS IIIA mice were
shown to be hypoactive at some time points in the work of Lau et al
[33] and male MPS IIIA mice were hypoactive at 15 weeks of age
in a more recent paper by Lau et al. [34]. Hypoactivity in male
mice was also observed at some time points in McIntyre et al. [21].
In columns 7, 8, 9 and 10 of Table 1 (marked as bold) we have also
presented markedly variable outcomes of observations of locomo-
tor behaviour of MPS IIIA and WT mice that received control
intracranial injections [18,21,23,35].
Patients with MPS IIIA are believed to have a reduced sense of
danger, which can be inferred in mice by the amount of time spent
in the centre of the open field test or by use of the elevated plus
maze test, both of which can be used to measure their tendency to
avoid open spaces and remain close to cover (thigmotaxis). No
difference in the time in centre of the open field was detected by
Lau et al. [33], however this could be due to the small size of the
open field used. In the elevated plus maze, male MPS IIIA mice
were reported to display reduced anxiety with a greater proportion
of their path length (distance travelled) spent in the open arms at
some time points but not others [33,34].
Overall, there are discrepancies in behaviour of this mouse
model that could be due to gender differences, the age of testing
and the methodology used to perform the tests. Therefore we have
attempted to perform a standardised analysis of MPS IIIA mice by
first backcrossing them to the C57BL/6J background for over 10
generations and subsequently testing a cohort of MPS IIIA and
WT mice at the same circadian time point at 4, 6 and 8 months
(16, 24 and 32 weeks) of age in the 60 minute open field test, the
elevated plus maze, as well as several other neuromuscular
evaluations that we have previously shown to be effective for
phenotyping MPS IIIB mice [36]. The female MPS IIIA mice
were hyperactivity, had a recued sense of danger and no
neuromuscular differences. The open field test performed at the
same point in the circadian rhythm was a consistent, sensitive and
reliable behavioural test for the evaluation of novel therapeutic
strategies in MPS IIIA mice.
Methods
Mouse maintenance
The MPS IIIA mouse colony was maintained through
heterozygous breeding at the University of Manchester, all
procedures were ethically approved by the University of
Manchester Ethical Review Process Committee and in accordance
with the UK Home Office regulations under project licence PPL
40/3117. Mice were housed in individually ventilated cages, had
access ad libitum to food and water and were in a 12 hour light and
dark cycle. Male mice were singly housed at 14 weeks of age due to
aggressive tendencies but female mice remained housed in groups
of 4–6. The MPS IIIA mice (B6.Cg-Sgshmps3a) have been
backcrossed from the original mixed 129SvJ, C57BL/6, SJL,
and CD1 background [26] onto the C57BL/6J background by
more than 10 generations of backcrossing with C57BL/6J mice
(Harlan, UK) and were maintained by heterozygous breeding.
WT and MPS IIIA littermates have been used in all behavioural
experiments.
Genotyping MPS IIIA mice
MPS IIIA mice have a G to A mutation in the SGSH gene which
removes a Msp1I restriction enzyme digestion site. Genotyping is
performed by PCR amplification of DNA followed by Msp1I
digestion and observation of the size of DNA fragments produced.
Genomic DNA was extracted from ear punches using the GenElute
Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich) following
the manufacturer’s instructions and SGSH was amplified by PCR
using the forward primer 59 GTGTTCCCTGCCTGCTCAC 39
and reverse primer 59 CCAGTCCCCTCATCCCACTA 39. The
DNA was digested with Msp1I (New England Biolabs, UK) and the
DNA fragments were separated by 2% agarose gel electrophoresis.
The genotype was determined from the pattern of DNA fragments;
wild type (WT) reveals 199 bp, 118 bp and 78 bp fragments, mutant
(MUT) 317 bp and 78 bp fragments and heterozygous (HET)
317 bp, 199 bp, 118 bp and 78 bp.
Behavioural testing
At 4, 6 and 8 months (16, 24 and 32 weeks) of age, the same
cohorts of 10 male WT and 10 male MPS IIIA mice and 10
female WT and 11 MPS IIIA mice were analysed with the
following behavioural tests. 1.5 hours into the 12 hour light phase
the mice were dropped into the centre of an open field arena
(width 450 mm, depth 450 mm, height 500 mm) made of matt
white acrylic. The behaviour was recorded for 60 minutes using a
digital camcorder (Sony) and analysed using Top Scan software
(Clever Sys. Inc., USA). The path length, frequency (number of
times) and duration of rapid exploratory behaviour (speed
.100 mm/s), frequency and duration of immobility (speed
,5 mm/s) and frequency of entering the centre and duration in
the centre (75 mm from each edge) was analysed. Rearing in the
open field was analysed by counting the number of unsupported
rears (front paws off the floor) and supported rears (front paws on
the wall) in the first 10 minutes. The same researcher performed
all experiments and was blinded to genotype.
After a 30 minute rest, the mice were placed onto the end of an
open arm of an elevated plus maze. The maze was constructed of
matt white acrylic, comprised of four 500 mm long by 100 mm
wide arms, two of which were enclosed by 500 mm high walls, and
was raised on a stand 500 mm off the floor. Mice were placed so
they faced towards the centre of the maze and were given
10 minutes to explore the maze before returning to a cage. The
maze was cleaned using 70% ethanol. 30 minutes later the mice
were tested for a second time, in the same manner. The results
were analysed using Top Scan software (Clever Sys) to examine
the amount of time spent on the open arm, the percentage of path
length in the open arm, and the percentage of open arm entries.
30 minutes later the inverted screen test was performed, as
described previously [36]. In brief, at 4, 6 and 8 months of age the
mouse was placed on a 470 mm square with a 13 mm square wire
mesh. The screen was then rotated through 180u over 1–
2 seconds. The mouse was then suspended upside down over a
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padded surface; the rear leg moves were counted and the duration
suspended was recorded up to 2 minutes.
One hour later the horizontal bar test was performed as
described previously [14,36]. In brief, a 2 mm diameter, 300 mm
long metal wire was secured between 2 posts, 320 mm above a
padded surface. The mouse was allowed to grip the centre of the
wire and the time taken to fall or to reach the side was recorded up
to 2 minutes. The test was repeated three times as a training run
followed by a 10 minute rest before three test runs. The results
were scored as follows: crossing the bar in x seconds was scored as
240-x, remaining on the bar was scored as 120 and falling off the
bar after y seconds was recorded as y.
Urine retention
Upon sacrifice 9 male WT, 8 male MPS IIIA, 7 female WT and
8 female MPS IIIA mice at 8 months (32 weeks) of age were
dissected and the urine was removed from the bladder and volume
measured using an insulin syringe (BD).
Statistical analysis
Statistical analysis was performed using JMP software (SAS
Institute Inc, Cary, NC, USA) and analysed by MANOVA with
repeated measures for overall significances and by one or two way
ANOVA, as appropriate, with Tukey post hoc tests at individual
time points. Significance was set at p#0.05. For the MANOVA
analysis the Genotype significance determines if there is a
difference between WT and MPS IIIA mice irrespective of the
age of the mice, the Time significance determines if there is a
change in the behaviour of the mice at different ages irrespective of
the genotype and the Genotype*Time significance determines if
MPS IIIA mouse behaviour changes over time in a different
manner to WT mice.
Results
Cohorts of male and female, WT and MPS IIIA mice (n = 10–
11 per group) were monitored in a 60 minute open field test as
outlined in Figure 1A. The path length minute by minute over
60 minutes is shown at 4 months (16 weeks) in Figure 1B, 6
months (24 weeks) in Figure 1C and at 8 months (32 weeks) in
Figure 1D. The behaviour in the first 3 minutes, 10 minutes and
60 minutes is presented to allow comparison against published
data and to identify the minimum amount of time required for
statistically significant analyses. At 4 months of age, female MPS
IIIA mice were significantly hyperactive and travel almost twice as
far as the WT mice over 60 minutes (p = 0.037; Figure 1B).
Examining the behaviour over the first 3 minutes showed no
difference and no trend in female behaviour, but over 10 minutes
there was a non-significant trend towards hyperactivity. No
difference was found in the path length of male WT or MPS
IIIA mice at 4 months.
At 6 months of age the same female MPS IIIA mice
demonstrated increased path length with significant differences
after 10 minutes (p = 0.030) and greater differences after 60 min-
utes (p = 0.005; Figure 1C). No difference was detected between
male WT and MPS IIIA mice (Figure 1C).
At 8 months of age there was a trend for the female mice to be
hyperactive but no significant differences were found after 3
(p = 0.73), 10 (p = 0.15) or 60 minutes (p = 0.18; Figure 1D).
Similarly, no significant differences were found with male mice
after 3, 10 or 60 minutes. Overall, using MANOVA repeated
measure analysis, a significant genotype difference (p = 0.011),
time difference (p = 1.261027) and a time*genotype difference
(p = 0.021) were found. This indicates that overall, MPS IIIA mice
are significantly more hyperactive than WT mice, that this
changes with time and that MPS IIIA and WT mice change their
behaviour in a different manner over time.
The number of unsupported rears (front paws off the floor),
supported rears (front paws on a wall) and total rears were counted
manually in the first 10 minutes of the open field test. The only
significant change observed was a decrease in the number of
unsupported rears by female MPS IIIA mice at 6 months of age
(Figure 1F). However, given that there were no other significant
genotype effects, this may be just a chance occurrence (Figure 1E
and G). MANOVA repeated measure analysis of the data showed
no significant genotype effect in the three rearing measures, but
there was a significant decline in all measures with time
(unsupported; p = 0.004, supported and total p = 0.00003) irre-
spective of genotype.
Rapid exploratory motion was analysed by measuring the
frequency and duration of speed over 100 mm/s (Figure 2A–F). At
4 months of age, female MPS IIIA mice show significant increases
in both the frequency (p = 0.048; Figure 2A) and duration
(p = 0.05; Figure 2D) of rapid exploration over 60 minutes.
However, no significant differences were observed after 3 or
10 minutes, although a trend was detected after 10 minutes
(Figure 2A). No significant differences were found between male
MPS IIIA or WT mice at 4 months of age.
At 6 months of age, there was a trend towards increased
frequency (Figure 2B) and duration (Figure 2E) of rapid
exploratory motion after 3 minutes in the female MPS IIIA mice
(p = 0.23, p = 0.10). After 10 (p = 0.021, p = 0.034) and 60 minutes
(p = 0.0003, p = 0.0057), female MPS IIIA mice had significantly
increased frequency (Figure 2B) and duration (Figure 2E) of rapid
exploratory motion over 100 mm/s. No significant differences
were observed between male WT and MPS IIIA mice. This rapid
exploratory behaviour is visible in Video S1 which shows the
median female WT and MPS IIIA mouse at 6 months of age at 4
times normal speed.
At 8 months of age, female MPS IIIA mice show a trend
towards increased frequency of rapid exploratory motion over
60 minutes (p = 0.18) (Figure 2C), with a trend to increase in
duration after 10 minutes (p = 0.083) and a significant increase
after 60 minutes (p = 0.02) (Figure 2F). Male MPS IIIA and WT
mice were indistinguishable. Using MANOVA repeated measure
analysis, there was a significant difference between WT and MPS
IIIA mice over all three time points for frequency (Genotype;
p = 0.004) and duration (Genotype; p = 0.013) of rapid exploratory
motion. There was a significant decline in frequency (Time;
p = 9.7610215) and duration (Time, p = 4.561028) of rapid
exploratory motion with time and also between genotypes over
Figure 1. Open field path length and rearing. At 4, 6 and 8 months (16, 24 and 32 weeks) of age, 10 WT male (light grey squares), 10 MPS IIIA
male (dark grey squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was
recorded for 60 minutes (A). The results of the open field behaviour are presented as a 60 minute period with the average of every minute presented
and as a bar chart of the first 3 minutes, first 10 minutes and the whole hour. Error bars represent the standard error of the mean (SEM). p values were
calculated by 2 Way ANOVA. The mean average path length in Metres at 4 (B), 6 (C) and 8 (D) months have been presented. The number of
unsupported, supported and total rears in the first 10 minutes at 4 (E), 6 (F) and 8 (G) months of age have also been presented.
doi:10.1371/journal.pone.0025717.g001
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time for frequency (Time*Genotype p = 0.00005) and duration
(Time*Genotype, p = 0.036).
The frequency and duration the mice spent immobile was also
recorded (Figure 3A–F). There were no significant differences in
frequency of immobility between either male or female MPS IIIA
and WT mice at any time point. However, female WT mice had
significantly increased duration of immobility over 60 minutes at 4
(p = 0.005) and 6 months (p = 0.004) but not at 8 months
(p = 0.70). Male MPS IIIA or WT mice had indistinguishable
duration of immobility at all time points measured. Using
MANOVA repeated measures there was an overall increase in
the frequency of WT immobility over MPS IIIA mice over the
three time points (Genotype; p = 0.027), but no change with time
(Time; p = 0.543), or genotype with time interaction (Genotype*-
Time; p = 0.636). MANOVA repeated measures analysis of
duration of immobility demonstrated a significant genotype effect
over the three time points (Genotype; p = 0.05), that changes
significantly with time (Time; p = 1.561029) and changes
differently with time between the two genotypes (Genotype*Time;
p = 0.030).
Mice being a prey species tend to display thigmotaxis,
remaining close to the sides of an open field arena. Increased
frequency and duration of time spent in the centre of the open
field test therefore demonstrates reduced thigmotaxis and this is
commonly considered to be a measure of reduced anxiety or
reduced sense of danger that the animal experiences [37]. Male
MPS IIIA and WT mice showed no significant differences in
frequency of centre entries at any age (Figure 4A, B and C). At 4
months of age, female MPS IIIA mice showed significantly
increased centre entries at 60 minutes (p = 0.0045). At 6 months
female MPS IIIA mice entered the centre significantly more at 3,
10 and 60 minutes (p = 0.057, p = 0.023, p = 0.0005; Figure 4B).
At 8 months of age female MPS IIIA showed no significant
increases in centre entries (p = 0.37)(Figure 4C). Using MANOVA
MPS IIIA mice showed significantly increased centre entries
(Genotype; p = 0.003), which changed significantly over time
(Time; p = 2.3610211) and between genotypes over time (Geno-
type*Time; p = 0.0013).
The duration spent in the centre has also been analysed. At 4
months of age, female MPS IIIA mice spent significantly more
time in the centre than WT, after 60 minutes (p = 0.012;
Figure 4D). Males were not significantly different. At 6 months
of age female MPS IIIA mice had increase duration in the centre
after 60 minutes (p = 0.012) and showed an almost significant
trend in male mice (p = 0.055; Figure 4E). At 8 months of age
there are no significant differences between genotypes (Figure 4F).
By MANOVA repeated measure analysis MPS IIIA mice spend
significantly increased duration in the centre area (Genotype;
p = 0.001), this changes significantly over time (Time;
p = 2.561026) and between genotypes over time (Time*Genotype;
p = 0.005).
Thirty minutes after behavioural analysis in the open field, the
same cohort of mice were tested on an elevated plus maze
(Figure 5A) for ten minutes, followed by a 30 minute rest and
another 10 minute trial. Several parameters were measured
(frequency of entering open arm, percentage of entries into the
open arm, path length in open arm, percentage of path length in
open arm and time in open arm) but none reached significance.
Here we have presented the percentage of entries to the open
arms, percentage of path length in the open arms and duration in
the open arms as measure of anxiety (Figure 5B, C, D), which is
representative of many of the other measures. At 4, 6 and 8
months of age there was no significant difference in male or female
WT or MPS IIIA open arm entries (Figure 5B, C, D). At 4, 6 and
8 months there was no difference between WT and MPS IIIA
mice in the repeat elevated plus maze and no difference between
first and second elevated plus maze tests except that in the second
test, all the mice performed fewer entries and had a shorter path
length (Figure S1A–C). Statistical analysis by MANOVA showed
no significant difference in genotype, or time but there was a
significant difference in how the genotypes behaved over time in
the percentage of path length in the open arm (p = 0.019) as the
MPS IIIA mouse path length decreased at 8 months but the WT
increased.
The inverted screen test (Figure 6A) and horizontal bar crossing
test (Figure 6B) were also performed. The inverted screen test
measures neuromuscular strength and the bar crossing test
measures both neuromuscular strength and motor coordination.
The bar crossing test showed no significant differences between
WT and MPS IIIA of either sex at 4, 6 or 8 months of age
(Figure 6C–E). Over time, there was a significant decrease in the
number of moves and time spent on the inverted screen
(p = 1.761026, p = 1.261025), and a significant sex difference in
the number of moves with females moving more (p = 0.004). Bar
crossing showed no genotype effect and no time effect but there
was a significant Time*Sex effect (p = 0.044), as the female score
decreased over time but the male score increased at 6 months and
then decreased at 8 months.
Discussion
We have backcrossed the mixed background MPS IIIA mouse
model onto the C57BL/6J background and characterised a
behavioural phenotype that can be used to accurately distinguish
female MPS IIIA mice from WT littermates. Our findings clearly
show that male mice show no significant difference to WT
littermates in the open field test or elevated plus maze, whilst
female MPS IIIA mice demonstrate characteristic hyperactive
behaviour initially at 4 months (16 weeks) and more strongly at 6
months (24 weeks), which declines again at 8 months (32 weeks) of
age. We also show that these mice have a reduced thigmotaxis at 4
and 6 months of age which would indicate a reduced sense of
danger. Hyperactivity and a reduced sense of danger are observed
in the behavioural phenotype of the MPS IIIA patients
[1,7,10,11].
In this study we observed no significant behavioural differences
between WT and MPS IIIA male mice. This is in contrast to
Hemsley et al. 2005 where hyperactivity was initially observed at 3
weeks, hypoactivity at 6 and 15 weeks and no changes at 10, 20
and 40 weeks in male mixed background mice [32]. Lau et al. 2008
used male MPS IIIA mice that had been back crossed onto the
C57BL/6 background and observed no differences at 3, 5 and 15
Figure 2. Open field rapid exploratory behaviour. At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey
squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was recorded for
60 minutes. The results of this test are presented as a 60 minute period with the average of every minute presented and as a bar chart of the first
3 minutes, first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 Way ANOVA. The frequency of moving
faster than 100 mm/s at 4 (A), 6 (B) and 8 (C) months and the duration spent moving faster than 100 mm/s at 4 (D), 6 (E) and 8 (F) months of age have
been presented.
doi:10.1371/journal.pone.0025717.g002
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weeks, with significant hypoactivity at 10, 18 and 22 weeks [33]
but subsequently observed hypoactivity in 15 week old male mice
[22]. Crawley et al., using male MPS IIIA mice on the same
C57BL/6 background, found no changes at 4, 6, 8, 10, 15, 18, 22,
25, 32 and 40 weeks and only observed hyperactivity at 12 weeks
[30]. Finally, using male mice independently crossed onto the
C57BL/6J background by Jackson laboratories, hypoactivity was
observed in MPS IIIA mice at 20 weeks of age by McIntyre et al.
but no difference was found at 24 or 32 weeks [38]. Clearly, it is
hard to obtain consistent behavioural readouts from male mice in
this context and it is always difficult to know if hypoactivity could
be confounded by any parameter affecting the mouse’s physical
ability to move. We find male MPS IIIA mice to be very aggressive
and are unable to keep them group housed, which is likely to
change their behaviour. Singly housing male C57BL/6 mice has
been shown to increase locomotor activity and reduce anxiety [39]
or alternatively in other researchers hands to have no effect [40].
At the very least, it certainly leads to weight gains, which will
restrict movement, and this may confound reliable open field
measures. Additionally we find that all MPS IIIA mice retain urine
over time, with male mice retaining significantly more urine at 8
months of age and urine retention is the humane endpoint (Figure
S2). Clearly urinary retention could be restricting movement
which would confound behavioural measures. Lastly, it is worth
pointing out that many male mouse studies are on mixed, C57BL/
6 or C57BL/6J backgrounds, some of which have been performed
in different laboratories, which could lead to inconsistencies in
outcomes. Overall, we would argue that comparisons of male MPS
IIIA mice with WT are not appropriate (or easy to perform) for
determination of treatment responses.
Several studies analysed behaviour of male MPS IIIA mice
following control intracranial injections. Fraldi et al. tested male
mice and found that the MPS IIIA mice were hyperactive at 21
weeks of age but not prior to this, but these mice had received
intracranial injections and this may have adversely affected the
mouse’s behaviour [23]. Other studies where intracranial
injections have been given to MPS IIIA mice all used male mice
and generally observed either no changes or hypoactivity
[18,21,35]. It is worth considering that intracranial injections
could have altered the natural behaviour of the mouse and this
may be why hypoactivity is observed.
We found female MPS IIIA mice to be hyperactive, having a
significantly increased path length, frequency and duration of
rapid exploratory behaviour and reduced duration of immobility
at 4 and 6 months of age, (16 and 24 weeks) whilst duration of
rapid exploratory behaviour was significantly increased at 8
months (32 weeks). At 4 months of age differences are only
significant after 60 minutes, but at 6 months they are all significant
after both 10 and 60 minutes. This indicates that the 60 minute
test is a more sensitive test to identify hyperactivity than the 10 or
3 minutes tests. No significant differences were observed over the
first 3 minutes at any time point, thus we would suggest that
studies such as that of Crawley et al. 2006 where this short test has
been used are not likely to yield significant differences [30].
Our hyperactivity findings in females are supported by Crawley
et al, where hyperactivity was observed at 22 and 32 weeks of age
in a 3 minute test with female MPS IIIA C57BL/6 mice, however
no difference was observed at any point prior to 18 weeks or at 25
or 40 weeks of age [30]. They also observed hypoactivity in
females at 4 weeks of age but we do not have comparative data to
comment on this. The longer testing time utilised in our study may
have meant that we were better able to detect behavioural changes
in the mice that were not detectable with the 3 minute test.
On the mixed background, female MPS IIIA mice were
hyperactive at 3 weeks of age but at subsequent ages no differences
were observed at 6, 10, 15, 20, 30 or 40 weeks of age [32]. In the
work of Lau et al., using the C57BL/6 backcross, no differences
were observed between female WT and MPS IIIA C57BL/6 mice
between 3–22 weeks of age [33].
MPS IIIB is a phenotypically indistinguishable disease to MPS
IIIA. In the mouse model of MPS IIIB, hyperactivity has been
observed in a 10 minute open field test [41] but hypoactivity in an
8 minute open field test performed half in the light half in the dark
[42]. A 60 minute open field test did not report differences in path
length in male or female mice [43], but a 60 minute open field test
that we performed on female mice at the same circadian time as
this study observed hyperactivity at 8 months of age [36], which is
consistent with our findings here. We also observed significant
increases in hyperactivity in male MPS IIIB mice at 8 months of
age, although they were less significant differences than those
observed in females [14]. The MPS IIIB mouse is a complete
knockout and thus may be slightly more severe than the MPS IIIA
mouse with ,3% residual enzyme activity. This may explain why
we were able to detect significant genotype differences at 8 months
of age in MPS IIIB in all parameters but only some in MPS IIIA.
We believe that the 60 minute open field test is still measuring
habituation behaviour due to the profiles of activity observed in
both MPSIIIA mice in this paper and in MPSIIIB mice [36] over
time. We found that differences in behaviour between MPS IIIB
and WT mice [36] and MPS IIIA and WT mice (Figure 1B and C)
became more pronounced from 3 to 10 to 60 minutes and
diverged in the first few minutes from a similar initial response.
When we compared MPS IIIB and WT mice over a 24 hour
period following 24 hours of habituation [36] the differences were
significantly muted and over 14 days there was no significant
difference [44]. This suggests that a 60 minute open field test does
not reflect home cage behaviour but instead probably measures
extended habituation to a novel environment.
A significant decrease in the number of unsupported rears by
female MPS IIIA mice was observed at 6 months of age, however,
there was no difference in the overall number of rears, or
supported rears, at this or any other time point. No consistent
trend in the number of rears with female mice is apparent in the
literature, Crawley et al. reported that female MPS IIIA mice
reared less at 15 and 25 weeks of age but there were no significant
differences at 9 other time points [30]. No significant differences in
rearing were observed in Lau et al. who also used backcrossed mice
[33], or Hemsley et al who used mixed background mice [32]. A
more consistent trend is observed in male mice with MPS IIIA
rearing less [18,30,32,33,35], but increased rearing has been
observed at 3 weeks [32]. However, at most time points no
significant difference is observed. Manual measurement of rears
Figure 3. Open field immobile behaviour. At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey squares), 10
WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was recorded for 60 minutes. The
results of this test are presented as a 60 minute period with the average of every minute presented and as a bar chart of the first 3 minutes, first
10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 Way ANOVA. The frequency of not moving at 4 (A), 6 (B)
and 8 (C) months and the duration spent not moving at 4 (D), 6 (E) and 8 (F) months of age have been presented.
doi:10.1371/journal.pone.0025717.g003
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can be subjective and there may be variations in the rearing
behaviour, such as amount of time per rear that cannot be
measured by simply counting the number of rears. This is why we
examined the number of supported and unsupported rears
[36,45]. In the MPS IIIB mouse model, no difference in rearing
was observed in the first 10 minutes of an open field test with
female mice at 8 months of age [36] and no difference in the first
30 minutes but a significant decrease in the number of rears by
4.5–5 month old male MPS IIIB mice in the second 30 minutes of
a 60 minute open field test [43]. Our conclusion is that rearing is
too variable an outcome in MPS IIIA and IIIB mice and is
therefore not a valuable informative test.
At 4 and 6 months of age the MPS IIIA female mice had a
reduced sense of danger and spent a greater proportion of time in
Figure 4. Open field sense of danger behaviour. At 4, 6 and 8 months of age 10 WT male (light grey squares), 10 MPS IIIA male (dark grey
squares), 10 WT female (white squares) and 11 MPS IIIA female (black squares) were placed in the open field and the behaviour was recorded for
60 minutes. The results of this test are presented as a 60 minute period with the average of every minute presented and as a bar chart of the first
3 minutes, first 10 minutes and the whole hour. Error bars represent the SEM. p values were calculated by 2 Way ANOVA. The frequency of entering
the centre at 4 (A), 6 (B) and 8 (C) months and the duration spent in the centre at 4 (D), 6 (E) and 8 (F) months of age have been presented.
doi:10.1371/journal.pone.0025717.g004
Figure 5. Elevated plus maze behaviour. At 4, 6 and 8 months of age 7–11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT female
(white bars) and MPS IIIA female (black bars) were placed on the elevated plus maze (A) and the behaviour was recorded for 10 minutes. After a
30 minute rest, the test was repeated. The results of the first test are presented as the mean of each measure with error bars representing the SEM. p
values were calculated by 2 Way ANOVA. The following measures have been presented; the percentage of total entries that were into the open arm,
the percentage of the path length in the open arm and the duration spent on the open arm at 4 (B), 6 (C) and 8 (D) months of age.
doi:10.1371/journal.pone.0025717.g005
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the centre of the open field, this measure was significant after
60 minutes but not after 3 or 10 minutes. This is supported by the
patients with MPS IIIA which are believed to have a reduced sense
of danger [1]. No difference in the time in centre was detected by
Lau et al. in both male and female mice [33], however this could be
because the open field was larger in our study and therefore more
sensitive to thigmotaxis [45,46]. In the MPS IIIB mouse model no
differences were observed in the duration spent in the centre of the
open field [36] but the open field used in that study was also
smaller than the one used in this study.
The elevated plus maze did not demonstrate a decrease in
anxiety or sense of danger in the MPS IIIA mice. There were also
no differences between repeat tests, and both WT and MPS IIIA
mice appeared to habituate equally. Lau et al. 2010, observed no
significant differences with male mice at 6.5 months (26 weeks) of
age with a 5 minute elevated plus maze test, but there was a trend
towards reduced anxiety [34]. However in Lau et al. 2008 a
significant increase in the time the male MPS IIIA mice spent in
the open arms at 18 weeks of age, the percentage of the path
length on the open arms at 15 and 18 weeks and the percentage of
entries into the open arms at 20 weeks was observed [33].
Additionally they observed significant differences between repeats
of the elevated plus maze, male MPS IIIA mice had a significantly
longer path length in the repeat elevated plus maze test while WT
mice remained unchanged [33]. We did not observe decreased
anxiety or a change in behaviour between repeat elevated plus
maze tests. The width of the arms could be affecting this test as this
study used 10 cm wide arms and Lau et al., used 7 cm wide arms.
It has been demonstrated that when using 5, 7 or 9 cm wide arms,
NMRI mice spent more time in the wider open arms compared to
C57BL/10J mice that showed no difference [47]. Ten minutes on
the elevated plus maze may also be too short a time to detect the
sense of danger differences in the MPS IIIA mice as the only
centre measure on open field that is significant after 10 minutes is
Figure 6. Neuromuscular behaviour. At 4, 6 and 8 months of age 8–11 WT male (light grey bars), MPS IIIA male (dark grey bars), WT female (white
bars) and MPS IIIA female (black bars) were placed on the inverted screen test (A) and horizontal bar crossing test (B). The number of rear leg moves,
the time spent on the inverted screen and the bar crossing score are presented at 4 (C), 6 (D) and 8 (E) moths of age. Error bars represent the SEM and
p values were calculated by 2 Way ANOVA.
doi:10.1371/journal.pone.0025717.g006
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the number of centre entries in female mice at 6 months of age
(p = 0.023). A lack of difference in the elevated plus maze
performed in daylight is supported by MPS IIIB mice which
showed no difference in the light but were less anxious in the dark
[41]. The increased number of centre entries and duration in the
open field could perhaps reflect increased but undirected anxiety
whereby mice are actually more agitated but have lost the ability
to determine what is dangerous. A more pragmatic explanation
could be due to the mice not being naively tested as they only
received a 30 minute break after the open field test before starting
the elevated plus maze test. Prior behavioural tests can affect the
result of elevated plus maze tests with C57BL/6J mice that have
previously been tested in an open field test [48].
No significant differences were observed in the inverted screen
or bar crossing tests which is consistent with the work of Crawley et
al. who observed no difference in neuromuscular strength with
back crossed MPS IIIA mice [30]. However on the mixed
background strain, there was a significant decrease in neuromus-
cular strength with MPS IIIA mice being unable to grip the
inverted screen for as long as the WT mice from 20 weeks of age
[32]. The work in our study is supported by work with the MPS
IIIB mouse model that does not show a decline in motor function
at 5 months of age by accelerating rotarod [43,49] but does by a
rocking rotarod test from 9 months onwards [50,51]. The decline
in motor function could relate to the presence of increasing urine
retention in the MPS IIIA and B mouse models [14,26,29]. Our
own tests in the MPS IIIB mouse model found that neuromuscular
decline only occurred at 10 months of age (40 weeks) [14,36].
Given that the MPS IIIA mouse has residual enzyme activity, it is
possible that progression of MPS IIIA disease is slightly less rapid
than in MPS IIIB which would explain why we did not see a trend
to changes in motor function at 8 months in MPS IIIA mice.
Standardisation of tests is a very important aspect of
behavioural test design that may have affected comparison of
our tests to those of other laboratories. In this study the size of the
open field was larger than that described in many studies and the
behaviour was observed for much longer (60 minutes compared to
3 minutes). The increased size and time of the test allows better
spatial and temporal resolution of the mouse behaviour and so
makes the test more sensitive [45]. Video analysis software was
used which has been shown to be more sensitive than line crossing
determined by an observer or beam breaks [52]. In this study, the
mouse was placed in the centre of the open field rather than in the
corner and the test was carried out at the same time point of
circadian rhythm for all mice as there is a known peak in activity
in the similar MPS IIIB mouse model [44]. The mice in this study
were also housed differently; females were group housed and male
mice were singly housed from 14 weeks of age. The background of
the mice can affect the behavioural phenotype, therefore we
backcrossed the MPS IIIA mice in this study onto the C57BL/6J
background for more than 10 generations. Other groups have
used MPS IIIA mice on a mixed background [18,32], or on a
C57BL/6 [23,30,33,34] or C57BL/6J [21] background. Strain
specific differences can also significantly affect behavioural
outcomes [53].
Conclusion
We have demonstrated that we can reliably detect differences in
the behaviour of female but not male MPS IIIA mice at 4 and 6
months (16 and 24 weeks) of age and these differences match the
patient phenotype. Male mice were singly housed due to their
aggression which may change comparative behavioural responses.
Female MPS IIIA mice are hyperactive, with a longer path length,
increased frequency and duration of rapid exploratory behaviour,
and spend less time immobile. They also show a trend to this
behaviour at 8 months of age with significantly increased duration
of rapid exploratory behaviour. Female MPS IIIA mice demon-
strate a reduced sense of danger with a greater proportion of the
time spent in the centre of the open field with a greater number of
centre entries. These two time points and multiple measures are
ideal to evaluate novel therapies for MPS IIIA as the effect of a
therapy can be sensitively determined using multiple measures.
This behavioural phenotype is supported by both the phenotype of
the patients and our recent similar observations in the MPS IIIB
mouse model [14,36]. The increased size of the open field, the
increased length of the test, the use of video analysis software and
performing the test at consistent point in the circadian rhythm
have produced a sensitive and robust test to evaluate the effect of
therapies on female MPS IIIA mice.
Supporting Information
Figure S1 Repeat elevated plus maze behaviour. At 4, 6
and 8 months of age 7–11 WT male (light grey bars), MPS IIIA
male (dark grey bars), WT female (white bars) and MPS IIIA
female (black bars) were placed on the elevated plus maze (A) and
the behaviour was recorded for 10 minutes. After a 30 minute
rest, the test was repeated. The results of the repeat test are
presented as the mean of each measure with error bars
representing the SEM. p values were calculated by 2 Way
ANOVA. The following measures have been presented; the
percentage of total entries that were into the open arm, the
percentage of the path length in the open arm and the duration
spent on the open arm at 4 (A), 6 (B) and 8 (C) months of age.
(TIF)
Figure S2 Urine retention at 8 months. At 8 months of age
9 WT male (light grey bars), 8 MPS IIIA male (dark grey bars), 7
WT female (white bars) and 8 MPS IIIA female (black bars) were
sacrificed and the urine volume in the bladder measured. The
results are presented as the mean with error bars representing the
SEM. p values were calculated by 2 Way ANOVA.
(TIF)
Video S1 Open field behaviour video. A video running at 4
times the normal speed showing the median female WT and MPS
IIIA mouse at 6 months of age. The MPS IIIA mouse is on the left
and the WT mouse is on the right.
(WMV)
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